[{"content":"This section covers the initial recognition and early management of sepsis in adults, including institutional performance improvement programs, screening tools, biomarkers, blood cultures, lactate measurement, initial fluid resuscitation, the timing and route of vasopressor initiation, mean arterial pressure targets, and ICU admission timing. These recommendations apply to adults with possible, probable, or definite sepsis or septic shock in the emergency department, hospital ward, and …","description":"Surviving Sepsis Campaign 2026 recommendations for performance improvement programs, code sepsis protocols, prehospital and in-hospital screening, biomarkers, blood cultures, lactate measurement, initial fluid resuscitation, vasopressor timing, peripheral vasopressor initiation, MAP targets, and ICU admission.","section":"icu","title":"SSC 2026 — Part 1: Screening \u0026 Early Management","url":"/icu/guidelines/surviving-sepsis-campaign-2026/ssc-2026-part-1-screening-early-management/"},{"content":"This section covers the initial recognition, screening, and antimicrobial management of sepsis in children, including institutional performance improvement programs, blood lactate measurement, blood cultures, molecular diagnostics, antimicrobial timing for septic shock and sepsis without shock, empiric broad-spectrum therapy, beta-lactam infusion strategies, antimicrobial de-escalation, procalcitonin-guided therapy, and infectious diseases consultation. These recommendations apply to pediatric …","description":"Surviving Sepsis Campaign 2026 pediatric recommendations for sepsis screening, performance improvement programs, blood lactate, blood cultures, molecular testing, antimicrobial timing, empiric broad-spectrum therapy, beta-lactam infusion strategies, de-escalation, procalcitonin-guided therapy, and infectious diseases consultation in children.","section":"icu","title":"SSC Children 2026 — Part 1: Recognition, Screening \u0026 Antimicrobial Therapy","url":"/icu/guidelines/surviving-sepsis-campaign-children-2026/ssc-children-2026-part-1-recognition-screening-antimicrobial-therapy/"},{"content":"1. The Chain of Survival The chain of survival is the conceptual framework upon which all resuscitation systems are built. Each link in the chain represents a critical intervention; weakness in any single link substantially reduces the probability of neurologically intact survival. The concept has evolved from its original four-link model into separate chains for out-of-hospital cardiac arrest (OHCA) and in-hospital cardiac arrest (IHCA), reflecting the distinct pathways and resources available …","description":"Chain of survival, high-quality CPR parameters, compression-only CPR, AED use, manual defibrillation energy levels, pad placement, waveform capnography, and refractory VF strategies.","section":"ed","title":"ACLS \u0026 Cardiac Arrest — Part 1: BLS Foundation, High-Quality CPR \u0026 Defibrillation","url":"/ed/guidelines/acls-cardiac-arrest/acls-cardiac-arrest-part-1-bls-foundation-high-quality-cpr-defibrillation/"},{"content":"1. Systematic Approach to Acute Abdominal Pain 1.1 Overview Acute abdominal pain is the most common reason for surgical consultation in the emergency department, representing approximately 5% to 10% of all ED visits. The differential diagnosis ranges from benign, self-limited conditions to life-threatening surgical emergencies. A structured, systematic approach that integrates history, physical examination, laboratory evaluation, and targeted imaging is essential for accurate diagnosis and …","description":"Structured approach to acute abdominal pain evaluation including history, physical exam, differential diagnosis by pain location, laboratory and imaging strategy, and comprehensive appendicitis management with Alvarado score, AIR score, and CODA trial evidence.","section":"ed","title":"Acute Abdominal Emergencies — Part 1: Systematic Approach to Acute Abdominal Pain \u0026 Appendicitis","url":"/ed/guidelines/acute-abdominal-emergencies/acute-abdominal-emergencies-part-1-systematic-approach-to-acute-abdominal-pain-appendicitis/"},{"content":"1. Principles of Airway Assessment 1.1 Overview Every patient who may require airway management should undergo a rapid, structured assessment to identify features that predict difficulty with laryngoscopy, bag-valve-mask (BVM) ventilation, supraglottic airway (SGA) placement, and front-of-neck access (FONA).1 2 No single predictor reliably identifies all difficult airways; therefore, a multi-dimensional assessment incorporating several validated tools is recommended. In the emergency setting, …","description":"LEMON assessment, Mallampati classification, Cormack-Lehane grading, MOANS/RODS/SHORT mnemonics, 3-3-2 rule, standard preoxygenation, HFNC apneic oxygenation, NIV preoxygenation, and optimal patient positioning.","section":"ed","title":"Acute Airway Management \u0026 RSI — Part 1: Airway Assessment \u0026 Preoxygenation","url":"/ed/guidelines/airway-management-rsi/acute-airway-management-rsi-part-1-airway-assessment-preoxygenation/"},{"content":"1. The Acute Coronary Syndrome Spectrum 1.1 Overview Acute coronary syndromes (ACS) encompass a spectrum of clinical presentations resulting from acute myocardial ischemia, unified by a common pathophysiology — disruption of a coronary atherosclerotic plaque with superimposed thrombosis, leading to reduction or cessation of myocardial blood flow. The ACS spectrum is classified into three categories based on ECG findings and biomarker status:1 2\nCategory ECG Finding Troponin Pathology STEMI …","description":"ACS spectrum definitions, Fourth Universal Definition of MI (Types 1-5), pathophysiology, initial ED evaluation, 12-lead ECG interpretation, STEMI criteria by territory, STEMI equivalents, and right ventricular MI.","section":"ed","title":"Acute Coronary Syndromes — Part 1: Definitions, Pathophysiology \u0026 Initial Evaluation","url":"/ed/guidelines/acute-coronary-syndromes/acute-coronary-syndromes-part-1-definitions-pathophysiology-initial-evaluation/"},{"content":"1. Definition of Acute Kidney Injury 1.1 Conceptual Framework Acute kidney injury (AKI) is defined as an abrupt decline in kidney function, occurring over hours to days, resulting in the retention of nitrogenous waste products (urea, creatinine), dysregulation of extracellular fluid volume, and disruption of electrolyte and acid-base homeostasis. Unlike chronic kidney disease (CKD), AKI is considered at least partially reversible in most cases, though it is increasingly recognized that even …","description":"KDIGO AKI definition and staging criteria, RIFLE and AKIN historical comparison, novel biomarkers (NGAL, KIM-1, NephroCheck), subclinical AKI, ICU epidemiology, and outcomes by stage.","section":"icu","title":"Acute Kidney Injury — Part 1: Definition, Staging \u0026 Epidemiology","url":"/icu/guidelines/acute-kidney-injury-rrt/acute-kidney-injury-part-1-definition-staging-epidemiology/"},{"content":"1. Pain Assessment in the Emergency Department Pain is the most common reason patients present to the emergency department, with estimates ranging from 60% to 78% of all ED visits involving a pain complaint. Accurate, timely, and repeated pain assessment is the foundation upon which all analgesic decision-making rests. Failure to assess pain consistently leads to oligoanalgesia — one of the most well-documented quality gaps in emergency medicine.1 2 3\n1.1 Principles of ED Pain Assessment Pain is …","description":"Pain assessment scales (NRS, VAS, FACES, FLACC, PAINAD), oligoanalgesia prevention, and first-line non-opioid analgesics including acetaminophen, NSAIDs, subdissociative ketamine, IV lidocaine, trigger point injections, and nitrous oxide.","section":"ed","title":"Acute Pain \u0026 Procedural Sedation — Part 1: Pain Assessment \u0026 Non-Opioid Analgesics","url":"/ed/guidelines/acute-pain-procedural-sedation/acute-pain-procedural-sedation-part-1-pain-assessment-non-opioid-analgesics/"},{"content":"1. Stroke Classification and Pathophysiology 1.1 Ischemic Stroke (87% of All Strokes) Ischemic stroke results from occlusion of a cerebral artery, leading to focal brain ischemia and infarction. The ischemic penumbra — tissue surrounding the infarct core that is hypoperfused but potentially salvageable — forms the basis for all acute reperfusion therapies.1\nSubtypes by Mechanism (TOAST Classification) Subtype Mechanism Proportion Key Features Large artery atherosclerosis Atherothrombosis or …","description":"Stroke types, prehospital stroke scales (CPSS, LAMS, RACE, FAST-ED), complete NIHSS scoring, focused history, laboratory evaluation, and neuroimaging (NCCT, CTA, CTP, MRI/DWI, ASPECTS).","section":"ed","title":"Acute Stroke Management — Part 1: Prehospital Recognition, ED Evaluation \u0026 Neuroimaging","url":"/ed/guidelines/acute-stroke/acute-stroke-management-part-1-prehospital-recognition-ed-evaluation-neuroimaging/"},{"content":"1. Nutritional Assessment in the ICU 1.1 Importance of Nutritional Assessment Malnutrition in the critically ill is independently associated with increased morbidity and mortality. Unlike ward patients, ICU patients often cannot participate in subjective assessment tools (e.g., Subjective Global Assessment), making validated screening instruments essential. The primary goals of nutritional assessment in the ICU are to:1 2\nIdentify patients at high nutritional risk who will benefit most from …","description":"Comprehensive guide to nutrition screening tools (NUTRIC score, NRS-2002, mNUTRIC), limitations of traditional biomarkers, body composition assessment, indirect calorimetry, predictive equations, caloric and protein targets, and obesity adjustments in the critically ill adult.","section":"icu","title":"Nutrition in Critical Illness — Part 1: Nutritional Assessment \u0026 Energy/Protein Requirements","url":"/icu/guidelines/nutrition-critical-illness/nutrition-in-critical-illness-part-1-nutritional-assessment-energy/protein-requirements/"},{"content":"The ABCDEF Bundle: A Framework for ICU Liberation The ABCDEF bundle is an evidence-based, interprofessional approach to managing the interrelated domains of pain, sedation, delirium, immobility, and sleep in critically ill patients. Each element is complementary, and maximal benefit is achieved when all components are implemented together with high fidelity.1 2\nBundle Components Letter Domain Core Intervention A Assess, Prevent, and Manage Pain Routine pain assessment with validated tools; …","description":"The ABCDEF bundle framework for ICU liberation, comprehensive pain assessment tools (BPS, CPOT, NRS) with complete scoring tables, and evidence-based analgesic management including opioid dosing, non-opioid adjuncts, and multimodal protocols.","section":"icu","title":"Part 1: ABCDEF Bundle Overview \u0026 Pain Assessment and Management","url":"/icu/guidelines/sedation-analgesia-delirium/part-1-abcdef-bundle-overview-pain-assessment-and-management/"},{"content":"1. Acute Respiratory Distress Syndrome: Definition and Classification 1.1 The Berlin Definition The internationally accepted definition of ARDS was established by a consensus task force in 2012 and is known as the Berlin Definition.1 This classification replaced the prior American-European Consensus Conference (AECC) definition from 1994, which used the terms acute lung injury (ALI) and ARDS. The Berlin Definition eliminated the ALI category and introduced three mutually exclusive severity …","description":"Berlin criteria for ARDS severity classification, initial ventilator mode selection, lung-protective tidal volume targets, ideal body weight calculations, plateau and driving pressure limits, ARDSNet PEEP/FiO2 tables, respiratory rate management, and permissive hypercapnia.","section":"icu","title":"Part 1: ARDS Definition and Initial Ventilator Setup","url":"/icu/guidelines/mechanical-ventilation-ards/part-1-ards-definition-and-initial-ventilator-setup/"},{"content":"1. Definitions 1.1 Central Line (Central Venous Catheter) A central line is defined as an intravascular catheter that terminates at or close to the heart or in one of the great vessels and is used for infusion, blood withdrawal, or hemodynamic monitoring. For the purpose of surveillance, the great vessels include the superior vena cava, inferior vena cava, brachiocephalic veins, internal jugular veins, subclavian veins, external iliac veins, common iliac veins, femoral veins, and — in neonates — …","description":"CLABSI and CRBSI definitions, NHSN surveillance criteria, mucosal barrier injury CLABSI, epidemiology by ICU type, attributable mortality and costs, pathogenesis of catheter colonization, microbiology, and risk factors.","section":"icu","title":"Part 1: Definitions, Epidemiology \u0026 Pathogenesis","url":"/icu/guidelines/clabsi-prevention/part-1-definitions-epidemiology-pathogenesis/"},{"content":"1. Pediatric Vital Signs by Age Pediatric vital signs vary dramatically with age, and failure to recognize age-specific normal ranges is a common source of missed deterioration. The following table provides comprehensive normal ranges for heart rate, respiratory rate, systolic blood pressure, and estimated weight from the neonatal period through adolescence. Values represent approximate 5th-95th percentile ranges for resting, afebrile children.1 2\n1.1 Complete Vital Signs Reference Table Age …","description":"Pediatric vital signs by age, pediatric assessment triangle, weight estimation, PALS algorithms for pulseless arrest, bradycardia, and tachycardia, weight-based medication dosing, defibrillation energy, and equipment sizing.","section":"ed","title":"Pediatric Emergencies — Part 1: Pediatric Assessment \u0026 Resuscitation (PALS)","url":"/ed/guidelines/pediatric-emergencies/pediatric-emergencies-part-1-pediatric-assessment-resuscitation-pals/"},{"content":"1. Post-Cardiac Arrest Syndrome — Overview The post-cardiac arrest syndrome is a unique and complex pathophysiological state that encompasses the sequelae of whole-body ischemia and reperfusion following return of spontaneous circulation (ROSC). First formally described in 2008 by a joint consensus statement from the major international resuscitation and critical care societies, this syndrome comprises four interrelated components that drive the high morbidity and mortality observed in the …","description":"Pathophysiology of post-cardiac arrest syndrome, airway and ventilation targets, hemodynamic optimization, coronary angiography indications, and initial workup after ROSC.","section":"icu","title":"Post-Cardiac Arrest Care — Part 1: Post-Cardiac Arrest Syndrome \u0026 Initial Post-ROSC Management","url":"/icu/guidelines/post-cardiac-arrest-ttm/post-cardiac-arrest-care-part-1-post-cardiac-arrest-syndrome-initial-post-rosc-management/"},{"content":"1. Evolution of Sepsis Definitions 1.1 Historical Context The conceptual framework for sepsis has undergone significant evolution over the past three decades. The original consensus conference in 1991 introduced the systemic inflammatory response syndrome (SIRS) paradigm, which defined sepsis as SIRS in the presence of suspected or confirmed infection.1 While this framework was widely adopted and formed the basis of clinical practice for over two decades, it was increasingly recognized as …","description":"Sepsis-3 definitions, SOFA and qSOFA scoring, septic shock criteria, comparison with SIRS/Sepsis-2, and screening tools (NEWS, MEWS, qSOFA, SIRS) with sensitivity and specificity data.","section":"icu","title":"Sepsis and Septic Shock — Part 1: Definitions, Screening \u0026 Early Identification","url":"/icu/guidelines/sepsis-septic-shock/sepsis-and-septic-shock-part-1-definitions-screening-early-identification/"},{"content":"1. Initial Approach to the Poisoned Patient 1.1 Scene Safety and Information Gathering The initial assessment of a poisoned patient begins with simultaneous stabilization and information gathering. Critical data sources include emergency medical services personnel, family members, pill bottles or containers found at the scene, pharmacy records, and the patient\u0026amp;rsquo;s own report when obtainable. However, the history in overdose is notoriously unreliable — the agent, quantity, timing, and intent …","description":"Initial approach to the poisoned patient including toxidrome recognition, diagnostic workup, toxicology screen interpretation, and gastrointestinal decontamination strategies including activated charcoal, whole bowel irrigation, gastric lavage, and multi-dose activated charcoal.","section":"ed","title":"Toxicology and Overdose Management — Part 1: General Approach, Toxidrome Recognition \u0026 GI Decontamination","url":"/ed/guidelines/toxicology-overdose/toxicology-and-overdose-management-part-1-general-approach-toxidrome-recognition-gi-decontamination/"},{"content":"1. Introduction: The Shift to Restrictive Transfusion Red blood cell transfusion is one of the most frequently performed therapeutic interventions in the intensive care unit. Historically, a liberal transfusion strategy maintaining hemoglobin above 10 g/dL (the so-called \u0026amp;ldquo;10/30 rule\u0026amp;rdquo; — hemoglobin 10 g/dL or hematocrit 30%) was standard practice for decades despite a lack of evidence supporting this threshold.1 Over the past 25 years, a robust body of randomized controlled trial …","description":"Evidence-based hemoglobin thresholds for RBC transfusion in the critically ill, landmark trial evidence (TRICC, TRISS, FOCUS, TITRe2, TRICS-III), physiologic triggers, single-unit policy, compatibility testing, and storage considerations.","section":"icu","title":"Transfusion in Critical Care — Part 1: Red Blood Cell Transfusion","url":"/icu/guidelines/transfusion-critical-care/transfusion-in-critical-care-part-1-red-blood-cell-transfusion/"},{"content":"1. Trauma Team Activation 1.1 Principles of Team Activation Trauma team activation (TTA) is a structured response system designed to ensure that critically injured patients are met by a prepared, multidisciplinary team upon arrival to the trauma center. Most verified trauma centers employ a two-tier (or multi-tier) activation system to allocate resources proportionally to injury severity, reserving full team mobilization for the most critically injured patients while still providing an organized …","description":"Two-tier trauma team activation criteria, CDC field triage, and complete ABCDE primary survey including airway with C-spine protection, breathing and ventilation, circulation with hemorrhage control, disability assessment with GCS, and exposure/environment.","section":"ed","title":"Trauma Primary and Secondary Survey — Part 1: Trauma Team Activation \u0026 Primary Survey (ABCDE)","url":"/ed/guidelines/trauma-primary-secondary-survey/trauma-primary-and-secondary-survey-part-1-trauma-team-activation-primary-survey-abcde/"},{"content":"1. Glasgow Coma Scale The Glasgow Coma Scale (GCS) remains the most widely used clinical tool for standardized assessment of consciousness after traumatic brain injury. Originally described in 1974 and subsequently refined, the GCS evaluates three independent behavioral responses — eye opening, verbal response, and motor response — yielding a composite score from 3 (deepest coma) to 15 (fully alert).1\n1.1 Complete GCS Scoring Table Component Response Score Eye Opening (E) Spontaneous 4 To voice …","description":"GCS scoring, TBI severity classification, Canadian CT Head Rule, New Orleans Criteria, PECARN pediatric head CT algorithm, and comparison of imaging decision rules with sensitivity and specificity data.","section":"ed","title":"Traumatic Brain Injury — Part 1: Classification \u0026 CT Imaging Decision Rules","url":"/ed/guidelines/traumatic-brain-injury/traumatic-brain-injury-part-1-classification-ct-imaging-decision-rules/"},{"content":"1. Definitions 1.1 Ventilator-Associated Pneumonia — Clinical Definition Ventilator-associated pneumonia (VAP) is defined as pneumonia that develops in a patient who has been mechanically ventilated (via endotracheal tube or tracheostomy) for at least 48 hours at the time of diagnosis, where the pneumonia was neither present nor incubating at the time of intubation.12\nThe clinical diagnosis of VAP requires the presence of:\nA new or progressive radiographic infiltrate (chest radiograph or CT), …","description":"Clinical and surveillance definitions of VAP, the VAE tier system (VAC, IVAC, PVAP), HAP versus VAP distinction, epidemiology including incidence and mortality data, pathogenesis of aspiration and biofilm formation, and modifiable and non-modifiable risk factors.","section":"icu","title":"Ventilator-Associated Pneumonia — Part 1: Definitions, Epidemiology, Pathogenesis \u0026 Risk Factors","url":"/icu/guidelines/ventilator-associated-pneumonia/ventilator-associated-pneumonia-part-1-definitions-epidemiology-pathogenesis-risk-factors/"},{"content":"Epidemiology of VTE in Critical Illness Incidence Venous thromboembolism — encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE) — is one of the most common preventable complications of hospitalization. In the intensive care unit, the convergence of multiple risk factors creates a uniquely high-risk environment.1 2\nPopulation DVT Incidence (Without Prophylaxis) DVT Incidence (With Prophylaxis) Clinically Detected PE General medical ICU 25–31% 5–15% 2–8% Surgical ICU 15–40% 5–10% …","description":"Incidence and pathophysiology of VTE in critically ill patients, comprehensive ICU risk factors, and complete risk assessment scoring systems including Padua Prediction Score, Caprini Score, and IMPROVE Score.","section":"icu","title":"VTE Prophylaxis in Critical Care — Part 1: Epidemiology, Risk Factors \u0026 Risk Assessment","url":"/icu/guidelines/vte-prophylaxis-critical-care/vte-prophylaxis-in-critical-care-part-1-epidemiology-risk-factors-risk-assessment/"},{"content":"Pain Screening Every patient with cancer should be screened for pain at each clinical encounter. Pain screening is a rapid, standardized process designed to identify patients who require a more detailed pain assessment. Professional oncology and palliative care organizations universally recommend routine pain screening as a fundamental component of quality cancer care.1\nRecommended Screening Frequency Clinical Setting Screening Frequency Outpatient oncology visits Every visit Inpatient admission …","description":"Comprehensive pain assessment tools, classification systems, and cancer-specific pain syndromes for systematic evaluation of pain in oncology patients.","section":"oncology","title":"Cancer Pain Management — Part 1: Pain Assessment and Classification","url":"/oncology/guidelines/cancer-pain-management/cancer-pain-management-part-1-pain-assessment-and-classification/"},{"content":"Epidemiology of Cancer-Associated Thrombosis Venous thromboembolism (VTE) is a major complication in patients with cancer, occurring in approximately 4-20% of patients depending on cancer type, stage, and treatment modality. Cancer-associated thrombosis (CAT) represents the second leading cause of death in ambulatory cancer patients receiving chemotherapy, after the malignancy itself.1\nIncidence and Impact The overall incidence of VTE in cancer patients is estimated at 0.5-2% per year, compared …","description":"Pathophysiology of cancer-associated thrombosis, Virchow's triad in malignancy, and validated VTE risk assessment models including the Khorana score, Vienna CATS score, PROTECHT score, and ONKOTEV score with complete scoring tables.","section":"oncology","title":"Cancer-Associated Thrombosis — Part 1: Pathophysiology and Risk Assessment","url":"/oncology/guidelines/cancer-associated-thrombosis/cancer-associated-thrombosis-part-1-pathophysiology-and-risk-assessment/"},{"content":"1. Introduction to Agent Classification The tissue damage potential of antineoplastic agents following extravasation is the primary determinant of clinical urgency, management approach, and patient outcome. International expert panels and professional societies classify intravenous chemotherapy agents into three categories based on their capacity to cause local tissue injury when they escape the vascular compartment.123\n1.1 Definitions Vesicant agents are drugs capable of causing tissue …","description":"Complete classification of antineoplastic agents by tissue damage potential (vesicants, irritants, non-vesicants), comprehensive risk factor analysis, and evidence-based prevention strategies including vein selection, device selection, and monitoring protocols.","section":"oncology","title":"Chemotherapy Extravasation — Part 1: Agent Classification, Risk Factors, and Prevention","url":"/oncology/guidelines/chemotherapy-extravasation/chemotherapy-extravasation-part-1-agent-classification-risk-factors-and-prevention/"},{"content":"Pathophysiology of Chemotherapy-Induced Emesis Chemotherapy-induced nausea and vomiting results from activation of multiple neural pathways. Understanding these pathways is essential for rational antiemetic selection.\nEmetic Reflex Arc The vomiting center — a functional region in the lateral medullary reticular formation — coordinates the emetic reflex. It receives afferent input from four principal sources:1\nChemoreceptor trigger zone (CTZ): Located in the area postrema on the floor of the …","description":"Complete emetogenic risk classification of intravenous and oral chemotherapy agents (high, moderate, low, minimal), types of CINV, pathophysiology of chemotherapy-induced emesis, and patient- and treatment-related risk factors.","section":"oncology","title":"CINV Guideline — Part 1: Emetogenic Classification and Risk Factors","url":"/oncology/guidelines/cinv-prevention/cinv-guideline-part-1-emetogenic-classification-and-risk-factors/"},{"content":"1. Definition of Febrile Neutropenia 1.1 Standard Definition Febrile neutropenia (FN) is defined by the concurrent presence of fever and neutropenia in a patient receiving myelosuppressive therapy.1 2\nFever is defined as:\nA single oral temperature of ≥ 38.3 °C (101.0 °F), OR A sustained oral temperature of ≥ 38.0 °C (100.4 °F) for ≥ 1 hour Neutropenia is defined as:\nAn absolute neutrophil count (ANC) of \u0026amp;lt; 500 cells/μL, OR An ANC of \u0026amp;lt; 1,000 cells/μL with a predicted decline to \u0026amp;lt; 500 …","description":"Definitions of febrile neutropenia, MASCC risk index, CISNE score, high-risk versus low-risk classification, and comprehensive initial workup including history, physical examination, laboratory studies, blood cultures, and imaging.","section":"oncology","title":"Febrile Neutropenia — Part 1: Definition, Risk Stratification \u0026 Initial Evaluation","url":"/oncology/guidelines/febrile-neutropenia/febrile-neutropenia-part-1-definition-risk-stratification-initial-evaluation/"},{"content":"Classes of Immune Checkpoint Inhibitors Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block inhibitory receptors on T cells or their ligands on tumor cells and antigen-presenting cells. By releasing these \u0026amp;ldquo;brakes\u0026amp;rdquo; on the adaptive immune system, ICIs restore T-cell-mediated antitumor immunity. The currently approved classes and agents are summarized below.1 2\nAnti-PD-1 (Programmed Death-1) Inhibitors PD-1 is an inhibitory receptor expressed on activated T cells. …","description":"Classes of immune checkpoint inhibitors, mechanism and epidemiology of irAEs, CTCAE grading, general management framework, corticosteroid protocols, immunosuppressive escalation, and infusion reactions.","section":"oncology","title":"Immune Checkpoint Inhibitor Adverse Event Management — Part 1: Overview of Checkpoint Inhibitors and General Principles of irAE Management","url":"/oncology/guidelines/immunotherapy-adverse-events/immune-checkpoint-inhibitor-adverse-event-management-part-1-overview-of-checkpoint-inhibitors-and-general-principles-of-irae-management/"},{"content":"1. Survivorship Care Plans 1.1 Definition and Rationale A survivorship care plan (SCP) is a formal document provided to cancer survivors at the completion of active treatment. It serves as both a summary of the treatment received and a forward-looking roadmap for ongoing surveillance, health maintenance, and management of potential late effects. Major professional societies recommend that every patient completing curative-intent cancer treatment receive a personalized SCP, ideally developed …","description":"Survivorship care plan components, structure, and evidence-based surveillance schedules for recurrence monitoring in breast, colorectal, prostate, lung, lymphoma, and head and neck cancer survivors.","section":"oncology","title":"Oncology Survivorship Care — Part 1: Survivorship Care Plans and Surveillance by Cancer Type","url":"/oncology/guidelines/survivorship-care/oncology-survivorship-care-part-1-survivorship-care-plans-and-surveillance-by-cancer-type/"},{"content":"1. Pathobiology of Mucositis 1.1 Overview Mucositis was historically viewed as a simple, inevitable consequence of cytotoxic damage to rapidly dividing mucosal epithelial cells. Contemporary understanding, based on the five-phase biological model, reveals mucositis to be a far more complex process involving multiple biological pathways, the submucosal and mucosal microenvironment, and intricate interactions between tissues, the immune system, and the oral/gastrointestinal microbiome.1 2\nThe …","description":"Five-phase pathobiology model of mucositis, comprehensive grading scales (WHO, NCI CTCAE, OMAS), treatment-related and patient-related risk factors, and pre-treatment dental assessment.","section":"oncology","title":"Oral and GI Mucositis — Part 1: Pathobiology, Grading Scales, and Risk Factors","url":"/oncology/guidelines/oral-gi-mucositis/oral-and-gi-mucositis-part-1-pathobiology-grading-scales-and-risk-factors/"},{"content":"1. Overview of Central Venous Access Devices in Oncology 1.1 Rationale for Central Venous Access in Cancer Patients The majority of systemic anticancer regimens require central venous access for safe and effective administration. Vesicant chemotherapy agents — including anthracyclines (doxorubicin, epirubicin), vinca alkaloids (vincristine, vinblastine, vinorelbine), nitrogen mustards, and taxanes — carry significant risk of tissue necrosis if extravasated through peripheral veins.12 Beyond …","description":"CVAD types and oncology-specific indications, patient assessment framework, vein selection in cancer patients, device selection algorithms, and special population considerations for central venous access in oncology.","section":"oncology","title":"Part 1: Device Selection and Patient Assessment","url":"/oncology/guidelines/central-venous-access/part-1-device-selection-and-patient-assessment/"},{"content":"1. Definition and Identification of Hazardous Drugs 1.1 Definition A hazardous drug (HD) is any drug that exhibits one or more of six specified characteristics based on established toxicological and clinical criteria. The definition encompasses far more than traditional cytotoxic chemotherapy — it includes hormonal agents, antiviral drugs, immunosuppressants, and other pharmaceutical classes that meet hazard thresholds.1\nA drug is classified as hazardous if it demonstrates any of the following …","description":"Hazardous drug definitions, NIOSH classification criteria, national drug list organization, exposure routes and health effects, facility risk assessment, and complete engineering control specifications including BSCs, CACIs, CSTDs, and ventilation requirements.","section":"oncology","title":"Safe Handling of Hazardous Drugs — Part 1: Drug Identification, Risk Assessment, and Engineering Controls","url":"/oncology/guidelines/hazardous-drug-handling/safe-handling-of-hazardous-drugs-part-1-drug-identification-risk-assessment-and-engineering-controls/"},{"content":"Clinical Practice Guidelines for Adults JANUARY SUPPLEMENT 2026 | VOLUME 31\nJournal of the Association for Vascular Access (JAVA)\nWith Gratitude The Association for Vascular Access (AVA) and the AVA Foundation extend sincere thanks to Solventum and BD for their generous grant support of the AVA Adult Clinical Practice Guidelines.\nThese grants supported the work of a professional research librarian who conducted two comprehensive systematic reviews forming the evidentiary foundation of the …","description":"Association for Vascular Access Adult Clinical Practice Guidelines (JAVA 2026, Vol. 31) — Part 1 covering guideline development, acknowledgments, foreword, introduction, and Sections 1–2: Infrastructure, Teams, Clinical Foundations, and Patient Assessment.","section":"vascular-access","title":"AVA CPG 2026 — Part 1: Guideline Development, Foreword \u0026 Introduction","url":"/vascular-access/guidelines/ava-clinical-practice-guidelines/ava-cpg-2026-part-1-guideline-development-foreword-introduction/"},{"content":"Purpose and Scope The guidelines committee (GLC) developed this handbook to define a uniform and rigorous methodology for use by sponsored writing groups that produce guidelines, expert guidance documents, consensus statements, and practice statements. This handbook is treated as a living document and may be revised at the committee\u0026amp;rsquo;s discretion.1\nThe handbook was first published in January 2016 and does not govern documents developed before that date. Subsequent revisions were completed …","description":"Purpose, definitions, proposal process, writing panel composition, systematic literature review, consensus methods, and review \u0026 approval procedures for infection prevention guideline development.","section":"infection-prevention","title":"IP Guideline Development Handbook — Part 1: Development Process","url":"/infection-prevention/guidelines/guideline-development-handbook/ip-guideline-development-handbook-part-1-development-process/"},{"content":"This section covers infection management in adults with sepsis and septic shock, including the timing and approach to antimicrobial therapy stratified by diagnostic certainty, prehospital antibiotic administration, source control, empiric coverage for multidrug-resistant pathogens and anaerobic organisms, antifungal therapy, rapid diagnostic tests, prolonged beta-lactam infusion, therapeutic drug monitoring, antimicrobial de-escalation and discontinuation, and selective decontamination of the …","description":"Surviving Sepsis Campaign 2026 recommendations for antimicrobial timing by diagnostic certainty, prehospital antibiotics, source control, empiric MDR and antifungal coverage, anaerobic coverage, rapid diagnostics, prolonged beta-lactam infusion, therapeutic drug monitoring, de-escalation, procalcitonin-guided discontinuation, and selective decontamination of the digestive tract.","section":"icu","title":"SSC 2026 — Part 2: Infection — Antimicrobial Therapy \u0026 Source Control","url":"/icu/guidelines/surviving-sepsis-campaign-2026/ssc-2026-part-2-infection-antimicrobial-therapy-source-control/"},{"content":"This section covers source control, fluid resuscitation, and hemodynamic management in pediatric sepsis and septic shock, including emergent source control interventions, intravascular access device removal, fluid bolus volumes and targets, fluid management in settings with and without ICU availability, crystalloid selection, clinical hemodynamic assessment, ScvO2 monitoring, advanced hemodynamic monitoring, and point-of-care ultrasound-guided resuscitation. These recommendations apply to …","description":"Surviving Sepsis Campaign 2026 pediatric recommendations for emergent source control, intravascular device removal, fluid bolus therapy in septic shock, fluid therapy in non-ICU settings, balanced crystalloids vs saline, hemodynamic assessment, ScvO2 targeting, advanced monitoring, and point-of-care ultrasound in pediatric sepsis.","section":"icu","title":"SSC Children 2026 — Part 2: Source Control, Fluid Therapy \u0026 Hemodynamic Management","url":"/icu/guidelines/surviving-sepsis-campaign-children-2026/ssc-children-2026-part-2-source-control-fluid-therapy-hemodynamic-management/"},{"content":"1. Cardiac Arrest Algorithm — Overview The cardiac arrest algorithm is initiated when a patient is confirmed to be in cardiac arrest (unresponsive, no normal breathing, no pulse). The algorithm immediately bifurcates based on whether the presenting rhythm is shockable (ventricular fibrillation or pulseless ventricular tachycardia) or non-shockable (asystole or pulseless electrical activity). The universal first step, regardless of rhythm, is the initiation of high-quality CPR.1 2 3\n1.1 Initial …","description":"VF/pVT and asystole/PEA algorithms, H's and T's reversible causes, epinephrine, amiodarone, lidocaine, sodium bicarbonate, calcium, magnesium, lipid emulsion, and advanced airway management during arrest.","section":"ed","title":"ACLS \u0026 Cardiac Arrest — Part 2: Cardiac Arrest Algorithms \u0026 ACLS Pharmacotherapy","url":"/ed/guidelines/acls-cardiac-arrest/acls-cardiac-arrest-part-2-cardiac-arrest-algorithms-acls-pharmacotherapy/"},{"content":"3. Acute Cholecystitis 3.1 Epidemiology and Pathophysiology Acute cholecystitis accounts for 3% to 10% of all patients presenting with abdominal pain. Approximately 90% to 95% of cases are calculous (gallstone-related), resulting from cystic duct obstruction by a gallstone leading to gallbladder distension, wall inflammation, and secondary bacterial infection. Acalculous cholecystitis (5–10% of cases) occurs predominantly in critically ill patients, the elderly, immunocompromised individuals, …","description":"Comprehensive guide to acute cholecystitis with Tokyo Guidelines severity grading, cholangitis management, ERCP indications, and acute pancreatitis with Revised Atlanta Classification, BISAP score, Ranson criteria, CTSI/Balthazar score, fluid resuscitation, nutrition, and necrotizing pancreatitis management.","section":"ed","title":"Acute Abdominal Emergencies — Part 2: Acute Cholecystitis, Cholangitis \u0026 Acute Pancreatitis","url":"/ed/guidelines/acute-abdominal-emergencies/acute-abdominal-emergencies-part-2-acute-cholecystitis-cholangitis-acute-pancreatitis/"},{"content":"1. Rapid Sequence Intubation: Definition and Rationale Rapid sequence intubation (RSI) is the near-simultaneous administration of a potent induction (sedative-hypnotic) agent and a neuromuscular blocking agent to produce rapid onset of unconsciousness and complete neuromuscular paralysis for the purpose of tracheal intubation.1 2 RSI is the technique of choice for emergency intubation in patients who have not fasted and are at risk for aspiration of gastric contents. It differs from standard …","description":"Complete RSI protocol including preparation, pretreatment agents, induction agents with dosing tables, neuromuscular blocking agents with contraindications and reversal, paralysis verification, post-intubation sedation, confirmation of intubation, awake intubation, and drug-assisted intubation without paralysis.","section":"ed","title":"Acute Airway Management \u0026 RSI — Part 2: RSI Protocol \u0026 Medications","url":"/ed/guidelines/airway-management-rsi/acute-airway-management-rsi-part-2-rsi-protocol-medications/"},{"content":"1. Cardiac Troponin — The Biomarker of Myocardial Necrosis 1.1 Biology of Cardiac Troponin Cardiac troponins are structural proteins of the sarcomere that regulate calcium-mediated contraction of cardiac myocytes. The troponin complex consists of three subunits:1\nTroponin C (TnC): Binds calcium; identical isoform in cardiac and skeletal muscle — not used as a cardiac biomarker Troponin I (cTnI): Inhibits actin-myosin interaction; cardiac-specific isoform distinct from skeletal muscle Troponin T …","description":"Troponin biology, high-sensitivity troponin algorithms (0/1h and 0/3h), HEART score, TIMI risk scores, GRACE score, HEART Pathway, and chest pain observation pathways.","section":"ed","title":"Acute Coronary Syndromes — Part 2: Cardiac Biomarkers \u0026 Risk Stratification","url":"/ed/guidelines/acute-coronary-syndromes/acute-coronary-syndromes-part-2-cardiac-biomarkers-risk-stratification/"},{"content":"1. Etiology of AKI in Critical Care 1.1 Classification by Anatomic Site AKI is traditionally classified according to the anatomic site of the predominant pathology. In critically ill patients, multiple mechanisms frequently coexist (e.g., sepsis-induced hemodynamic compromise superimposed on nephrotoxin exposure), and the traditional \u0026amp;ldquo;pre-renal / intrinsic / post-renal\u0026amp;rdquo; framework — while clinically useful — represents a simplification of complex, overlapping pathophysiology.1 2\n1.2 …","description":"Pre-renal, intrinsic, and post-renal AKI causes; diagnostic workup including urinalysis, FENa, FEUrea, and imaging; prevention strategies; nephrotoxin avoidance; contrast-associated AKI evidence; drug dose adjustment table.","section":"icu","title":"Acute Kidney Injury — Part 2: Etiology, Diagnostic Workup \u0026 Prevention","url":"/icu/guidelines/acute-kidney-injury-rrt/acute-kidney-injury-part-2-etiology-diagnostic-workup-prevention/"},{"content":"3. Opioid Analgesics Opioids remain an important component of the ED analgesic armamentarium for moderate-to-severe pain that is refractory to non-opioid therapies. However, the contemporary approach positions opioids as second- or third-line agents in most clinical scenarios, used at the lowest effective dose for the shortest duration necessary. The emergency department has been identified as a significant contributor to new persistent opioid use — studies show that 6–8% of opioid-naive …","description":"Opioid dosing tables, equianalgesic conversions, intranasal fentanyl, opioid stewardship, risk assessment tools, ultrasound-guided nerve blocks, local anesthetic agents, and LAST protocol.","section":"ed","title":"Acute Pain \u0026 Procedural Sedation — Part 2: Opioid Analgesics \u0026 Regional Anesthesia in the ED","url":"/ed/guidelines/acute-pain-procedural-sedation/acute-pain-procedural-sedation-part-2-opioid-analgesics-regional-anesthesia-in-the-ed/"},{"content":"1. Intravenous Thrombolysis — Overview Intravenous thrombolysis with alteplase remains the cornerstone of acute ischemic stroke treatment. The landmark National Institute of Neurological Disorders and Stroke (NINDS) trial, published in 1995, established that IV alteplase administered within 3 hours of symptom onset significantly improves functional outcomes at 90 days, despite a 6.4% absolute increase in symptomatic intracerebral hemorrhage. The European Cooperative Acute Stroke Study III …","description":"Alteplase and tenecteplase dosing, complete inclusion/exclusion criteria for 0-3h and 3-4.5h windows, blood pressure management peri-thrombolysis, orolingual angioedema, and hemorrhagic transformation.","section":"ed","title":"Acute Stroke Management — Part 2: Intravenous Thrombolysis","url":"/ed/guidelines/acute-stroke/acute-stroke-management-part-2-intravenous-thrombolysis/"},{"content":"1. Early Enteral Nutrition — Timing and Rationale 1.1 Recommendation Enteral nutrition (EN) should be initiated within 24 to 48 hours of ICU admission in critically ill patients who are unable to maintain volitional oral intake, provided they are hemodynamically stable (i.e., mean arterial pressure is at target with stable or decreasing vasopressor doses, and no active titration of fluid resuscitation).1 2 3\n1.2 Physiological Rationale for Early EN Early enteral feeding exerts benefits beyond …","description":"Comprehensive guide to enteral nutrition in the critically ill: timing of initiation, gastric vs post-pyloric access, advancement protocols, formula selection, gastric residual volume management, prokinetic agents, complications including aspiration and refeeding syndrome, and EN during prone positioning and vasopressor therapy.","section":"icu","title":"Nutrition in Critical Illness — Part 2: Enteral Nutrition","url":"/icu/guidelines/nutrition-critical-illness/nutrition-in-critical-illness-part-2-enteral-nutrition/"},{"content":"Sedation Assessment Routine, validated sedation assessment is the foundation of optimal sedation management. Sedation depth should be assessed at least every 2–4 hours and more frequently during titration (every 15–30 minutes). The two recommended scales are the Richmond Agitation-Sedation Scale (RASS) and the Sedation-Agitation Scale (SAS).1 2\nRichmond Agitation-Sedation Scale (RASS) — Complete Scoring Table The RASS is a 10-point scale ranging from −5 (unarousable) to +4 (combative). It is the …","description":"Comprehensive sedation assessment (RASS, SAS complete scoring tables), light sedation targets, sedative agent pharmacology and dosing (propofol, dexmedetomidine, midazolam, ketamine), propofol infusion syndrome, daily sedation interruption protocols, and nurse-driven sedation algorithms.","section":"icu","title":"Part 2: Agitation and Sedation Assessment and Management","url":"/icu/guidelines/sedation-analgesia-delirium/part-2-agitation-and-sedation-assessment-and-management/"},{"content":"1. The Bundle Concept The concept of a \u0026amp;ldquo;bundle\u0026amp;rdquo; — a structured set of evidence-based interventions that, when implemented together and reliably, produce significantly better outcomes than when any element is used individually — was pioneered by a major healthcare improvement organization for CLABSI prevention and has become a cornerstone of patient safety worldwide.12\nThe fundamental principle is all-or-none compliance: partial implementation of bundle elements yields suboptimal …","description":"Evidence-based insertion bundle components (hand hygiene, maximal sterile barriers, chlorhexidine antisepsis, site selection, daily necessity review) and maintenance bundle components (hub disinfection, CHG bathing, dressing management, needleless connectors, administration set changes) with supporting evidence.","section":"icu","title":"Part 2: Insertion Bundle \u0026 Maintenance Bundle","url":"/icu/guidelines/clabsi-prevention/part-2-insertion-bundle-maintenance-bundle/"},{"content":"5. Prone Positioning in ARDS 5.1 Physiological Rationale Prone positioning (placing the patient face-down) improves oxygenation and reduces mortality in severe ARDS through several complementary mechanisms:12\nImproved ventilation-perfusion matching: In the supine position, the dependent (dorsal) lung regions are compressed by the weight of the heart, mediastinum, and abdominal contents, causing atelectasis and shunt. When prone, gravitational redistribution allows recruitment of these dorsal …","description":"Indications, protocols, and evidence for prone positioning in ARDS based on the PROSEVA trial, procedural checklists and contraindications, neuromuscular blockade evidence from ACURASYS and ROSE trials, train-of-four monitoring, and current recommendations.","section":"icu","title":"Part 2: Prone Positioning and Neuromuscular Blockade","url":"/icu/guidelines/mechanical-ventilation-ards/part-2-prone-positioning-and-neuromuscular-blockade/"},{"content":"1. Croup (Laryngotracheobronchitis) Croup is the most common cause of acute upper airway obstruction in children aged 6 months to 6 years, with a peak incidence at 1 to 2 years of age. It is caused by viral infection (most commonly parainfluenza types 1 and 3, but also RSV, influenza, adenovirus, and human metapneumovirus) producing inflammation and edema of the subglottic airway. The hallmark triad of barky (seal-like) cough, inspiratory stridor, and hoarseness is usually preceded by 1-3 days …","description":"Croup scoring and management, bronchiolitis evaluation and supportive care, acute asthma severity classification and stepwise treatment, anaphylaxis recognition and epinephrine dosing, and foreign body aspiration management.","section":"ed","title":"Pediatric Emergencies — Part 2: Pediatric Respiratory Emergencies","url":"/ed/guidelines/pediatric-emergencies/pediatric-emergencies-part-2-pediatric-respiratory-emergencies/"},{"content":"1. Historical Evolution of Temperature Management After Cardiac Arrest The concept of therapeutic hypothermia for neuroprotection after cardiac arrest has undergone significant evolution over the past two decades, shaped by a series of landmark clinical trials that have progressively refined our understanding of optimal temperature targets and the mechanisms by which temperature management benefits (or fails to benefit) post-arrest patients.1 2 3 4 5\n1.1 Timeline of Key Evidence Year Milestone …","description":"Complete TTM protocol including historical evolution, landmark trial evidence, temperature targets, cooling methods, shivering management, complications, and special populations.","section":"icu","title":"Post-Cardiac Arrest Care — Part 2: Targeted Temperature Management","url":"/icu/guidelines/post-cardiac-arrest-ttm/post-cardiac-arrest-care-part-2-targeted-temperature-management/"},{"content":"1. The Hour-1 Resuscitation Bundle In 2018, the international surviving sepsis working group consolidated the previous 3-hour and 6-hour bundles into a single hour-1 bundle, emphasizing that resuscitation should begin immediately upon sepsis recognition rather than being delayed by risk stratification or sequential assessments.1 2\n1.1 Hour-1 Bundle Components All five elements should be initiated within 1 hour of sepsis recognition. \u0026amp;ldquo;Initiated\u0026amp;rdquo; means that the process has begun — not …","description":"Hour-1 bundle components, fluid resuscitation strategy, crystalloid selection, fluid responsiveness assessment, vasopressor selection and dosing, inotrope use, hemodynamic monitoring, and lactate-guided resuscitation.","section":"icu","title":"Sepsis and Septic Shock — Part 2: Initial Resuscitation \u0026 Hemodynamic Management","url":"/icu/guidelines/sepsis-septic-shock/sepsis-and-septic-shock-part-2-initial-resuscitation-hemodynamic-management/"},{"content":"1. Acetaminophen (Paracetamol) Poisoning Acetaminophen is the most common cause of acute liver failure in the United States and many developed nations. The margin between the therapeutic ceiling (4 g/day in adults) and potentially hepatotoxic doses (\u0026amp;gt; 150 mg/kg or 7.5 g in adults, whichever is less) is relatively narrow, making this a frequent and high-stakes toxicologic presentation.1 2 3\n1.1 Mechanism of Hepatotoxicity At therapeutic doses, approximately 90% of acetaminophen is metabolized …","description":"Complete management of acetaminophen overdose (NAC protocols), salicylate poisoning (alkalinization, hemodialysis), opioid overdose (naloxone titration), benzodiazepine reversal (flumazenil), and sedative-hypnotic poisonings.","section":"ed","title":"Toxicology and Overdose Management — Part 2: Analgesic, Opioid, Benzodiazepine \u0026 Sedative Poisonings","url":"/ed/guidelines/toxicology-overdose/toxicology-and-overdose-management-part-2-analgesic-opioid-benzodiazepine-sedative-poisonings/"},{"content":"1. Platelet Transfusion 1.1 Platelet Products — Overview Product Description Platelet Content Volume Shelf Life Storage Apheresis platelets (single-donor) Collected from a single donor via apheresis; equivalent to 4–6 pooled random donor units ≥ 3.0 × 10¹¹ per unit 200–300 mL 5 days (with agitation) 20–24°C with continuous gentle agitation Pooled random donor platelets Whole-blood-derived platelets from 4–6 donors, pooled into a single bag ≥ 3.0 × 10¹¹ per pool 250–350 mL 5 days from collection …","description":"Evidence-based indications, thresholds, and dosing for platelet, plasma (FFP/FP24), and cryoprecipitate/fibrinogen concentrate transfusion, including platelet refractoriness, warfarin reversal, and special considerations for HIT, TTP, ITP, and DIC.","section":"icu","title":"Transfusion in Critical Care — Part 2: Platelet, Plasma \u0026 Cryoprecipitate Transfusion","url":"/icu/guidelines/transfusion-critical-care/transfusion-in-critical-care-part-2-platelet-plasma-cryoprecipitate-transfusion/"},{"content":"1. Adjuncts to the Primary Survey Adjuncts to the primary survey are diagnostic and therapeutic interventions performed concurrently with or immediately following the ABCDE assessment. They provide additional information to guide resuscitation and disposition decisions.1 2\n1.1 Extended FAST (eFAST) The eFAST expands the standard four-view FAST examination by adding bilateral anterior thoracic views to detect pneumothorax. The eFAST is performed during the primary survey and has largely replaced …","description":"Extended FAST technique, chest and pelvis radiography, Foley and NG tube placement, complete head-to-toe secondary survey, AMPLE history, and hemorrhagic shock classification with Classes I-IV.","section":"ed","title":"Trauma Primary and Secondary Survey — Part 2: Adjuncts to Primary Survey, Secondary Survey \u0026 Hemorrhagic Shock","url":"/ed/guidelines/trauma-primary-secondary-survey/trauma-primary-and-secondary-survey-part-2-adjuncts-to-primary-survey-secondary-survey-hemorrhagic-shock/"},{"content":"1. Airway Management in TBI 1.1 Indications for Endotracheal Intubation Definitive airway management with endotracheal intubation is one of the most critical early interventions in TBI. Indications include.1 2\nIndication Rationale GCS ≤ 8 Inability to protect airway; universal threshold for intubation in severe TBI Declining GCS (drop of ≥ 2 points) Indicates clinical deterioration and impending airway compromise Loss of protective airway reflexes Aspiration risk Hypoxemia refractory to …","description":"Airway management and RSI in TBI, oxygenation and ventilation targets, blood pressure management, seizure prophylaxis, coagulopathy reversal, TXA (CRASH-3), and cerebral herniation emergency management.","section":"ed","title":"Traumatic Brain Injury — Part 2: Initial Management \u0026 Resuscitation","url":"/ed/guidelines/traumatic-brain-injury/traumatic-brain-injury-part-2-initial-management-resuscitation/"},{"content":"6. VAP Prevention Bundle — Overview The VAP prevention bundle is a structured set of evidence-based interventions designed to be implemented together as a standard of care for all mechanically ventilated patients. The bundle concept recognizes that while individual interventions may each provide modest risk reduction, their combined and reliably applied implementation produces a greater, synergistic effect.12\n6.1 Evolution of the VAP Bundle The original ventilator bundle consisted of four …","description":"Comprehensive evidence review of VAP prevention bundle components including head-of-bed elevation, sedation management, oral care and chlorhexidine controversy, subglottic secretion drainage, ETT cuff pressure, suctioning, circuit management, early mobility, stress ulcer prophylaxis, and supplemental strategies including SDD/SOD, silver-coated ETTs, and probiotics.","section":"icu","title":"Ventilator-Associated Pneumonia — Part 2: Prevention Bundles \u0026 Supplemental Strategies","url":"/icu/guidelines/ventilator-associated-pneumonia/ventilator-associated-pneumonia-part-2-prevention-bundles-supplemental-strategies/"},{"content":"Pharmacologic Prophylaxis: Overview Pharmacologic prophylaxis is the cornerstone of VTE prevention in critically ill patients. The choice of agent, dose, and monitoring strategy must be individualized based on renal function, weight, bleeding risk, platelet count, and clinical context.1 2 3\nAgent Selection Summary Agent Standard Prophylaxis Dose Route Key Advantages Key Disadvantages Enoxaparin 40 mg once daily or 30 mg q12h Subcutaneous Predictable pharmacokinetics; once-daily dosing; lower HIT …","description":"Complete dosing tables for LMWH, UFH, and fondaparinux in ICU patients, renal and obesity dose adjustments, anti-Xa monitoring, key trial evidence (PROTECT, PREVENT, INSPIRATION), and duration of prophylaxis.","section":"icu","title":"VTE Prophylaxis in Critical Care — Part 2: Pharmacologic Prophylaxis","url":"/icu/guidelines/vte-prophylaxis-critical-care/vte-prophylaxis-in-critical-care-part-2-pharmacologic-prophylaxis/"},{"content":"The Analgesic Ladder: Framework and Modern Adaptations Original Three-Step Ladder The three-step analgesic ladder, first published in 1986 and updated in subsequent editions, provides a systematic framework for the pharmacological management of cancer pain based on pain intensity and response to treatment. When applied correctly, this approach achieves adequate pain relief in approximately 70% to 90% of cancer patients.1\nStep 1 — Mild pain (NRS 1–3): Non-opioid analgesic (acetaminophen or NSAID) …","description":"Updated WHO analgesic ladder framework, non-opioid analgesic selection and dosing, and weak opioid therapy for cancer pain management.","section":"oncology","title":"Cancer Pain Management — Part 2: The Analgesic Ladder and Non-Opioid Pharmacotherapy","url":"/oncology/guidelines/cancer-pain-management/cancer-pain-management-part-2-the-analgesic-ladder-and-non-opioid-pharmacotherapy/"},{"content":"VTE Prophylaxis in Ambulatory Cancer Patients General Principles The majority of cancer-associated VTE events occur in the outpatient setting during systemic anticancer therapy. Routine pharmacologic thromboprophylaxis for all ambulatory cancer patients is not recommended due to the overall modest absolute VTE risk, the bleeding risk associated with anticoagulation, patient burden, and cost. Instead, a risk-stratified approach is endorsed by the major guideline panels.1 2 3\nRecommendations for …","description":"Evidence-based recommendations for VTE prophylaxis in ambulatory, hospitalized, and surgical cancer patients, including CVAD-related thrombosis prevention, with complete dosing tables and key trial data.","section":"oncology","title":"Cancer-Associated Thrombosis — Part 2: VTE Prophylaxis in Cancer Patients","url":"/oncology/guidelines/cancer-associated-thrombosis/cancer-associated-thrombosis-part-2-vte-prophylaxis-in-cancer-patients/"},{"content":"1. Signs and Symptoms of Extravasation Early recognition of extravasation is the single most important factor in determining outcome. The severity of tissue injury correlates directly with the volume of drug that escapes the vascular compartment, the vesicant potential of the agent, the concentration of the drug, and the duration of tissue exposure.12 Clinicians must be familiar with both early and late signs of extravasation and must distinguish extravasation from other infusion-related …","description":"Signs and symptoms of extravasation (early and late), differential diagnosis, step-by-step immediate management algorithm, specific antidote protocols with complete dosing for dexrazoxane, hyaluronidase, sodium thiosulfate, and DMSO, and thermal management by agent class.","section":"oncology","title":"Chemotherapy Extravasation — Part 2: Recognition, Immediate Management, and Antidote Protocols","url":"/oncology/guidelines/chemotherapy-extravasation/chemotherapy-extravasation-part-2-recognition-immediate-management-and-antidote-protocols/"},{"content":"NK1 Receptor Antagonists NK1 receptor antagonists (NK1 RAs) block the binding of substance P at neurokinin-1 receptors in both the central nervous system and the GI tract. Substance P is the primary mediator of the delayed phase of CINV (24 to 120 hours after chemotherapy), though NK1 RAs also enhance control of the acute phase when added to 5-HT3 RA–based regimens. NK1 RAs are a cornerstone of antiemetic prophylaxis for both highly emetogenic chemotherapy (HEC) and, in select situations, …","description":"Comprehensive review of antiemetic drug classes used in CINV prophylaxis and treatment: NK1 receptor antagonists, 5-HT3 receptor antagonists, corticosteroids, olanzapine, dopamine antagonists, benzodiazepines, and cannabinoids with complete dosing, pharmacokinetics, and adverse effect profiles.","section":"oncology","title":"CINV Guideline — Part 2: Antiemetic Agents — Pharmacology, Dosing, and Adverse Effects","url":"/oncology/guidelines/cinv-prevention/cinv-guideline-part-2-antiemetic-agents-pharmacology-dosing-and-adverse-effects/"},{"content":"4. Empiric Antibiotic Therapy — Inpatient Management 4.1 Principles of Empiric Therapy Empiric antibiotic therapy in febrile neutropenia must provide coverage against the most common and most virulent pathogens, with particular attention to gram-negative organisms including Pseudomonas aeruginosa. Key principles include:1 2 3\nAntibiotics must be initiated within 60 minutes of presentation — delays are associated with increased mortality. Empiric therapy should cover gram-negative bacilli, …","description":"Empiric intravenous antibiotic monotherapy and combination regimens with complete dosing, indications for vancomycin and anti-gram-positive agents, antibiotic de-escalation and duration criteria, outpatient eligibility for low-risk febrile neutropenia, oral antibiotic regimens, and monitoring requirements.","section":"oncology","title":"Febrile Neutropenia — Part 2: Empiric Antibiotic Therapy \u0026 Outpatient Management","url":"/oncology/guidelines/febrile-neutropenia/febrile-neutropenia-part-2-empiric-antibiotic-therapy-outpatient-management/"},{"content":"Dermatologic Immune-Related Adverse Events Dermatologic irAEs are the most common class of irAEs overall, occurring in approximately 30% to 40% of patients on anti-PD-1/PD-L1 monotherapy and up to 50% of patients on combination immunotherapy. They are typically among the earliest irAEs to manifest, often appearing within the first 2 to 6 weeks of therapy. While the majority of cutaneous irAEs are mild and manageable, severe presentations including Stevens-Johnson syndrome (SJS) and toxic …","description":"Grade-based management of immune-mediated dermatologic toxicities (rash, pruritus, bullous pemphigoid, SJS/TEN), colitis/diarrhea, and hepatitis including workup, corticosteroid protocols, and immunosuppressive escalation.","section":"oncology","title":"Immune Checkpoint Inhibitor Adverse Event Management — Part 2: Dermatologic, Gastrointestinal, and Hepatic irAEs","url":"/oncology/guidelines/immunotherapy-adverse-events/immune-checkpoint-inhibitor-adverse-event-management-part-2-dermatologic-gastrointestinal-and-hepatic-iraes/"},{"content":"1. Cardiovascular Late Effects of Cancer Treatment Cardiovascular disease is the leading non-cancer cause of morbidity and mortality in cancer survivors. The risk of cardiovascular death is increased 2- to 6-fold in certain survivor populations compared to the general population. Anthracycline chemotherapy, chest-directed radiation therapy, targeted agents (trastuzumab, tyrosine kinase inhibitors), and immune checkpoint inhibitors can each cause distinct forms of cardiac injury. Risk is …","description":"Anthracycline cardiomyopathy, radiation-associated cardiovascular disease, cardiac monitoring protocols, cardioprotective strategies, and screening for secondary malignancies in cancer survivors.","section":"oncology","title":"Oncology Survivorship Care — Part 2: Cardiovascular Late Effects and Secondary Malignancies","url":"/oncology/guidelines/survivorship-care/oncology-survivorship-care-part-2-cardiovascular-late-effects-and-secondary-malignancies/"},{"content":"5. Prevention of Oral Mucositis 5.1 Summary of Recommendations The following table summarizes the evidence-based recommendations for oral mucositis prevention, synthesized from international guideline panels and systematic reviews.1 2 3 4\nIntervention Setting Recommendation Strength Oral cryotherapy Bolus 5-FU Recommended Strong (in favor) Oral cryotherapy High-dose melphalan (HSCT) Recommended Strong (in favor) Oral cryotherapy Bolus edatrexate Suggested Moderate (in favor) Low-level laser …","description":"Evidence-based oral mucositis prevention including cryotherapy, photobiomodulation, palifermin, and basic oral care; pain management; nutritional support; infection management; agents with evidence against use.","section":"oncology","title":"Oral and GI Mucositis — Part 2: Oral Mucositis Prevention and Management","url":"/oncology/guidelines/oral-gi-mucositis/oral-and-gi-mucositis-part-2-oral-mucositis-prevention-and-management/"},{"content":"1. Pre-Insertion Planning 1.1 Informed Consent Informed consent should be obtained before CVAD placement, with discussion of:12\nThe type of device being placed and rationale for selection Alternatives considered and reasons for recommendation Procedural risks including bleeding, pneumothorax (for subclavian and jugular approaches), arterial puncture, nerve injury, air embolism, arrhythmia, and malposition Device-specific long-term risks including infection, thrombosis, and mechanical …","description":"Insertion site selection, ultrasound-guided placement, tip confirmation, skin antisepsis, dressing and securement, and site care protocols for central venous access devices in oncology patients.","section":"oncology","title":"Part 2: Insertion Techniques and Site Care","url":"/oncology/guidelines/central-venous-access/part-2-insertion-techniques-and-site-care/"},{"content":"6. Personal Protective Equipment (PPE) Personal protective equipment is the last line of defense in the hierarchy of controls but remains essential for all hazardous drug handling activities. PPE must be used in conjunction with, not as a substitute for, engineering controls. The type and extent of PPE required varies by the specific activity being performed and the dosage form of the hazardous drug being handled.1\n6.1 Chemotherapy-Tested Gloves Gloves are the most fundamental PPE element for …","description":"Complete PPE specifications for hazardous drug handling by activity type, including glove, gown, eye/face, and respiratory protection requirements; detailed procedures for receiving, storage, compounding, administration, patient care, and transport.","section":"oncology","title":"Safe Handling of Hazardous Drugs — Part 2: Personal Protective Equipment and Safe Handling Procedures","url":"/oncology/guidelines/hazardous-drug-handling/safe-handling-of-hazardous-drugs-part-2-personal-protective-equipment-and-safe-handling-procedures/"},{"content":"JAVA | 2026 | Supplemental Issue Section 1 (Continued) Implementation Considerations (Continued) Tailored tools and product selection customize kits and checklists for high-acuity areas, difficult intravenous access patients, or settings like ICU and oncology.2,11 Checklist design and iteration: Involve frontline staff in designing concise, role-specific checklists that match the workflow and avoid duplication.11 Technology and EHR integration: Embed checklists into electronic health records …","description":"Association for Vascular Access Adult Clinical Practice Guidelines (JAVA 2026, Vol. 31) — Part 2 continuing Section 1 on implementation considerations, barriers, products, bundles, and checklists for vascular access infrastructure.","section":"vascular-access","title":"AVA CPG 2026 — Part 2: Section 1 Continued (Products, Bundles \u0026 Checklists)","url":"/vascular-access/guidelines/ava-clinical-practice-guidelines/ava-cpg-2026-part-2-section-1-continued-products-bundles-checklists/"},{"content":"Appendix A: Definitions of Organization-Sponsored Documents The development, review, and publication processes described in this Handbook apply to guidelines, expert guidance documents (including Compendium documents), consensus documents, and practice statements. The preparation of other manuscript types falls outside the scope of this Handbook.1\nPeer Reviewers for Sponsored Documents Submitted to Affiliated Journals Two distinct sets of peer reviewers are responsible for organization-sponsored …","description":"Appendices covering document type definitions with peer review responsibilities, expert guidance and consensus statement proposal forms, recommendation terminology, and evidence quality classifications for infection prevention guideline development.","section":"infection-prevention","title":"IP Guideline Development Handbook — Part 2: Document Types, Proposal Forms \u0026 Evidence Classification","url":"/infection-prevention/guidelines/guideline-development-handbook/ip-guideline-development-handbook-part-2-document-types-proposal-forms-evidence-classification/"},{"content":"This section covers hemodynamic management of adults with sepsis and septic shock, including blood pressure monitoring modality, fluid type selection (crystalloids, balanced solutions, albumin, starches, gelatin), liberal versus restrictive fluid strategies, dynamic measures of fluid responsiveness, cardiac output monitoring, serial lactate measurement, capillary refill time-guided resuscitation, vasopressor selection and sequencing (norepinephrine, vasopressin, epinephrine, angiotensin II), …","description":"Surviving Sepsis Campaign 2026 recommendations for blood pressure monitoring, fluid type selection, balanced crystalloids, albumin, liberal vs restrictive fluid strategies, dynamic measures for fluid responsiveness, cardiac output monitoring, serial lactate, capillary refill time, vasopressor hierarchy, inotropes, methylene blue, midodrine, and beta-blockers in adult sepsis and septic shock.","section":"icu","title":"SSC 2026 — Part 3: Hemodynamic Management","url":"/icu/guidelines/surviving-sepsis-campaign-2026/ssc-2026-part-3-hemodynamic-management/"},{"content":"This section covers vasoactive medication management and ventilation strategies in pediatric sepsis and septic shock, including the timing of vasoactive initiation relative to fluid resuscitation, first-line vasoactive agent selection, peripheral venous access for vasoactive infusions, adjunctive vasopressor and inotropic agents, intubation decisions, choice of induction agents, and oxygen saturation targets. These recommendations apply to pediatric patients from 37 weeks gestational age at …","description":"Surviving Sepsis Campaign 2026 pediatric recommendations for vasoactive medication timing, epinephrine vs norepinephrine, peripheral vasoactive initiation, vasopressin, inodilators, angiotensin II, methylene blue, intubation in septic shock, etomidate avoidance, and conservative SpO2 targets in children.","section":"icu","title":"SSC Children 2026 — Part 3: Vasoactive Medications \u0026 Ventilation","url":"/icu/guidelines/surviving-sepsis-campaign-children-2026/ssc-children-2026-part-3-vasoactive-medications-ventilation/"},{"content":"1. Approach to the Patient with Tachyarrhythmia The management of tachyarrhythmias in the ACLS framework begins with a single critical decision point: Is the patient hemodynamically stable or unstable? This determines whether the provider has time for a pharmacologic approach or must proceed immediately to electrical cardioversion.1 2\n1.1 Signs of Hemodynamic Instability Sign Description Hypotension Systolic blood pressure \u0026amp;lt;90 mmHg or signs of shock (altered mental status, cool extremities, …","description":"Narrow and wide complex tachycardia algorithms, synchronized cardioversion energy levels, SVT management with adenosine, atrial fibrillation rate and rhythm control, bradycardia algorithm, atropine, transcutaneous pacing, and vasopressor infusions.","section":"ed","title":"ACLS \u0026 Cardiac Arrest — Part 3: Tachyarrhythmia \u0026 Bradyarrhythmia Management","url":"/ed/guidelines/acls-cardiac-arrest/acls-cardiac-arrest-part-3-tachyarrhythmia-bradyarrhythmia-management/"},{"content":"6. Small Bowel Obstruction 6.1 Epidemiology and Etiology Small bowel obstruction (SBO) accounts for approximately 15% of all emergency department visits for abdominal pain and is responsible for approximately 300,000 hospitalizations annually in the United States. SBO is the most common indication for emergency abdominal surgery.1 2\nEtiology by Frequency:\nCause Frequency Key Features Adhesions (postoperative) 60–75% Most common cause overall; risk increases with number of prior abdominal …","description":"Comprehensive guide to adhesive small bowel obstruction with CT findings, conservative management, water-soluble contrast challenge, and surgical indications; large bowel obstruction including volvulus and Ogilvie syndrome; and diverticulitis with Hinchey classification, DIABOLO trial evidence, and surgical decision-making.","section":"ed","title":"Acute Abdominal Emergencies — Part 3: Small Bowel Obstruction, Large Bowel Obstruction \u0026 Diverticulitis","url":"/ed/guidelines/acute-abdominal-emergencies/acute-abdominal-emergencies-part-3-small-bowel-obstruction-large-bowel-obstruction-diverticulitis/"},{"content":"1. The Emergency Difficult Airway Algorithm The structured approach to the unanticipated difficult airway follows a sequential plan-based algorithm. Each plan represents a progressively more invasive rescue strategy. The key principle is to declare failure early and move to the next plan rather than persisting with a failing technique.1 2 3\n1.1 Algorithm Overview PLAN A: Face-mask ventilation and tracheal intubation ├── Optimize: head position, laryngoscope choice, bougie, ELM, suction ├── …","description":"Failed first attempt optimization, video laryngoscopy types and evidence, bougie technique, supraglottic airways with sizing tables, intubating through SGA, front-of-neck access (FONA), surgical cricothyrotomy (scalpel-bougie-tube), needle cricothyrotomy, and the complete difficult airway algorithm.","section":"ed","title":"Acute Airway Management \u0026 RSI — Part 3: Difficult Airway Management \u0026 Surgical Airway","url":"/ed/guidelines/airway-management-rsi/acute-airway-management-rsi-part-3-difficult-airway-management-surgical-airway/"},{"content":"1. Systems of Care and Time Targets 1.1 Reperfusion Time Goals Time to reperfusion is the single most important modifiable determinant of outcome in STEMI. The relationship between delay and mortality is approximately linear in the first 2-3 hours after symptom onset, with the greatest benefit from reperfusion occurring in the first 1-2 hours (\u0026amp;ldquo;golden hour\u0026amp;rdquo;).1 2\nMetric Target Definition ECG acquisition ≤ 10 minutes from first medical contact (FMC) Time from arrival at ED door (or EMS …","description":"Systems of care, primary PCI, fibrinolytic therapy with dosing, pharmacoinvasive strategy, dual antiplatelet therapy, anticoagulation, adjunctive therapy, cardiogenic shock, and mechanical complications.","section":"ed","title":"Acute Coronary Syndromes — Part 3: STEMI Management — Reperfusion, Pharmacotherapy \u0026 Complications","url":"/ed/guidelines/acute-coronary-syndromes/acute-coronary-syndromes-part-3-stemi-management-reperfusion-pharmacotherapy-complications/"},{"content":"1. Fluid Management in AKI 1.1 Assessment of Volume Status Accurate assessment of volume status is fundamental to AKI management. Both hypovolemia and hypervolemia are harmful to the injured kidney. The challenge in critically ill patients is that traditional clinical signs (JVP, peripheral edema, lung crackles) have poor sensitivity and specificity for intravascular volume status.1 2\nIntegrated Volume Assessment Assessment Tool What It Measures Utility Limitations Clinical examination Skin …","description":"Fluid management, hyperkalemia emergency algorithm, electrolyte and acid-base management, diuretic therapy including furosemide stress test, drug dosing in AKI, and nutritional considerations.","section":"icu","title":"Acute Kidney Injury — Part 3: Conservative Management of AKI Complications","url":"/icu/guidelines/acute-kidney-injury-rrt/acute-kidney-injury-part-3-conservative-management-of-aki-complications/"},{"content":"5. Topical and Local Anesthesia Topical and local anesthetic techniques are fundamental to ED practice, reducing pain from procedures and reducing the need for systemic analgesics. When applied correctly, these techniques can eliminate procedural pain entirely for many common ED procedures.1 2\n5.1 LET Gel (Lidocaine-Epinephrine-Tetracaine) LET gel is the standard topical anesthetic for laceration repair in the ED, providing excellent anesthesia to wound edges without the need for injectable …","description":"LET gel, EMLA cream, lidocaine buffering, hematoma block, intra-articular injection, sedation continuum, pre-sedation assessment, sedation agents with complete dosing, ketamine considerations, modified Aldrete score, and recovery criteria.","section":"ed","title":"Acute Pain \u0026 Procedural Sedation — Part 3: Topical \u0026 Local Anesthesia and Procedural Sedation","url":"/ed/guidelines/acute-pain-procedural-sedation/acute-pain-procedural-sedation-part-3-topical-local-anesthesia-and-procedural-sedation/"},{"content":"1. Endovascular Thrombectomy — Overview Endovascular thrombectomy (EVT), also termed mechanical thrombectomy, is the removal of an intracranial thrombus via a catheter-based approach, most commonly using stent-retriever or aspiration devices. Five landmark randomized controlled trials published in 2015 — collectively known as the \u0026amp;ldquo;Big Five\u0026amp;rdquo; — established EVT as the standard of care for acute ischemic stroke due to large vessel occlusion (LVO) in the anterior circulation. A subsequent …","description":"EVT indications, landmark trials, extended window therapy (DAWN, DEFUSE-3), anesthesia considerations, and comprehensive blood pressure management with antihypertensive dosing tables.","section":"ed","title":"Acute Stroke Management — Part 3: Endovascular Thrombectomy \u0026 Blood Pressure Management","url":"/ed/guidelines/acute-stroke/acute-stroke-management-part-3-endovascular-thrombectomy-blood-pressure-management/"},{"content":"1. Parenteral Nutrition — Indications 1.1 When to Use Parenteral Nutrition Parenteral nutrition (PN) should be considered when the enteral route is contraindicated, insufficient, or not feasible to meet the patient\u0026amp;rsquo;s nutritional requirements. The enteral route is always preferred when functional; PN is not a substitute for EN in patients who can tolerate enteral feeding.1 2 3\nAbsolute Indications for PN Indication Clinical Scenario Non-functional GI tract Mechanical bowel obstruction; …","description":"Comprehensive guide to parenteral nutrition in the ICU: indications, timing controversies, composition, lipid emulsions, monitoring, complications, transition to EN, and micronutrient supplementation including thiamine, vitamin C, vitamin D, selenium, zinc, and refeeding syndrome prevention.","section":"icu","title":"Nutrition in Critical Illness — Part 3: Parenteral Nutrition \u0026 Micronutrients","url":"/icu/guidelines/nutrition-critical-illness/nutrition-in-critical-illness-part-3-parenteral-nutrition-micronutrients/"},{"content":"7. Recruitment Maneuvers 7.1 Concept and Rationale Recruitment maneuvers (RMs) are transient increases in airway pressure intended to open collapsed alveoli, thereby increasing the volume of aerated lung available for tidal ventilation. The theoretical benefit is to reduce atelectrauma (cyclic opening and closing of collapsed units) and to improve oxygenation by converting shunt to functional gas-exchanging units. Once recruited, these units are held open by adequate PEEP (the \u0026amp;ldquo;open …","description":"Recruitment maneuvers and evidence from the ART trial, conservative fluid management from the FACTT trial, inhaled pulmonary vasodilators, ECMO indications and referral criteria from the EOLIA trial, high-frequency oscillatory ventilation, and corticosteroids in ARDS.","section":"icu","title":"Part 3: Adjunctive and Rescue Therapies","url":"/icu/guidelines/mechanical-ventilation-ards/part-3-adjunctive-and-rescue-therapies/"},{"content":"Delirium in the ICU: Overview Delirium is an acute, fluctuating disturbance in attention and awareness, accompanied by additional cognitive dysfunction (disorientation, memory deficit, language disturbance, visuospatial impairment, or perceptual disturbance) that is not better explained by a pre-existing neurocognitive disorder and does not occur in the context of a severely reduced level of arousal (e.g., coma).1 2\nEpidemiology Population Delirium Prevalence Mechanically ventilated patients …","description":"Complete delirium assessment tools (CAM-ICU flowsheet, ICDSC scoring), delirium subtypes, modifiable and non-modifiable risk factors, evidence-based non-pharmacologic prevention bundles, and pharmacologic management including haloperidol, quetiapine, and dexmedetomidine dosing.","section":"icu","title":"Part 3: Delirium Assessment, Prevention, and Management","url":"/icu/guidelines/sedation-analgesia-delirium/part-3-delirium-assessment-prevention-and-management/"},{"content":"1. Supplemental Prevention Strategies The following strategies are recommended as supplemental approaches — to be considered when CLABSI rates remain elevated despite full implementation of and high compliance with the standard insertion and maintenance bundles, or in specific high-risk patient populations.12\n1.1 Antimicrobial-Impregnated Catheters Antimicrobial-impregnated or -coated central venous catheters deliver antimicrobial agents at the catheter surface to inhibit microbial adhesion and …","description":"Antimicrobial-impregnated catheters, antimicrobial lock therapy, CHG-impregnated dressings, antibiotic ointments, diagnosis of CRBSI (paired blood cultures, differential time to positivity, catheter tip culture), empiric therapy, catheter removal vs salvage, duration of therapy by organism, and suppurative thrombophlebitis.","section":"icu","title":"Part 3: Supplemental Prevention Strategies, Diagnosis \u0026 Management of CRBSI","url":"/icu/guidelines/clabsi-prevention/part-3-supplemental-prevention-strategies-diagnosis-management-of-crbsi/"},{"content":"1. Pediatric Sepsis: Recognition and Definitions Sepsis remains a leading cause of morbidity and mortality in children worldwide. Early recognition is challenging because children compensate effectively through tachycardia and increased systemic vascular resistance, maintaining blood pressure until late in the course. The transition from compensated to decompensated shock can be precipitous and fatal if not anticipated. A high index of suspicion, use of standardized screening tools, and …","description":"Pediatric sepsis recognition with age-specific SIRS criteria, sepsis resuscitation protocol, vasopressor selection, antibiotic guidance, febrile infant risk stratification by age, Rochester-Philadelphia-Boston criteria comparison, PECARN febrile infant rule, and neonatal CSF interpretation.","section":"ed","title":"Pediatric Emergencies — Part 3: Pediatric Sepsis \u0026 Febrile Infant Evaluation","url":"/ed/guidelines/pediatric-emergencies/pediatric-emergencies-part-3-pediatric-sepsis-febrile-infant-evaluation/"},{"content":"1. Principles of Neuroprognostication Neuroprognostication — the systematic assessment of likely neurologic recovery after cardiac arrest — is one of the most consequential clinical activities in post-arrest care. The accuracy of prognostication directly determines whether life-sustaining treatment is continued or withdrawn, making the stakes of this process uniquely high.1 2 3\n1.1 Why Multimodal Prognostication is Mandatory No single test, biomarker, or clinical finding is sufficient to predict …","description":"Comprehensive multimodal neuroprognostication framework including timing, clinical examination, EEG, SSEPs, biomarkers, neuroimaging, confounders, and prognostication algorithm.","section":"icu","title":"Post-Cardiac Arrest Care — Part 3: Neuroprognostication After Cardiac Arrest","url":"/icu/guidelines/post-cardiac-arrest-ttm/post-cardiac-arrest-care-part-3-neuroprognostication-after-cardiac-arrest/"},{"content":"1. Timing of Antimicrobial Administration 1.1 Guideline Recommendations The timing of antimicrobial administration is one of the most critical determinants of survival in sepsis and septic shock.1 2\nRecommendation: For adults with possible septic shock or a high likelihood of sepsis, the panel recommends administering antimicrobials immediately, ideally within 1 hour of recognition.\nStrength: Strong recommendation (septic shock); Best practice statement (high likelihood sepsis)1\nRecommendation: …","description":"Timing of antibiotics, empiric broad-spectrum regimens by suspected source, de-escalation, duration of therapy, procalcitonin-guided discontinuation, antifungal considerations, and source control procedures.","section":"icu","title":"Sepsis and Septic Shock — Part 3: Antimicrobial Therapy \u0026 Source Control","url":"/icu/guidelines/sepsis-septic-shock/sepsis-and-septic-shock-part-3-antimicrobial-therapy-source-control/"},{"content":"1. Tricyclic Antidepressant (TCA) Poisoning Tricyclic antidepressant overdose remains one of the most dangerous drug ingestions encountered in the emergency department. Despite declining prescribing rates, TCAs continue to cause significant mortality due to their narrow therapeutic index and multiple toxic mechanisms.1 2\n1.1 Toxic Mechanisms TCAs exert toxicity through at least four pharmacologic actions:\nMechanism Clinical Effect Sodium channel blockade (fast cardiac Na+ channels) QRS …","description":"Complete management of TCA poisoning (sodium bicarbonate protocol), calcium channel blocker overdose (high-dose insulin), beta-blocker toxicity, digoxin poisoning (DigiFab), serotonin syndrome, neuroleptic malignant syndrome, lithium toxicity, and antipsychotic overdose.","section":"ed","title":"Toxicology and Overdose Management — Part 3: Cardiovascular Drug, Antidepressant \u0026 Psychotropic Poisonings","url":"/ed/guidelines/toxicology-overdose/toxicology-and-overdose-management-part-3-cardiovascular-drug-antidepressant-psychotropic-poisonings/"},{"content":"1. Definition and Scope 1.1 Definitions of Massive Transfusion Definition Criteria Notes Classic definition ≥ 10 units pRBC in 24 hours Most commonly cited; identifies patients retrospectively Alternative (time-sensitive) ≥ 4 units pRBC in 1 hour with ongoing bleeding anticipated More clinically useful for prospective MTP activation Critical administration threshold (CAT) ≥ 3 units pRBC in 1 hour Used in some trauma systems as an early activation trigger Replacement of entire blood volume …","description":"Massive transfusion protocol activation, fixed-ratio transfusion (1:1:1 per PROPPR), TEG/ROTEM viscoelastic testing and interpretation, damage control resuscitation, TXA (CRASH-2), calcium replacement, permissive hypotension, and hemorrhage management in trauma, obstetric, and GI bleeding.","section":"icu","title":"Transfusion in Critical Care — Part 3: Massive Transfusion \u0026 Hemorrhage Management","url":"/icu/guidelines/transfusion-critical-care/transfusion-in-critical-care-part-3-massive-transfusion-hemorrhage-management/"},{"content":"1. Damage Control Resuscitation — Overview 1.1 Concept and Evolution Damage control resuscitation (DCR) is a systematic approach to the management of the severely hemorrhaging trauma patient that integrates permissive hypotension, hemostatic resuscitation with balanced blood product ratios, limitation of crystalloid administration, and aggressive prevention/correction of the lethal triad of hypothermia, acidosis, and coagulopathy. DCR is performed in parallel with damage control surgery (DCS), …","description":"Permissive hypotension, massive transfusion protocol with 1:1:1 ratio, tranexamic acid (CRASH-2), crystalloid limitation, hypothermia prevention, acidosis correction, viscoelastic hemostatic assays, and whole blood resuscitation.","section":"ed","title":"Trauma Primary and Secondary Survey — Part 3: Damage Control Resuscitation \u0026 Transfusion","url":"/ed/guidelines/trauma-primary-secondary-survey/trauma-primary-and-secondary-survey-part-3-damage-control-resuscitation-transfusion/"},{"content":"1. Intracranial Pressure Monitoring 1.1 Pathophysiology of Elevated ICP The Monro-Kellie doctrine states that the intracranial compartment is a fixed volume composed of brain parenchyma (~80%), cerebrospinal fluid (~10%), and blood (~10%). An increase in any one component must be compensated by a decrease in another, or intracranial pressure will rise. In TBI, compensation mechanisms (CSF displacement into the spinal canal, reduction in cerebral venous blood volume) are rapidly exhausted, after …","description":"ICP monitoring indications, ICP and CPP targets, complete tiered ICP management protocol with dosing, hyperosmolar therapy, EVD drainage, decompressive craniectomy (DECRA, RESCUEicp), barbiturate coma, and surgical indications for epidural hematoma, subdural hematoma, depressed skull fracture, and posterior fossa lesions.","section":"ed","title":"Traumatic Brain Injury — Part 3: ICP Management \u0026 Surgical Indications","url":"/ed/guidelines/traumatic-brain-injury/traumatic-brain-injury-part-3-icp-management-surgical-indications/"},{"content":"10. Diagnostic Approach to VAP 10.1 Clinical Suspicion Criteria VAP should be suspected in any mechanically ventilated patient (intubated ≥ 48 hours) who develops a new or progressive pulmonary infiltrate on chest imaging PLUS at least two of the following clinical features:12\nFever: Temperature \u0026amp;gt; 38.0 °C (or hypothermia \u0026amp;lt; 36.0 °C) Leukocytosis or leukopenia: WBC \u0026amp;gt; 12,000 cells/μL or \u0026amp;lt; 4,000 cells/μL Purulent tracheobronchial secretions: New onset or change in character (increased …","description":"Clinical diagnostic criteria, CPIS scoring table, microbiologic sampling strategies (ETA, BAL, mini-BAL) with quantitative thresholds, biomarker guidance, empiric antibiotic selection stratified by MDR risk with complete dosing tables and renal adjustments, de-escalation principles, short-course duration evidence, inhaled antibiotics, and treatment failure evaluation.","section":"icu","title":"Ventilator-Associated Pneumonia — Part 3: Diagnosis \u0026 Antimicrobial Treatment","url":"/icu/guidelines/ventilator-associated-pneumonia/ventilator-associated-pneumonia-part-3-diagnosis-antimicrobial-treatment/"},{"content":"Mechanical Prophylaxis Mechanical prophylaxis devices enhance venous blood flow in the lower extremities and reduce venous stasis — a key component of Virchow\u0026amp;rsquo;s triad. In the ICU, they serve as the primary prophylactic strategy when pharmacologic prophylaxis is contraindicated, and as an adjunct in high-risk patients.1 2\nIntermittent Pneumatic Compression (IPC) Devices IPC devices are the most effective form of mechanical prophylaxis and are the recommended mechanical method for critically …","description":"Evidence for intermittent pneumatic compression and graduated compression stockings, IVC filter indications and complications, screening ultrasound protocols, CTPA decision-making, and transition from prophylaxis to treatment.","section":"icu","title":"VTE Prophylaxis in Critical Care — Part 3: Mechanical Prophylaxis, IVC Filters \u0026 Diagnosis of ICU-Acquired VTE","url":"/icu/guidelines/vte-prophylaxis-critical-care/vte-prophylaxis-in-critical-care-part-3-mechanical-prophylaxis-ivc-filters-diagnosis-of-icu-acquired-vte/"},{"content":"Opioid Selection and Initiation General Principles Strong opioids are the mainstay of treatment for moderate-to-severe cancer pain. There is no single \u0026amp;ldquo;best\u0026amp;rdquo; opioid for cancer pain; selection should be individualized based on pain intensity, patient comorbidities, prior opioid exposure, available formulations, renal and hepatic function, potential drug interactions, and cost/availability.1\nKey principles for opioid initiation:\nStart with an immediate-release (IR) formulation for …","description":"Complete opioid pharmacotherapy for cancer pain including equianalgesic dosing, titration protocols, opioid rotation, breakthrough pain management, methadone pharmacology, and side effect treatment.","section":"oncology","title":"Cancer Pain Management — Part 3: Opioid Therapy — Selection, Titration, Rotation, and Adverse Effect Management","url":"/oncology/guidelines/cancer-pain-management/cancer-pain-management-part-3-opioid-therapy-selection-titration-rotation-and-adverse-effect-management/"},{"content":"Overview of Anticoagulation for Cancer-Associated VTE The treatment of established venous thromboembolism in cancer patients requires special consideration beyond standard VTE management. Cancer patients have both a higher risk of VTE recurrence and a higher risk of anticoagulation-related bleeding compared with the general VTE population. The choice of anticoagulant, dosing strategy, and treatment duration must account for the patient\u0026amp;rsquo;s cancer type (particularly gastrointestinal and …","description":"Complete treatment protocols for cancer-associated VTE including LMWH dosing, DOAC regimens (rivaroxaban, edoxaban, apixaban), warfarin considerations, duration of anticoagulation, and landmark trial data from SELECT-D, HOKUSAI-VTE Cancer, ADAM-VTE, and CARAVAGGIO.","section":"oncology","title":"Cancer-Associated Thrombosis — Part 3: Treatment of Established Cancer-Associated VTE","url":"/oncology/guidelines/cancer-associated-thrombosis/cancer-associated-thrombosis-part-3-treatment-of-established-cancer-associated-vte/"},{"content":"1. Surgical Consultation Criteria Surgical consultation should be obtained for extravasation injuries that meet any of the following criteria. Timely surgical evaluation is essential because delayed intervention increases the risk of permanent tissue damage, functional impairment, and complex wound management.123\n1.1 Indications for Immediate Surgical Consultation (Within 24–72 Hours) Indication Rationale Extravasation of a DNA-binding vesicant with significant tissue involvement DNA-binding …","description":"Surgical consultation criteria, wound grading, patient follow-up protocols, peripheral vs. central line extravasation management, documentation requirements, incident reporting, legal considerations, staff competency assessment, and institutional protocol development.","section":"oncology","title":"Chemotherapy Extravasation — Part 3: Follow-Up Care, Documentation, Legal Considerations, and Staff Education","url":"/oncology/guidelines/chemotherapy-extravasation/chemotherapy-extravasation-part-3-follow-up-care-documentation-legal-considerations-and-staff-education/"},{"content":"Recommended Antiemetic Regimens by Emetogenic Risk Antiemetic regimen selection must be guided by the emetogenic risk classification of the chemotherapy regimen. The following recommendations represent the current evidence-based consensus from major international guideline bodies.123\nHigh Emetogenic Chemotherapy (HEC) — Recommended Regimens The standard of care for HEC prophylaxis is a four-drug combination regimen. All four agents should be initiated before chemotherapy on Day 1.\nPreferred …","description":"Guideline-recommended antiemetic regimens by emetogenic risk level, multi-day chemotherapy protocols, oral chemotherapy CINV, radiation-induced nausea and vomiting, breakthrough and refractory CINV management, and considerations for pediatric, geriatric, and organ-impaired populations.","section":"oncology","title":"CINV Guideline — Part 3: Recommended Antiemetic Regimens and Special Populations","url":"/oncology/guidelines/cinv-prevention/cinv-guideline-part-3-recommended-antiemetic-regimens-and-special-populations/"},{"content":"7. Antimicrobial Prophylaxis in High-Risk Patients Antimicrobial prophylaxis aims to prevent infection during the period of neutropenia. The decision to use prophylaxis is based on the expected depth and duration of neutropenia, the type of malignancy, and the chemotherapy regimen.1 2 3\n7.1 Antibacterial Prophylaxis — Fluoroquinolones Indications Fluoroquinolone prophylaxis is recommended for patients at high risk for febrile neutropenia, defined as those expected to have:1 2\nProfound …","description":"Fluoroquinolone prophylaxis, antifungal prophylaxis, antiviral and PJP prophylaxis, G-CSF primary and secondary prophylaxis with dosing and timing, therapeutic G-CSF in established febrile neutropenia, and management of persistent fever and documented infections.","section":"oncology","title":"Febrile Neutropenia — Part 3: Antimicrobial Prophylaxis, G-CSF \u0026 Special Situations","url":"/oncology/guidelines/febrile-neutropenia/febrile-neutropenia-part-3-antimicrobial-prophylaxis-g-csf-special-situations/"},{"content":"Endocrine Immune-Related Adverse Events Endocrine irAEs are among the most common irAEs and are unique in that they often result in permanent glandular destruction requiring lifelong hormone replacement. Importantly, well-controlled endocrine irAEs on appropriate hormone replacement do not typically require ICI discontinuation. Endocrine irAEs are frequently underrecognized because their symptoms (fatigue, nausea, weakness, weight changes) overlap with those of cancer, chemotherapy, and general …","description":"Grade-based management of immune-mediated endocrine toxicities (thyroid disorders, adrenal insufficiency, hypophysitis, type 1 diabetes) and pneumonitis including workup, corticosteroid protocols, hormone replacement, and immunosuppressive escalation.","section":"oncology","title":"Immune Checkpoint Inhibitor Adverse Event Management — Part 3: Endocrine and Pulmonary irAEs","url":"/oncology/guidelines/immunotherapy-adverse-events/immune-checkpoint-inhibitor-adverse-event-management-part-3-endocrine-and-pulmonary-iraes/"},{"content":"1. Endocrine Dysfunction in Cancer Survivors 1.1 Gonadal Dysfunction and Infertility Cancer treatment can cause temporary or permanent gonadal dysfunction through direct gonadotoxic effects of alkylating chemotherapy, pelvic or gonadal radiation, surgical oophorectomy or orchiectomy, and endocrine therapies. The impact depends on the patient\u0026amp;rsquo;s age at treatment, the specific agents used, cumulative doses, and baseline ovarian reserve or testicular function.1 2\nGonadotoxicity Risk by …","description":"Gonadal dysfunction, fertility preservation, thyroid dysfunction, metabolic syndrome, bone health, cognitive dysfunction, cancer-related fatigue, chemotherapy-induced peripheral neuropathy, and lymphedema in cancer survivors.","section":"oncology","title":"Oncology Survivorship Care — Part 3: Endocrine, Neurological, and Musculoskeletal Late Effects","url":"/oncology/guidelines/survivorship-care/oncology-survivorship-care-part-3-endocrine-neurological-and-musculoskeletal-late-effects/"},{"content":"12. Gastrointestinal Mucositis: Pathophysiology and Grading 12.1 Pathophysiology Gastrointestinal (GI) mucositis encompasses the spectrum of mucosal injury affecting the esophagus, stomach, small intestine, and colon caused by cytotoxic cancer therapies. The clinical manifestation most frequently encountered is chemotherapy-induced diarrhea (CID), which reflects injury predominantly to the small intestinal and colonic mucosa.1 2\nThe pathophysiology of GI mucositis follows the same five-phase …","description":"Chemotherapy-induced diarrhea management, irinotecan-specific protocols, immune checkpoint inhibitor colitis, head and neck radiation mucositis, pelvic radiation enteritis, chemoradiation, TBI-related mucositis, palifermin in HSCT, and engraftment syndrome.","section":"oncology","title":"Oral and GI Mucositis — Part 3: GI Mucositis, Radiation-Induced Mucositis, and HSCT Considerations","url":"/oncology/guidelines/oral-gi-mucositis/oral-and-gi-mucositis-part-3-gi-mucositis-radiation-induced-mucositis-and-hsct-considerations/"},{"content":"1. Flushing Protocols 1.1 General Principles Flushing maintains catheter patency, prevents intraluminal occlusion, and clears the lumen of incompatible medication residues. Every CVAD lumen must be flushed according to a defined protocol. An occluded lumen should never be left untreated simply because another lumen remains functional — prolonged fibrin formation within untreated lumens constitutes a risk factor for catheter-associated bloodstream infection.123\nStandard Flushing Solution: …","description":"Flushing and locking protocols, dressing change procedures, needleless connector management, port access and deaccess procedures, blood sampling, and patency assessment for CVADs in oncology patients.","section":"oncology","title":"Part 3: Catheter Maintenance Protocols","url":"/oncology/guidelines/central-venous-access/part-3-catheter-maintenance-protocols/"},{"content":"9. Spill Management Spills of hazardous drugs represent acute exposure events that require immediate, trained, and systematic response. Every facility that handles hazardous drugs must have written spill procedures, maintain spill kits in all areas where hazardous drugs are handled, and ensure that all personnel who might encounter a spill are trained in spill response.1\n9.1 Spill Kit Contents Spill kits must be readily accessible in every area where hazardous drugs are stored, compounded, …","description":"Spill classification and step-by-step response procedures, spill kit contents, personnel exposure management during spills, hazardous drug waste segregation and disposal, and surface decontamination protocols including deactivation, decontamination, and cleaning agents.","section":"oncology","title":"Safe Handling of Hazardous Drugs — Part 3: Spill Management, Waste Disposal, and Decontamination","url":"/oncology/guidelines/hazardous-drug-handling/safe-handling-of-hazardous-drugs-part-3-spill-management-waste-disposal-and-decontamination/"},{"content":"2026 | Supplemental Issue | JAVA Chapter 4.2—Site Selection Optimal site selection is a critical component of safe and effective vascular access. The insertion site directly influences the risk of complications, including phlebitis, endothelial injury, thrombosis, catheter malposition, and mechanical failure. Areas of flexion (e.g., antecubital fossa, wrist) are associated with higher rates of dislodgement, occlusion, and patient discomfort.\nA thorough evaluation of vessel condition, depth, …","description":"Association for Vascular Access Adult Clinical Practice Guidelines (JAVA 2026, Vol. 31) — Part 3 covering Sections 3–4: Vascular Access Device Selection, Site Selection, and Insertion Techniques including ultrasound guidance.","section":"vascular-access","title":"AVA CPG 2026 — Part 3: Sections 3–4 (Device Selection \u0026 Insertion)","url":"/vascular-access/guidelines/ava-clinical-practice-guidelines/ava-cpg-2026-part-3-sections-34-device-selection-insertion/"},{"content":"Appendix E: Development Checklists 1 Timelines are subject to change based on topic complexity, publisher scheduling, or other factors.\n32-Month Expert Guidance Checklist Month and Phase Steps Meetings and Votes Before month 1 / Topic proposal 1. Topic proposal 2. GLC review 3. Proposal ranking survey Electronic vote (GLC and Board) 4. Manuscript proposal drafted and submitted 5. Review by Publications Committee 6. Review by Board 7. Manuscript queue updated 8. Editor/Editorial Team informed of …","description":"Development checklists (32-month, 22-month, and 6-month timelines), review and comment period procedures, writing panel author responsibilities, inclusive language guide, and acronyms for infection prevention guideline development.","section":"infection-prevention","title":"IP Guideline Development Handbook — Part 3: Development Checklists, Author Roles \u0026 Inclusive Language","url":"/infection-prevention/guidelines/guideline-development-handbook/ip-guideline-development-handbook-part-3-development-checklists-author-roles-inclusive-language/"},{"content":"This section covers respiratory support in adults with sepsis, septic shock, and sepsis-associated acute respiratory distress syndrome (ARDS), including oxygenation monitoring, oxygen targets, noninvasive respiratory support strategies (high flow nasal cannula, noninvasive positive pressure ventilation), awake proning, lung-protective mechanical ventilation, PEEP strategy, prone positioning, neuromuscular blockade, and venovenous extracorporeal membrane oxygenation (VV-ECMO).\nRespiratory failure …","description":"Surviving Sepsis Campaign 2026 recommendations for oxygenation monitoring, oxygen targets, high flow nasal cannula, noninvasive positive pressure ventilation, awake proning, lung-protective ventilation, tidal volumes, plateau pressure limits, PEEP strategy, prone ventilation, neuromuscular blockade, and veno-venous ECMO in adult sepsis and septic shock.","section":"icu","title":"SSC 2026 — Part 4: Respiratory Support","url":"/icu/guidelines/surviving-sepsis-campaign-2026/ssc-2026-part-4-respiratory-support/"},{"content":"This section covers corticosteroids, metabolic management, and adjunctive therapies in pediatric sepsis and septic shock, including hydrocortisone use, temperature management, sodium bicarbonate, calcium, thyroid hormone, vitamins C, B1, and D, fluid balance optimization, renal replacement therapy and high-volume hemofiltration, plasma exchange for thrombocytopenia-associated multiple organ failure (TAMOF), extracorporeal blood purification, ECMO, management of immunosuppressive therapies, and …","description":"Surviving Sepsis Campaign 2026 pediatric recommendations for hydrocortisone, fever management, sodium bicarbonate, calcium, levothyroxine, vitamin C, thiamine, vitamin D, fluid balance, high-volume hemofiltration, plasma exchange for TAMOF, extracorporeal blood purification, ECMO, immunosuppressive therapy management, and IVIG in pediatric sepsis.","section":"icu","title":"SSC Children 2026 — Part 4: Corticosteroids, Metabolic \u0026 Adjunctive Therapies","url":"/icu/guidelines/surviving-sepsis-campaign-children-2026/ssc-children-2026-part-4-corticosteroids-metabolic-adjunctive-therapies/"},{"content":"1. Cardiac Arrest in Pregnancy Cardiac arrest during pregnancy represents one of the most challenging resuscitation scenarios, requiring simultaneous management of two patients. The incidence is approximately 1 in 12,000 admissions for delivery. Maternal physiology undergoes profound changes that affect both the pathophysiology of arrest and the approach to resuscitation.1 2 3\n1.1 Key Physiological Changes Affecting Resuscitation Change Effect on Resuscitation Aortocaval compression The gravid …","description":"Cardiac arrest management in pregnancy, drowning, hypothermia, pulmonary embolism, tension pneumothorax, cardiac tamponade, opioid overdose, hyperkalemia, anaphylaxis, and toxicologic emergencies.","section":"ed","title":"ACLS \u0026 Cardiac Arrest — Part 4: Special Circumstances in Cardiac Arrest","url":"/ed/guidelines/acls-cardiac-arrest/acls-cardiac-arrest-part-4-special-circumstances-in-cardiac-arrest/"},{"content":"9. Perforated Peptic Ulcer 9.1 Overview Perforated peptic ulcer (PPU) remains a life-threatening surgical emergency, representing the second most common complication of peptic ulcer disease (after bleeding). Despite the widespread use of proton pump inhibitors and Helicobacter pylori eradication, PPU continues to affect approximately 2 to 10 per 100,000 population annually. Mortality ranges from 5% to 25%, increasing significantly with delayed presentation, advanced age, and comorbidities.1\nRisk …","description":"Comprehensive guide to perforated peptic ulcer with Boey score, mesenteric ischemia types and management, ruptured AAA emergency management, ectopic pregnancy evaluation and treatment, and special populations including pediatric, elderly, immunocompromised, and pregnant patients.","section":"ed","title":"Acute Abdominal Emergencies — Part 4: Perforated Peptic Ulcer, Mesenteric Ischemia, Vascular Emergencies \u0026 Special Populations","url":"/ed/guidelines/acute-abdominal-emergencies/acute-abdominal-emergencies-part-4-perforated-peptic-ulcer-mesenteric-ischemia-vascular-emergencies-special-populations/"},{"content":"1. Trauma Airway 1.1 Unique Challenges Trauma patients present the most complex airway scenarios, combining anatomic difficulty (blood, vomit, facial injury, cervical spine immobilization) with physiologic compromise (hemorrhagic shock, traumatic brain injury, chest injury).1 2\nChallenge Mechanism Strategy Blood and vomit in airway Obscures visualization; aspiration risk Aggressive suction (have 2 Yankauer catheters); head-up positioning (if not C-spine restricted); consider lateral position for …","description":"Scenario-specific airway management for trauma, elevated ICP, status asthmaticus, morbid obesity, pregnancy, pediatric patients, angioedema/anaphylaxis, and burns. Complete post-intubation ventilator settings, sedation/analgesia regimens, extubation criteria, and equipment reference tables by age and weight.","section":"ed","title":"Acute Airway Management \u0026 RSI — Part 4: Clinical Scenarios \u0026 Post-Intubation Management","url":"/ed/guidelines/airway-management-rsi/acute-airway-management-rsi-part-4-clinical-scenarios-post-intubation-management/"},{"content":"1. NSTEMI/UA — Invasive Strategy Selection 1.1 Early Invasive vs. Initially Conservative Strategy The fundamental management decision in NSTE-ACS is whether to pursue an early invasive strategy (routine coronary angiography with intent to revascularize) or an initially conservative strategy (ischemia-guided approach with angiography only for recurrent or provocable ischemia). This decision is driven by risk stratification.1 2 3\nStrategy Definition Indications Immediate invasive (\u0026amp;lt; 2 hours) …","description":"Early invasive vs conservative strategy, timing of angiography, antiplatelet and anticoagulation for NSTEMI, special populations (women, elderly, diabetes, CKD, cocaine), arrhythmias, and chest pain disposition.","section":"ed","title":"Acute Coronary Syndromes — Part 4: NSTEMI/UA Management, Special Populations \u0026 Disposition","url":"/ed/guidelines/acute-coronary-syndromes/acute-coronary-syndromes-part-4-nstemi/ua-management-special-populations-disposition/"},{"content":"1. Renal Replacement Therapy Modalities 1.1 Overview Three broad categories of RRT are used in the ICU setting: intermittent hemodialysis (IHD), continuous renal replacement therapy (CRRT), and hybrid therapies (SLED/PIRRT). The choice of modality is determined by hemodynamic stability, the primary indication for RRT, institutional expertise, and resource availability.1 2\n1.2 CRRT Submodes Submode Abbreviation Mechanism Solute Removal Fluid Used Continuous Venovenous Hemofiltration CVVH …","description":"RRT modalities comparison (IHD, CRRT, SLED/PIRRT), timing evidence (STARRT-AKI, AKIKI, IDEAL-ICU, ELAIN), CRRT prescription and dose, citrate and heparin anticoagulation protocols, vascular access, troubleshooting, and discontinuation criteria.","section":"icu","title":"Acute Kidney Injury — Part 4: Renal Replacement Therapy — Modalities, Timing \u0026 Prescription","url":"/icu/guidelines/acute-kidney-injury-rrt/acute-kidney-injury-part-4-renal-replacement-therapy-modalities-timing-prescription/"},{"content":"7. Specific Pain Scenarios The following sections address evidence-based analgesic approaches for common ED pain presentations that benefit from targeted multimodal strategies. Each scenario emphasizes condition-specific first-line therapies, appropriate escalation pathways, and pitfalls to avoid.1 2\n7.1 Renal Colic Renal colic is one of the most severe pain presentations encountered in the ED. Evidence strongly supports an NSAID-first approach, with several randomized controlled trials and …","description":"Renal colic, fractures, headache, sickle cell crisis, burns, pediatric procedural pain, geriatric considerations, discharge multimodal prescribing, opioid alternatives, PDMP requirements, and quality metrics.","section":"ed","title":"Acute Pain \u0026 Procedural Sedation — Part 4: Specific Pain Scenarios, Discharge Management \u0026 Quality Metrics","url":"/ed/guidelines/acute-pain-procedural-sedation/acute-pain-procedural-sedation-part-4-specific-pain-scenarios-discharge-management-quality-metrics/"},{"content":"1. Intracerebral Hemorrhage — Overview Spontaneous (non-traumatic) intracerebral hemorrhage (ICH) accounts for approximately 10-15% of all strokes and carries the highest acute mortality rate of any stroke subtype. Approximately 30-50% of patients die within 30 days, and only 20% of survivors are functionally independent at 6 months. ICH represents a true medical emergency, with early hematoma expansion occurring in up to 30% of patients within the first few hours, a process that is strongly …","description":"ICH pathophysiology, ICH Score, hematoma expansion, blood pressure management (INTERACT2, ATACH-2), anticoagulant reversal protocols, surgical intervention criteria (STICH, MISTIE III, ENRICH), and ICP management.","section":"ed","title":"Acute Stroke Management — Part 4: Intracerebral Hemorrhage","url":"/ed/guidelines/acute-stroke/acute-stroke-management-part-4-intracerebral-hemorrhage/"},{"content":"1. Immunonutrition — Overview Immunonutrition refers to the provision of specific nutrients — including arginine, glutamine, omega-3 fatty acids, and antioxidant vitamins/minerals — at pharmacologic doses with the intent of modulating the immune response and improving clinical outcomes. The evidence for immunonutrition in critical illness is mixed and highly context-dependent. Specific nutrient effects may be beneficial in some populations and harmful in others.1 2 3\n2. Arginine 2.1 Mechanism …","description":"Comprehensive guide to immunonutrition (arginine, glutamine, omega-3 fatty acids, antioxidants), and nutrition management in special ICU populations including sepsis, burns, trauma, TBI, acute pancreatitis, ECMO, obesity, chronic critical illness, open abdomen, and CRRT.","section":"icu","title":"Nutrition in Critical Illness — Part 4: Immunonutrition \u0026 Special Populations","url":"/icu/guidelines/nutrition-critical-illness/nutrition-in-critical-illness-part-4-immunonutrition-special-populations/"},{"content":"Early Mobility and Exercise in the ICU Rationale Prolonged immobility in the ICU leads to rapid and profound skeletal muscle wasting (up to 2–4% loss of muscle cross-sectional area per day), ICU-acquired weakness (ICUAW), functional decline, prolonged ventilator dependence, and worse long-term outcomes. Early mobility — defined as rehabilitation and mobilization initiated within 24–72 hours of ICU admission — is a core element of the ABCDEF bundle and is supported by strong evidence.1 2 3\nKey …","description":"Safety screening criteria for ICU mobilization, progressive mobility levels, ICU-acquired weakness diagnosis and prevention, barriers to early mobility, sleep disruption assessment and causes, non-pharmacologic and pharmacologic sleep interventions, and circadian rhythm management.","section":"icu","title":"Part 4: Early Mobility and Exercise \u0026 Sleep Promotion","url":"/icu/guidelines/sedation-analgesia-delirium/part-4-early-mobility-and-exercise-sleep-promotion/"},{"content":"14. Non-Invasive Respiratory Support 14.1 High-Flow Nasal Cannula (HFNC) 14.1.1 Mechanism and Physiological Effects High-flow nasal cannula delivers heated, humidified oxygen at flow rates up to 60–80 L/min through large-bore nasal prongs. Its physiological benefits include:12\nEffect Mechanism Washout of nasopharyngeal dead space High flow flushes CO2-rich gas from the upper airway, improving alveolar ventilation efficiency Positive airway pressure Low-level PEEP effect (2–7 cmH2O, …","description":"High-flow nasal cannula and FLORALI trial evidence, NIV/BiPAP in ARDS, daily spontaneous breathing trial protocols, SAT-SBT coordination, RSBI, extubation criteria, cuff leak test, post-extubation support, and tracheostomy timing.","section":"icu","title":"Part 4: Non-Invasive Support and Ventilator Liberation","url":"/icu/guidelines/mechanical-ventilation-ards/part-4-non-invasive-support-and-ventilator-liberation/"},{"content":"1. Special Populations 1.1 Neonates Neonatal ICU (NICU) patients — particularly very low birth weight (VLBW, \u0026amp;lt;1500 g) and extremely low birth weight (ELBW, \u0026amp;lt;1000 g) infants — face unique challenges for CLABSI prevention due to limited vascular access options, thin and immature skin, prolonged need for central venous access (TPN, medications), and immune system immaturity.12\n1.1.1 Epidemiology in Neonates CLABSI rates in NICUs are directly correlated with birthweight, with the smallest and …","description":"CLABSI prevention in neonates, immunocompromised patients, hemodialysis catheters, and long-term catheters; NHSN surveillance methodology; SIR calculation; CUSP framework; daily goals checklist; nurse empowerment; zero CLABSI sustainability.","section":"icu","title":"Part 4: Special Populations, Surveillance \u0026 Implementation Science","url":"/icu/guidelines/clabsi-prevention/part-4-special-populations-surveillance-implementation-science/"},{"content":"1. Febrile Seizures Febrile seizures are the most common seizure type in childhood, affecting 2-5% of children between 6 months and 5 years of age. They are defined as seizures occurring in the setting of fever (temperature ≥38°C / 100.4°F) in a child aged 6 months to 5 years, without evidence of central nervous system infection, metabolic disturbance, or a history of afebrile seizures. Despite their frightening presentation, febrile seizures are generally benign with an excellent prognosis.1 2 …","description":"Febrile seizure evaluation, status epilepticus protocol with stepwise treatment, clinical dehydration assessment, WHO dehydration classification, ORT protocol, IV fluid calculation with Holliday-Segar rule, hyponatremia correction, and pediatric diabetic ketoacidosis management including 2-bag system and cerebral edema monitoring.","section":"ed","title":"Pediatric Emergencies — Part 4: Neurologic, Metabolic \u0026 Fluid Emergencies","url":"/ed/guidelines/pediatric-emergencies/pediatric-emergencies-part-4-neurologic-metabolic-fluid-emergencies/"},{"content":"1. Seizures After Cardiac Arrest — Overview Seizures and seizure-like phenomena are common in the post-cardiac arrest population, occurring in approximately 10–35% of comatose survivors. The spectrum ranges from isolated electrographic seizures detectable only on continuous electroencephalography (cEEG) to overt convulsive status epilepticus. The clinical significance, prognostic implications, and management of post-arrest seizures depend critically on accurate classification and …","description":"Continuous EEG monitoring, seizure and status epilepticus treatment, organ donation considerations, cardiac rehabilitation, ICD evaluation, cognitive recovery, and quality metrics after cardiac arrest.","section":"icu","title":"Post-Cardiac Arrest Care — Part 4: Seizure Management, Organ Donation \u0026 Long-Term Recovery","url":"/icu/guidelines/post-cardiac-arrest-ttm/post-cardiac-arrest-care-part-4-seizure-management-organ-donation-long-term-recovery/"},{"content":"1. Corticosteroids in Septic Shock 1.1 Guideline Recommendation Recommendation: For adults with septic shock and an ongoing requirement for vasopressor therapy, the panel suggests using IV corticosteroids.\nStrength: Weak recommendation, moderate quality of evidence1\nSpecific regimen:\nHydrocortisone 200 mg/day administered as either: 50 mg IV every 6 hours, OR 100 mg IV bolus followed by continuous infusion of 200 mg/day (8.3 mg/hour) Duration: Continue for the duration of vasopressor therapy; …","description":"Corticosteroid indications and evidence in septic shock, mechanical ventilation in sepsis-induced ARDS, renal replacement therapy, blood product management, glucose management, DVT and stress ulcer prophylaxis, and nutrition.","section":"icu","title":"Sepsis and Septic Shock — Part 4: Corticosteroids \u0026 Organ Support","url":"/icu/guidelines/sepsis-septic-shock/sepsis-and-septic-shock-part-4-corticosteroids-organ-support/"},{"content":"1. Methanol Poisoning 1.1 Sources and Mechanism Methanol (wood alcohol) is found in windshield washer fluid, antifreeze formulations, industrial solvents, and illicitly produced spirits. Methanol itself has relatively low toxicity; the danger lies in its metabolites. Alcohol dehydrogenase (ADH) converts methanol to formaldehyde, which is then rapidly converted to formic acid by aldehyde dehydrogenase. Formic acid inhibits cytochrome oxidase (complex IV of the mitochondrial electron transport …","description":"Complete management of methanol and ethylene glycol poisoning (fomepizole, hemodialysis), carbon monoxide, cyanide, organophosphates and nerve agents, iron poisoning, caustic ingestions, local anesthetic systemic toxicity (LAST), sympathomimetic toxicity, and enhanced elimination techniques including urinary alkalinization and EXTRIP hemodialysis indications.","section":"ed","title":"Toxicology and Overdose Management — Part 4: Toxic Alcohols, Metals, Organophosphates, Environmental \u0026 Chemical Poisonings","url":"/ed/guidelines/toxicology-overdose/toxicology-and-overdose-management-part-4-toxic-alcohols-metals-organophosphates-environmental-chemical-poisonings/"},{"content":"1. Overview of Transfusion Reactions Transfusion reactions encompass a spectrum of adverse events that may occur during or following blood product administration. Prompt recognition and appropriate management are essential to minimize morbidity and mortality. All transfusion reactions — regardless of severity — must be reported to the blood bank/transfusion service for investigation and regulatory documentation.1\n1.1 Initial Response to Any Suspected Transfusion Reaction When a transfusion …","description":"Recognition and management of all transfusion reactions (hemolytic, FNHTR, allergic, TRALI, TACO), TRALI vs TACO differential table, reporting requirements, patient blood management (PBM), special populations including Jehovah's Witness patients, and quality metrics.","section":"icu","title":"Transfusion in Critical Care — Part 4: Transfusion Reactions, Safety \u0026 Patient Blood Management","url":"/icu/guidelines/transfusion-critical-care/transfusion-in-critical-care-part-4-transfusion-reactions-safety-patient-blood-management/"},{"content":"1. Head Injury Assessment 1.1 Scalp and Skull The scalp is highly vascularized, and lacerations can cause significant hemorrhage, particularly in children and patients on anticoagulant therapy. Hemorrhage control is achieved with direct pressure, Raney clips, or a running locked suture. Palpate the entire scalp for depressed fractures (palpable step-off), open fractures (visible bone or brain tissue), and hematomas.1 2\n1.2 Basilar Skull Fracture Signs Basilar skull fractures are clinical …","description":"Head injury assessment, cervical spine clearance (Canadian C-Spine Rule, NEXUS), chest injury evaluation, abdominal assessment with AAST organ injury grading (liver, spleen, kidney), pelvic fracture management, extremity vascular injury and compartment syndrome, and spinal injury with TLICS scoring.","section":"ed","title":"Trauma Primary and Secondary Survey — Part 4: Focused Injury-Specific Assessment","url":"/ed/guidelines/trauma-primary-secondary-survey/trauma-primary-and-secondary-survey-part-4-focused-injury-specific-assessment/"},{"content":"1. Epidural Hematoma (EDH) 1.1 Epidemiology and Pathophysiology Epidural hematomas occur in approximately 1–4% of all TBI patients and up to 10% of patients with severe TBI. They result from hemorrhage between the dura mater and the inner table of the skull.1\nFeature Detail Most common source Middle meningeal artery (80–90% of cases), typically from a temporal bone fracture Venous sources Dural venous sinuses (especially posterior fossa EDH), diploic veins, middle meningeal vein Associated skull …","description":"Epidural hematoma, acute and chronic subdural hematoma, traumatic subarachnoid hemorrhage, diffuse axonal injury, skull fractures, penetrating TBI, cerebral herniation syndromes, and advanced neuromonitoring including PbtO2, cerebral microdialysis, continuous EEG, and transcranial Doppler.","section":"ed","title":"Traumatic Brain Injury — Part 4: Specific Injury Types, Herniation \u0026 Advanced Monitoring","url":"/ed/guidelines/traumatic-brain-injury/traumatic-brain-injury-part-4-specific-injury-types-herniation-advanced-monitoring/"},{"content":"16. Pathogen-Directed Therapy Once culture and susceptibility data are available (typically at 48–72 hours), empiric therapy should be de-escalated to targeted, pathogen-directed treatment. The following sections provide comprehensive guidance for the most important VAP pathogens.12\n16.1 Methicillin-Resistant Staphylococcus aureus (MRSA) MRSA is responsible for 10–30% of VAP episodes in units with endemic MRSA. MRSA VAP carries a crude mortality rate of 30–60%, though attributable mortality over …","description":"Pathogen-directed therapy for MRSA, Pseudomonas aeruginosa, Acinetobacter baumannii, ESBL-producing Enterobacterales, and Stenotrophomonas maltophilia with dosing tables, VAE versus traditional VAP surveillance reporting, NHSN definitions and algorithms, quality metrics including VAE rates and bundle compliance, and antibiotic stewardship considerations.","section":"icu","title":"Ventilator-Associated Pneumonia — Part 4: Specific Pathogens, Surveillance \u0026 Quality Metrics","url":"/icu/guidelines/ventilator-associated-pneumonia/ventilator-associated-pneumonia-part-4-specific-pathogens-surveillance-quality-metrics/"},{"content":"Special ICU Populations Traumatic Brain Injury (TBI) Patients with traumatic brain injury face a dual challenge: extremely high VTE risk from immobility, trauma-associated coagulopathy, and inflammatory activation, combined with a high risk of intracranial hemorrhage expansion from pharmacologic prophylaxis. The timing of pharmacologic prophylaxis initiation is the critical decision.1 2\nVTE Risk in TBI DVT incidence without prophylaxis: 20–54% (by screening ultrasonography) PE incidence: 2–24% …","description":"VTE prophylaxis in traumatic brain injury, spinal cord injury, neurosurgery, burns, stroke, cardiac surgery, orthopedic trauma, ECMO, thrombocytopenia, active bleeding, pregnancy, and obesity; HIT recognition and alternative anticoagulants; quality metrics and compliance monitoring.","section":"icu","title":"VTE Prophylaxis in Critical Care — Part 4: Special ICU Populations, HIT \u0026 Quality Metrics","url":"/icu/guidelines/vte-prophylaxis-critical-care/vte-prophylaxis-in-critical-care-part-4-special-icu-populations-hit-quality-metrics/"},{"content":"Adjuvant Analgesics Adjuvant analgesics are medications with a primary indication other than pain that possess analgesic properties in specific pain states. They are essential components of multimodal cancer pain management, particularly for neuropathic pain, bone pain, and pain syndromes with inflammatory or compressive components. Adjuvants may be used at any step of the analgesic ladder and can reduce opioid requirements.1\nAnticonvulsants for Neuropathic Pain Anticonvulsants acting on …","description":"Adjuvant analgesic dosing for neuropathic and bone pain, interventional pain procedures, palliative radiation, and chemotherapy-induced peripheral neuropathy prevention and treatment.","section":"oncology","title":"Cancer Pain Management — Part 4: Adjuvant Analgesics, Interventional Approaches, and CIPN Management","url":"/oncology/guidelines/cancer-pain-management/cancer-pain-management-part-4-adjuvant-analgesics-interventional-approaches-and-cipn-management/"},{"content":"Brain Tumors and Central Nervous System Malignancies VTE Risk in Brain Tumors Primary brain tumors and CNS metastases carry among the highest VTE risks of any cancer type. The cumulative VTE incidence in high-grade gliomas (glioblastoma multiforme) is 20-30% over the course of the disease. The risk is particularly elevated in the postoperative period and during concurrent chemoradiation.1 2\nRisk factors specific to brain tumors: Tumor histology: high-grade gliomas (grade III-IV) \u0026amp;gt; meningiomas …","description":"Management of cancer-associated VTE in special populations including brain tumors, thrombocytopenia, renal impairment, GI/GU cancers, recurrent VTE on anticoagulation, incidental and subsegmental PE, and IVC filter indications.","section":"oncology","title":"Cancer-Associated Thrombosis — Part 4: Special Situations and Populations","url":"/oncology/guidelines/cancer-associated-thrombosis/cancer-associated-thrombosis-part-4-special-situations-and-populations/"},{"content":"Patient Assessment and Monitoring Systematic assessment of nausea and vomiting is essential for evaluating the efficacy of antiemetic prophylaxis, detecting breakthrough CINV, and guiding treatment modifications. Assessment should occur at each clinical encounter during and after chemotherapy and should document the presence, severity, timing, and impact of nausea and vomiting separately, as these are distinct symptoms that may not correlate with one another.1\nKey Assessment Elements Element …","description":"Patient assessment and grading tools for CINV including CTCAE and MASCC Antiemesis Tool, evidence-based non-pharmacological interventions, guideline implementation strategies, quality improvement metrics, and patient education.","section":"oncology","title":"CINV Guideline — Part 4: Assessment Tools, Non-Pharmacological Interventions, and Guideline Implementation","url":"/oncology/guidelines/cinv-prevention/cinv-guideline-part-4-assessment-tools-non-pharmacological-interventions-and-guideline-implementation/"},{"content":"10. Antifungal Therapy in Febrile Neutropenia 10.1 Empiric Antifungal Therapy Empiric antifungal therapy is indicated when fever persists after 4–7 days of appropriate broad-spectrum antibacterial therapy in patients with prolonged neutropenia (expected ANC \u0026amp;lt; 500 cells/μL for \u0026amp;gt; 7 days), as invasive fungal infections (IFI) are a major cause of morbidity and mortality in this population.1 2 3\nCriteria for Initiating Empiric Antifungal Therapy Criterion Details Persistent fever Fever …","description":"Empiric and targeted antifungal therapy for invasive aspergillosis and candidemia, central line-associated bloodstream infections in neutropenic patients, infection prevention measures, and patient and caregiver education.","section":"oncology","title":"Febrile Neutropenia — Part 4: Antifungal Therapy, Central Line Infections \u0026 Infection Prevention","url":"/oncology/guidelines/febrile-neutropenia/febrile-neutropenia-part-4-antifungal-therapy-central-line-infections-infection-prevention/"},{"content":"Cardiac Immune-Related Adverse Events Myocarditis Immune-mediated myocarditis is the most feared cardiac irAE because of its high mortality rate, reported at 25% to 50% in published case series. Although uncommon (overall incidence approximately 0.04%–1.1%), it is the leading cause of irAE-related death. It is more common with combination anti-CTLA-4 plus anti-PD-1 therapy and tends to present early in the treatment course, often within the first 1–3 cycles (median onset approximately 30 days). …","description":"Grade-based management of immune-mediated myocarditis, pericarditis, neurologic toxicities (myasthenia gravis, encephalitis, Guillain-Barre, neuropathy), nephritis, inflammatory arthritis, and myositis.","section":"oncology","title":"Immune Checkpoint Inhibitor Adverse Event Management — Part 4: Cardiac, Neurologic, Renal, and Musculoskeletal irAEs","url":"/oncology/guidelines/immunotherapy-adverse-events/immune-checkpoint-inhibitor-adverse-event-management-part-4-cardiac-neurologic-renal-and-musculoskeletal-iraes/"},{"content":"1. Psychosocial Health in Cancer Survivors 1.1 Prevalence and Importance Psychosocial distress affects a substantial proportion of cancer survivors and can persist for years after treatment completion. Untreated psychological distress impairs quality of life, adherence to surveillance and health-promoting behaviors, functional capacity, and may even adversely affect cancer outcomes. All survivorship care guidelines recommend routine screening for psychosocial distress as a standard component of …","description":"Depression, anxiety, PTSD, fear of recurrence, sexual health, physical activity, nutrition, smoking cessation, alcohol, sun protection, and immunizations for cancer survivors.","section":"oncology","title":"Oncology Survivorship Care — Part 4: Psychosocial Health, Sexual Dysfunction, and Health Promotion","url":"/oncology/guidelines/survivorship-care/oncology-survivorship-care-part-4-psychosocial-health-sexual-dysfunction-and-health-promotion/"},{"content":"1. Central Line-Associated Bloodstream Infection (CLABSI) 1.1 Epidemiology in Oncology CLABSI rates are disproportionately elevated in oncology populations compared to the general hospitalized population. Hematologic malignancy patients, stem cell transplant recipients, and patients with prolonged neutropenia face the highest risk. The oncology professional society and infection prevention expert panels identify the following risk factors as oncology-specific contributors:123\nOncology-Specific …","description":"CLABSI prevention and treatment, catheter-associated thrombosis, occlusion management, extravasation, catheter malposition, pinch-off syndrome, and catheter damage in oncology CVAD patients.","section":"oncology","title":"Part 4: Complication Prevention and Management","url":"/oncology/guidelines/central-venous-access/part-4-complication-prevention-and-management/"},{"content":"12. Medical Surveillance Program A medical surveillance program is a systematic approach to monitoring the health of workers who are exposed to hazardous drugs. The program serves multiple purposes: early detection of adverse health effects, identification of workers at increased risk, evaluation of the effectiveness of engineering and administrative controls, and documentation of exposure history for legal and regulatory purposes.1\n12.1 Workers Who Require Medical Surveillance Medical …","description":"Medical surveillance program design and components, biological monitoring, reproductive health counseling and alternative duty policies, training and competency assessment requirements, documentation and record-keeping, non-antineoplastic hazardous drug considerations, home administration guidance, and quality assurance.","section":"oncology","title":"Safe Handling of Hazardous Drugs — Part 4: Medical Surveillance, Training, Reproductive Health, and Special Topics","url":"/oncology/guidelines/hazardous-drug-handling/safe-handling-of-hazardous-drugs-part-4-medical-surveillance-training-reproductive-health-and-special-topics/"},{"content":"JAVA | 2026 | Supplemental Issue Chapter 5.3—Complication Identification \u0026amp;amp; Management Extravasation include localized swelling, burning, tightness, blanching, erythema, pain, or damp dressings. High-risk drugs may cause tissue damage even with small volumes. Early identification, symptom grading, and clinical context must guide escalation and management.\nSummary of Evidence Identification: Extravasation refers to the leakage of vesicants and irritating infusates into surrounding tissues, …","description":"Association for Vascular Access Adult Clinical Practice Guidelines (JAVA 2026, Vol. 31) — Part 4 covering Sections 5–6: Device Maintenance, Complication Identification \u0026 Management, and Special Patient Populations.","section":"vascular-access","title":"AVA CPG 2026 — Part 4: Sections 5–6 (Maintenance, Complications \u0026 Special Populations)","url":"/vascular-access/guidelines/ava-clinical-practice-guidelines/ava-cpg-2026-part-4-sections-56-maintenance-complications-special-populations/"},{"content":"This section covers adjunctive therapies specifically for the management of sepsis (corticosteroids, antipyretics, vitamin C, immunoglobulins, blood purification, vitamin D, XueBiJing) and additional supportive therapies pertinent to patients with sepsis but not prescribed specifically for sepsis treatment (stress ulcer prophylaxis, probiotics, active fluid removal, blood transfusion, nutrition, insulin therapy, renal replacement therapy, sodium bicarbonate, and VTE prophylaxis).\n1. IV …","description":"Surviving Sepsis Campaign 2026 recommendations for IV corticosteroids, antipyretic therapy, IV vitamin C, IV immunoglobulins, blood purification, polymyxin B hemoperfusion, vitamin D, XueBiJing, stress ulcer prophylaxis, probiotics, active fluid removal, restrictive transfusion, enteral nutrition, insulin therapy, renal replacement therapy, sodium bicarbonate, and VTE prophylaxis in adult sepsis and septic shock.","section":"icu","title":"SSC 2026 — Part 5: Adjunctive \u0026 Supportive Therapies","url":"/icu/guidelines/surviving-sepsis-campaign-2026/ssc-2026-part-5-adjunctive-supportive-therapies/"},{"content":"This section covers immune-modulating therapies, early rehabilitation, long-term follow-up, and prophylaxis topics in pediatric sepsis and septic shock, including immune stimulants for leukopenia and immunoparalysis, immunosuppressive therapies for hyperferritinemia syndromes, early rehabilitation bundles, targeted posthospital follow-up programs, post-sepsis morbidity screening, and prophylaxis domains deferred to other guidelines. These recommendations apply to pediatric patients from 37 weeks …","description":"Surviving Sepsis Campaign 2026 pediatric recommendations for immune stimulants in immunoparalysis, immunosuppressive therapy for hyperferritinemia, early rehabilitation bundles, targeted posthospital follow-up, post-sepsis morbidity screening, stress ulcer prophylaxis, VTE prophylaxis, nutrition, and blood products in children with sepsis.","section":"icu","title":"SSC Children 2026 — Part 5: Long-Term Follow-Up \u0026 Prophylaxis","url":"/icu/guidelines/surviving-sepsis-campaign-children-2026/ssc-children-2026-part-5-long-term-follow-up-prophylaxis/"},{"content":"1. Extracorporeal CPR (ECPR) Extracorporeal cardiopulmonary resuscitation (ECPR) refers to the emergent initiation of venoarterial extracorporeal membrane oxygenation (VA-ECMO) during cardiac arrest to provide mechanical circulatory support and gas exchange while the underlying cause of arrest is identified and treated. ECPR has emerged as a potentially transformative intervention for selected patients with refractory cardiac arrest.1 2 3\n1.1 Mechanism and Rationale During conventional CPR, even …","description":"Extracorporeal CPR indications and evidence, CPR quality metrics and physiologic targets, pediatric cardiac arrest differences with weight-based dosing, neonatal resuscitation overview, termination of resuscitation criteria, and post-arrest care cross-reference.","section":"ed","title":"ACLS \u0026 Cardiac Arrest — Part 5: ECPR, CPR Quality Metrics, Pediatric Considerations \u0026 Termination of Resuscitation","url":"/ed/guidelines/acls-cardiac-arrest/acls-cardiac-arrest-part-5-ecpr-cpr-quality-metrics-pediatric-considerations-termination-of-resuscitation/"},{"content":"1. Dual Antiplatelet Therapy (DAPT) Duration 1.1 Standard DAPT Duration After ACS The default DAPT duration (aspirin + P2Y12 inhibitor) after ACS with PCI is 12 months, regardless of stent type. However, the optimal duration is increasingly individualized based on the balance of ischemic and bleeding risk.1 2 3\nScenario Recommended DAPT Duration Evidence/Rationale ACS with PCI (standard risk) 12 months (Class I, LOE A) Default duration supported by landmark trials (PLATO, TRITON-TIMI 38, CURE) …","description":"Long-term antiplatelet therapy and DAPT duration, statin therapy, ACE inhibitor/ARB, beta-blocker, aldosterone antagonists, cardiac rehabilitation, lifestyle modification, and quality metrics.","section":"ed","title":"Acute Coronary Syndromes — Part 5: Post-ACS Care, Secondary Prevention \u0026 Quality Metrics","url":"/ed/guidelines/acute-coronary-syndromes/acute-coronary-syndromes-part-5-post-acs-care-secondary-prevention-quality-metrics/"},{"content":"1. Sepsis-Associated AKI (SA-AKI) 1.1 Epidemiology Sepsis is the most common cause of AKI in the ICU, accounting for approximately 40-50% of all ICU-associated AKI cases. Sepsis-associated AKI carries a higher mortality than either sepsis or AKI alone, with hospital mortality rates of 40-60%.1 2\n1.2 Pathophysiology — Distinct from Classical Ischemic ATN The pathophysiology of SA-AKI is fundamentally different from classical hypovolemic/ischemic ATN, and this distinction has important management …","description":"Sepsis-associated AKI, cardiac surgery-associated AKI, contrast-associated AKI, hepatorenal syndrome, rhabdomyolysis, tumor lysis syndrome, AKI in pregnancy, long-term outcomes, CKD progression, nephrology referral criteria, and quality metrics.","section":"icu","title":"Acute Kidney Injury — Part 5: Special Populations \u0026 Long-Term Outcomes","url":"/icu/guidelines/acute-kidney-injury-rrt/acute-kidney-injury-part-5-special-populations-long-term-outcomes/"},{"content":"1. Subarachnoid Hemorrhage — Overview Aneurysmal subarachnoid hemorrhage (aSAH) results from rupture of an intracranial saccular aneurysm, releasing blood into the subarachnoid space. It accounts for approximately 3-5% of all strokes but causes a disproportionate share of stroke-related morbidity and mortality, affecting a relatively younger population (mean age ~55 years). Approximately 10-15% of patients die before reaching the hospital, and overall case fatality is 25-50%. Among survivors, …","description":"SAH presentation, Hunt \u0026 Hess scale, WFNS grade, Fisher CT grading, aneurysm management, vasospasm prevention, DCI, TIA evaluation (ABCD2, dual antiplatelet), stroke mimics, posterior circulation, wake-up stroke, pregnancy, and pediatric stroke.","section":"ed","title":"Acute Stroke Management — Part 5: Subarachnoid Hemorrhage, TIA \u0026 Special Populations","url":"/ed/guidelines/acute-stroke/acute-stroke-management-part-5-subarachnoid-hemorrhage-tia-special-populations/"},{"content":"Special Populations Post-Operative ICU Patients Post-surgical patients admitted to the ICU present unique challenges in PADIS management due to acute surgical pain, anesthetic carryover effects, and high delirium risk, particularly in elderly patients and those undergoing cardiac or major abdominal surgery.1 2\nPain Management Considerations Principle Details Multimodal analgesia is the standard Combine opioids with acetaminophen, NSAIDs (if not contraindicated), gabapentinoids, ketamine, and …","description":"PADIS management in special populations including post-operative, neurological injury, substance withdrawal (alcohol/CIWA, opioid/COWS), ECMO and CRRT dosing adjustments, plus quality metrics, bundle compliance measurement, and implementation strategies.","section":"icu","title":"Part 5: Special Populations \u0026 Quality Metrics","url":"/icu/guidelines/sedation-analgesia-delirium/part-5-special-populations-quality-metrics/"},{"content":"17. COVID-19 ARDS 17.1 Overview The SARS-CoV-2 pandemic (2020–2023) generated an unprecedented volume of experience with ARDS management and raised important questions about whether COVID-19-associated ARDS represents a distinct phenotype requiring modified ventilatory strategies. The weight of evidence supports that standard lung-protective ventilation principles remain the foundation of management, with some etiology-specific considerations.12\n17.2 Proposed COVID-19 ARDS Phenotypes Early in …","description":"COVID-19 ARDS phenotypes and management, transfusion-related acute lung injury, aspiration-related ARDS, immunocompromised patients, obesity and ARDS, pediatric considerations, long-term outcomes, and ICU quality benchmarks for ventilator management.","section":"icu","title":"Part 5: Specific Etiologies, Special Populations, and Quality Metrics","url":"/icu/guidelines/mechanical-ventilation-ards/part-5-specific-etiologies-special-populations-and-quality-metrics/"},{"content":"1. Intussusception Intussusception is the most common cause of intestinal obstruction in children aged 3 months to 6 years, with a peak incidence at 5-10 months. It occurs when a proximal segment of bowel (intussusceptum) telescopes into an adjacent distal segment (intussuscipiens), most commonly at the ileocolic junction. The majority of cases in children are idiopathic, thought to be triggered by hypertrophied Peyer patches following viral illness. A pathologic lead point (Meckel diverticulum, …","description":"Intussusception, pyloric stenosis, testicular torsion, PECARN head CT and abdominal trauma decision rules, solid organ injury non-operative management, non-accidental trauma screening, neonatal emergencies including hypoglycemia, congenital heart disease with PGE1, hyperbilirubinemia, and a comprehensive pediatric medication dosing reference table.","section":"ed","title":"Pediatric Emergencies — Part 5: Common Surgical Emergencies, Trauma \u0026 Neonatal Emergencies","url":"/ed/guidelines/pediatric-emergencies/pediatric-emergencies-part-5-common-surgical-emergencies-trauma-neonatal-emergencies/"},{"content":"1. Sepsis in the Immunocompromised Patient 1.1 Overview Immunocompromised patients represent a distinct and challenging subset of sepsis management. These patients have an altered spectrum of potential pathogens, may present with atypical signs and symptoms, and frequently have higher mortality rates.1 2\nCategories of immunocompromised patients:\nCategory Examples Key Considerations Neutropenia Chemotherapy-induced, hematologic malignancy, aplastic anemia Absent or blunted inflammatory response; …","description":"Sepsis management in immunocompromised patients, elderly, and pregnancy; bundle compliance and quality metrics; post-sepsis syndrome; long-term outcomes and performance improvement.","section":"icu","title":"Sepsis and Septic Shock — Part 5: Special Populations, Quality Metrics \u0026 Long-Term Outcomes","url":"/icu/guidelines/sepsis-septic-shock/sepsis-and-septic-shock-part-5-special-populations-quality-metrics-long-term-outcomes/"},{"content":"1. Pediatric Poisoning — Special Considerations 1.1 Epidemiology and Patterns Unintentional poisoning is one of the leading causes of injury-related morbidity and mortality in children. The epidemiology differs substantially from adult poisoning:1 2\nChildren \u0026amp;lt; 6 years account for approximately half of all poison center calls Most pediatric exposures are unintentional (exploratory behavior) Adolescent exposures are more likely intentional (self-harm, substance abuse) Toddlers (1–3 years) are …","description":"One pill can kill agents, weight-based pediatric antidote dosing, comprehensive antidote dosing reference table, toxicologic cardiac arrest management by agent, alcohol withdrawal protocols, synthetic cannabinoids, novel psychoactive substances, and poison center consultation guidance.","section":"ed","title":"Toxicology and Overdose Management — Part 5: Pediatric Poisoning, Antidote Reference Table, Toxicologic Cardiac Arrest \u0026 Substance Abuse Emergencies","url":"/ed/guidelines/toxicology-overdose/toxicology-and-overdose-management-part-5-pediatric-poisoning-antidote-reference-table-toxicologic-cardiac-arrest-substance-abuse-emergencies/"},{"content":"1. Pediatric Trauma 1.1 Overview Trauma is the leading cause of death in children older than 1 year in developed nations. Pediatric trauma differs from adult trauma in anatomy, physiology, injury patterns, and psychosocial considerations. Key principles include:1 2 3\nChildren have a larger body surface area to mass ratio, leading to greater heat loss and susceptibility to hypothermia The head is proportionally larger, and TBI is the most common cause of death in pediatric trauma The thorax is …","description":"Pediatric trauma (vital signs by age, Broselow, non-accidental trauma), geriatric trauma (anticoagulant reversal, occult shock), pregnant trauma (physiologic changes, perimortem C-section), burns (Parkland formula, rule of nines, escharotomy), and penetrating vs blunt selective non-operative management.","section":"ed","title":"Trauma Primary and Secondary Survey — Part 5: Special Trauma Populations","url":"/ed/guidelines/trauma-primary-secondary-survey/trauma-primary-and-secondary-survey-part-5-special-trauma-populations/"},{"content":"1. Concussion / Mild Traumatic Brain Injury 1.1 Definition Concussion is defined as a traumatic brain injury induced by biomechanical forces, resulting in a complex pathophysiological process affecting the brain. The 6th International Consensus Conference on Concussion in Sport (Amsterdam, 2022) provides the current consensus definition.1\nFeature Detail Mechanism Direct blow to the head, face, neck, or body with an impulsive force transmitted to the head Clinical features Rapid onset of …","description":"Concussion assessment (SCAT6), return-to-play and return-to-learn protocols, post-concussive syndrome, pediatric TBI, geriatric TBI, TBI in pregnancy, IMPACT and CRASH prognostic models, biomarkers (GFAP, UCH-L1, S100B, NSE), and rehabilitation referral criteria.","section":"ed","title":"Traumatic Brain Injury — Part 5: Concussion, Special Populations \u0026 Prognosis","url":"/ed/guidelines/traumatic-brain-injury/traumatic-brain-injury-part-5-concussion-special-populations-prognosis/"},{"content":"Special Populations Elderly Patients Cancer is disproportionately a disease of older adults, and pain management in the elderly requires specific adjustments to account for age-related pharmacokinetic and pharmacodynamic changes, comorbidities, polypharmacy, and altered pain perception and reporting.1\nPharmacokinetic Considerations Parameter Age-Related Change Clinical Implication Body composition Increased fat-to-lean ratio; decreased total body water Increased volume of distribution for …","description":"Pain management in elderly, pediatric, renal/hepatic impairment, and substance use disorder populations; non-pharmacological interventions; palliative sedation; and survivorship chronic pain strategies.","section":"oncology","title":"Cancer Pain Management — Part 5: Special Populations, Non-Pharmacological Approaches, Palliative Sedation, and Survivorship Pain","url":"/oncology/guidelines/cancer-pain-management/cancer-pain-management-part-5-special-populations-non-pharmacological-approaches-palliative-sedation-and-survivorship-pain/"},{"content":"CVAD-Related Thrombosis: Epidemiology and Definitions Definitions Central venous access device (CVAD)-related thrombosis encompasses a spectrum of thrombotic events associated with the presence of a central venous catheter:1 2\nTerm Definition Catheter-related thrombosis (CRT) Thrombosis of the vein in which the catheter resides, or thrombosis involving a fibrin sheath or mural thrombus at the catheter tip Upper extremity deep vein thrombosis (UEDVT) DVT involving the subclavian, axillary, …","description":"Comprehensive management of central venous access device-related thrombosis including diagnosis, treatment, catheter management decisions, upper extremity DVT, patient education, monitoring, and follow-up.","section":"oncology","title":"Cancer-Associated Thrombosis — Part 5: CVAD-Related Thrombosis Management and Patient Education","url":"/oncology/guidelines/cancer-associated-thrombosis/cancer-associated-thrombosis-part-5-cvad-related-thrombosis-management-and-patient-education/"},{"content":"Hematologic Immune-Related Adverse Events Hematologic irAEs are uncommon (\u0026amp;lt; 1%–3%) but include potentially life-threatening cytopenias. They can be challenging to diagnose because cytopenias in oncology patients have a broad differential including disease progression, chemotherapy effects, and bone marrow infiltration.1 2 3\nImmune Thrombocytopenia (ITP) ICI-associated immune thrombocytopenia presents with isolated thrombocytopenia, often with mucocutaneous bleeding (petechiae, purpura, …","description":"Management of immune-mediated hematologic toxicities, ophthalmologic irAEs, combination immunotherapy toxicity profiles, rechallenge criteria, preexisting autoimmune disease, special populations, multidisciplinary triggers, and patient education.","section":"oncology","title":"Immune Checkpoint Inhibitor Adverse Event Management — Part 5: Hematologic, Ophthalmologic irAEs, Special Populations, and Rechallenge","url":"/oncology/guidelines/immunotherapy-adverse-events/immune-checkpoint-inhibitor-adverse-event-management-part-5-hematologic-ophthalmologic-iraes-special-populations-and-rechallenge/"},{"content":"1. Survivorship Care Models 1.1 Overview of Care Delivery Models The optimal model for delivering survivorship care depends on the complexity of the survivor\u0026amp;rsquo;s needs, available resources, and local healthcare infrastructure. No single model is universally superior; rather, the choice of model should be tailored to the patient\u0026amp;rsquo;s risk level and the capacity of the care system.1 2\nComparison of Survivorship Care Delivery Models Model Description Advantages Limitations Best Suited For …","description":"Risk-stratified survivorship care models, shared care integration, transition from oncology to primary care, pediatric and AYA survivorship, childhood cancer late effects, financial toxicity, and psychosocial support resources.","section":"oncology","title":"Oncology Survivorship Care — Part 5: Care Models, Pediatric/AYA Survivorship, Transition of Care, and Financial Toxicity","url":"/oncology/guidelines/survivorship-care/oncology-survivorship-care-part-5-care-models-pediatric/aya-survivorship-transition-of-care-and-financial-toxicity/"},{"content":"1. Special Populations in Oncology Vascular Access 1.1 Pediatric Oncology 1.1.1 Device Selection Implanted ports are the preferred vascular access device for children with cancer requiring long-term treatment, based on evidence demonstrating lower venous thromboembolism and infection rates compared to tunneled catheters and PICCs.123\nAge Group Preferred Device Considerations Infants (\u0026amp;lt;1 year) Tunneled catheter (Broviac) Small vessel size may limit port placement; may use single-lumen silicone …","description":"Pediatric oncology, elderly patients, thrombocytopenic and anticoagulated patients, device removal criteria and procedures, patient and caregiver education, and quality surveillance for CVADs in oncology.","section":"oncology","title":"Part 5: Special Populations, Device Removal, Patient Education, and Quality Metrics","url":"/oncology/guidelines/central-venous-access/part-5-special-populations-device-removal-patient-education-and-quality-metrics/"},{"content":"JAVA | 2026 | Supplemental Issue Glossary of Terms Chronic Kidney Disease (CKD) A progressive decline in kidney function that influences vascular access planning; requires vessel preservation to support future dialysis access.\nClinically Indicated Replacement A device removal and replacement strategy in which vascular access devices are removed only when clinically necessary (e.g., completion of therapy, signs of complication, or device malfunction), rather than on a fixed schedule.\nPractical …","description":"Association for Vascular Access Adult Clinical Practice Guidelines (JAVA 2026, Vol. 31) — Part 5: Comprehensive glossary of vascular access terminology and definitions referenced throughout the guidelines.","section":"vascular-access","title":"AVA CPG 2026 — Part 5: Glossary of Terms","url":"/vascular-access/guidelines/ava-clinical-practice-guidelines/ava-cpg-2026-part-5-glossary-of-terms/"},{"content":"This section covers the goals of care, transitions of care, and long-term outcomes and recovery for adults with sepsis and septic shock. It addresses goals of care discussions, advanced directives, time-limited trials, palliative care integration, in-hospital transitions (ICU to floor), medication reconciliation, hospital discharge planning, patient and family education about sepsis, education of primary care providers, post-hospital follow-up services, physical rehabilitation, mental health …","description":"Surviving Sepsis Campaign 2026 recommendations for goals of care discussions, advanced directives, time-limited trials, palliative care, ICU transition programs, handoff processes, medication reconciliation, discharge planning, patient and family education, post-critical illness follow-up, physical rehabilitation, mental health support, and cognitive recovery in adult sepsis and septic shock.","section":"icu","title":"SSC 2026 — Part 6: Goals of Care, Transitions \u0026 Long-Term Outcomes","url":"/icu/guidelines/surviving-sepsis-campaign-2026/ssc-2026-part-6-goals-of-care-transitions-long-term-outcomes/"},{"content":"Air Embolism in Vascular Access: Prevention, Recognition, and Emergency Management Venous air embolism (VAE) is a rare but potentially catastrophic complication of central vascular access devices. When air enters the central venous system, it travels to the right heart and pulmonary vasculature, where it can cause immediate cardiovascular collapse. Because most causes of air embolism during vascular access care are preventable with known techniques, every clinician who inserts, accesses, or …","description":"Complete guide to air embolism in vascular access: pathophysiology, prevention during insertion and removal, recognition of venous air embolism, emergency management (Durant's maneuver, aspiration, oxygen therapy), and high-risk scenarios.","section":"vascular-access","title":"Air Embolism in Vascular Access: Prevention, Recognition, and Emergency Management","url":"/vascular-access/guides/catheter-complications/air-embolism-prevention-guide/"},{"content":"Antimicrobial Catheters and Dressings: Evidence for High-Risk CLABSI Settings Standard insertion and maintenance bundles reduce CLABSI rates by 60–70% in most settings. For units that still experience CLABSI events despite full bundle compliance, antimicrobial-impregnated catheters and supplemental antimicrobial dressing strategies offer evidence-based additive risk reduction. These technologies should be deployed strategically — as part of an escalation response to persistent high rates, not as …","description":"Evidence-based guide to antimicrobial-impregnated catheters (CHG/SS, minocycline-rifampin), antimicrobial dressings, and antimicrobial lock therapy for CLABSI prevention in high-risk settings — indications, evidence, and limitations.","section":"vascular-access","title":"Antimicrobial Catheters and Dressings: Evidence for High-Risk CLABSI Settings","url":"/vascular-access/guides/clabsi-prevention/antimicrobial-catheters-dressings/"},{"content":"Catheter Malposition: Recognition, Types, and Management A malpositioned CVAD tip is a catheter whose tip is located anywhere other than the lower SVC at the cavoatrial junction — the defined standard tip position for all CVADs. Malposition is reported in 1–10% of CVAD insertions depending on device type, insertion approach, and definition used. Unrecognized malposition exposes patients to vessel injury from improperly positioned infusions, catheter dysfunction, thrombosis, and cardiac …","description":"Guide to CVAD malposition types, recognition, and management: primary malposition (at insertion), secondary malposition (tip migration), IJ, azygos, subclavian, and RA malpositions, repositioning techniques, and prevention.","section":"vascular-access","title":"Catheter Malposition: Recognition, Types, and Management","url":"/vascular-access/guides/catheter-complications/catheter-malposition-guide/"},{"content":"Catheter Occlusion Management: Alteplase, Troubleshooting, and Prevention Catheter occlusion — defined as any situation preventing adequate blood withdrawal or infusion through a vascular access device — affects 10–25% of CVADs during their dwell. It is the most common non-infectious catheter complication requiring intervention. Prompt recognition and systematic troubleshooting prevent unnecessary catheter replacement and maintain infusion therapy continuity.\nParent guide: Catheter …","description":"Complete clinical guide to catheter occlusion management: occlusion types (thrombotic, non-thrombotic, mechanical), alteplase protocol (2 mg/2 mL), troubleshooting approach, non-thrombotic occlusion management, and prevention with SASH flushing.","section":"vascular-access","title":"Catheter Occlusion Management: Alteplase, Troubleshooting, and Prevention","url":"/vascular-access/guides/catheter-complications/catheter-occlusion-management/"},{"content":"Catheter-Associated Thrombosis: Upper Extremity DVT and Fibrin Sheath Management Catheter-associated thrombosis is the most common non-infectious complication of central venous access devices. It ranges from asymptomatic fibrin deposition (nearly universal with prolonged dwell) to symptomatic upper extremity deep vein thrombosis (UEDVT) requiring anticoagulation. Understanding the spectrum, risk factors, diagnostic approach, and treatment decision framework is essential for any clinician …","description":"Complete clinical guide to catheter-associated thrombosis: PICC-associated UEDVT (incidence, risk factors, diagnosis), fibrin sheath, treatment options (anticoagulation, catheter removal decision), and prevention strategies.","section":"vascular-access","title":"Catheter-Associated Thrombosis: Upper Extremity DVT and Fibrin Sheath Management","url":"/vascular-access/guides/catheter-complications/catheter-thrombosis-guide/"},{"content":"Chlorhexidine Gluconate (CHG) in CLABSI Prevention: Evidence and Clinical Application Chlorhexidine gluconate (CHG) is the cornerstone antiseptic agent in vascular access infection prevention. It appears in three distinct CLABSI prevention applications: pre-insertion skin antisepsis (2% CHG/IPA solution), CHG-impregnated catheter dressings, and daily CHG patient bathing. Understanding the evidence, mechanism, application requirements, and safety considerations for each application enables …","description":"Evidence-based guide to chlorhexidine gluconate (CHG) in CLABSI prevention: skin antisepsis (2% CHG vs povidone-iodine), CHG-impregnated dressings, daily CHG bathing, application technique, dry time requirements, and CHG safety considerations.","section":"vascular-access","title":"Chlorhexidine Gluconate (CHG) in CLABSI Prevention: Evidence and Clinical Application","url":"/vascular-access/guides/clabsi-prevention/chlorhexidine-gluconate-clabsi/"},{"content":"CLABSI Definition, Epidemiology, and Surveillance: What Clinicians Need to Know Central line-associated bloodstream infection (CLABSI) is one of the most serious, costly, and largely preventable hospital-acquired infections. Despite decades of evidence-based prevention efforts, approximately 30,000–41,000 CLABSIs occur annually in US acute care hospitals, each carrying a 12–25% attributable mortality and $46,000–$68,000 in excess hospital costs.\nUnderstanding how CLABSI is defined, measured, and …","description":"Complete overview of CLABSI definition (NHSN criteria), epidemiology (incidence, mortality, cost), CLABSI vs CRBSI distinction, NHSN surveillance methodology, SIR benchmarking, and how CLABSI rates are calculated.","section":"vascular-access","title":"CLABSI Definition, Epidemiology, and Surveillance: What Clinicians Need to Know","url":"/vascular-access/guides/clabsi-prevention/clabsi-definition-epidemiology/"},{"content":"CLABSI Insertion Bundle: The 5 Elements That Prevent Central Line Infections The central line insertion bundle — first described by Peter Pronovost in the landmark Michigan Keystone study — is the foundational intervention for CLABSI prevention. When all five bundle elements are implemented consistently for every central line insertion, the results are dramatic: the Keystone study reduced Michigan ICU CLABSI rates by 66% within 3 months and brought median rates to zero, where they remained for …","description":"Evidence-based guide to the CLABSI insertion bundle: 5 elements (hand hygiene, maximal sterile barrier, CHG antisepsis, optimal site selection, daily necessity review), implementation, and bundle compliance documentation.","section":"vascular-access","title":"CLABSI Insertion Bundle: The 5 Elements That Prevent Central Line Infections","url":"/vascular-access/guides/clabsi-prevention/clabsi-insertion-bundle/"},{"content":"CLABSI Maintenance Bundle: Post-Insertion Central Line Infection Prevention The central line maintenance bundle addresses the ongoing infection risks present throughout a catheter\u0026amp;rsquo;s dwell — intraluminal contamination at hubs and connectors, extraluminal contamination at the insertion site, and prolonged unnecessary dwell. Studies analyzing CLABSI events consistently find that failures of maintenance practice, not insertion technique, are responsible for the majority of late-onset CLABSIs …","description":"Complete guide to the CLABSI maintenance bundle: scrub-the-hub technique, CHG-impregnated dressings, CHG daily bathing, needleless connector management, administration set change intervals, and daily necessity review and CDC guidelines.","section":"vascular-access","title":"CLABSI Maintenance Bundle: Post-Insertion Central Line Infection Prevention","url":"/vascular-access/guides/clabsi-prevention/clabsi-maintenance-bundle/"},{"content":"CLABSI Prevention Framework: Complete Evidence-Based Reference for Clinical Teams Central line-associated bloodstream infection (CLABSI) is one of the most preventable and most costly healthcare-associated infections. The evidence that CLABSIs are preventable — not merely reducible — was established by the Keystone ICU project, in which 103 Michigan ICUs reduced median CLABSI rates to zero within 18 months using a structured bundle approach. This framework consolidates the evidence base for …","description":"Comprehensive CLABSI prevention framework covering the complete evidence base: insertion bundle, maintenance bundle, CHG antisepsis, antimicrobial catheters, needleless connector management, surveillance definitions, and zero CLABSI implementation strategy.","section":"vascular-access","title":"CLABSI Prevention Framework: Complete Evidence-Based Reference for Clinical Teams","url":"/vascular-access/resources/clabsi-prevention-framework/"},{"content":"Critical Care Vascular Access: ICU Device Selection, Arterial Lines, and High-Acuity Protocols The ICU patient presents the most complex vascular access scenario in clinical medicine: multiple simultaneous access needs, hemodynamic instability that precludes repositioning or waiting, coagulopathy that complicates insertion, high-acuity medications (vasopressors, high-concentration electrolytes, insulin drips) that mandate central venous access, and extended CVAD dwell times in a patient …","description":"Clinical guide to critical care vascular access: CVC site selection in the ICU, arterial line placement and management, vasopressor central access requirements, CRRT/CVVHD access, pulmonary artery catheter, CLABSI prevention in the ICU, and simultaneous multi-device management in the critically ill.","section":"vascular-access","title":"Critical Care Vascular Access: ICU Device Selection, Arterial Lines, and High-Acuity Protocols","url":"/vascular-access/guides/vascular-access-special-populations/critical-care-vascular-access-guide/"},{"content":"CRNI Certification: Complete Guide to Certified Registered Nurse Infusion The CRNI (Certified Registered Nurse Infusion) is the specialty certification for infusion nursing practice in the United States, administered by CVAA. The CRNI validates advanced knowledge across the full scope of infusion therapy — vascular access, medication infusion, infection prevention, and patient care — and is the recognized credential for infusion nursing specialists.\nParent guide: Vascular Access Credentialing: …","description":"Complete guide to CRNI (Certified Registered Nurse Infusion) certification: eligibility requirements, exam content domains, application process, CRNI vs VA-BC comparison, and recertification.","section":"vascular-access","title":"CRNI Certification: Complete Guide to Certified Registered Nurse Infusion","url":"/vascular-access/guides/vascular-access-credentialing/crni-certification-guide/"},{"content":"CVAD Tip Location Standards: CEVAD Consensus and Clinical Application Correct tip placement is fundamental to safe CVAD use. An incorrectly positioned catheter tip — whether too proximal, too distal, or in a lateral branch vessel — prevents adequate hemodilution of infusates, increases complication rates, and may cause cardiac arrhythmias or perforation. The international vascular access community has converged on the cavoatrial junction (CAJ) as the universal standard tip position for all CVADs …","description":"CVAD tip location standards per CEVAD 2020 consensus: cavoatrial junction target, radiographic landmarks, device-specific tip positions, tip confirmation methods (ECG, CXR, fluoroscopy), and malposition classification.","section":"vascular-access","title":"CVAD Tip Location Standards: CEVAD Consensus and Clinical Application","url":"/vascular-access/guides/central-venous-catheters/cvad-tip-location-standards/"},{"content":"Evidence-Based Vascular Access Device Selection: Clinical Decision Framework The choice of vascular access device is not a trivial clinical decision. Inappropriate device selection — using a central device when a peripheral approach would suffice, or using a peripheral device for therapy requiring central access — carries real patient harm risks. Vascular access device selection requires systematic clinical reasoning grounded in evidence-based standards.\nThis guide covers the key frameworks and …","description":"Evidence-based vascular access device selection using  standards, the Vessel Health and Preservation (VHP) framework, DIVA score, osmolarity thresholds, and the MAGIC appropriateness criteria.","section":"vascular-access","title":"Evidence-Based Vascular Access Device Selection: Clinical Decision Framework","url":"/vascular-access/guides/vascular-access/evidence-based-device-selection/"},{"content":"Flushing and Locking Vascular Access Devices: SASH Protocol and Evidence Flushing and locking are fundamental maintenance practices for all vascular access devices. Proper technique maintains catheter patency, prevents medication interactions within the catheter lumen, and reduces the risk of intraluminal thrombosis. Improper flushing — too little saline, no pulsatile technique, no positive pressure — is the primary cause of catheter occlusion, one of the most common CVAD complications.\nParent …","description":"Evidence-based guide to vascular access device flushing and locking: SASH protocol (Saline-Administer-Saline-Heparin), pulsatile flush technique, positive pressure locking, heparin vs saline evidence, flush volumes, and device-specific protocols.","section":"vascular-access","title":"Flushing and Locking Vascular Access Devices: SASH Protocol and Evidence","url":"/vascular-access/guides/infusion-therapy-safety/flushing-locking-sash-protocol/"},{"content":"Hemodialysis Vascular Access: AV Fistula, Graft, and Tunneled Dialysis Catheter Guide Hemodialysis requires vascular access capable of delivering blood flow rates of 300–450 mL/min to the dialysis circuit — far beyond what standard CVADs can provide. The choice and management of hemodialysis vascular access determines dialysis efficiency, patient quality of life, and complication risk. For vascular access clinicians, understanding the hemodialysis access hierarchy is essential because decisions …","description":"Clinical guide to hemodialysis vascular access: AV fistula (preferred), AV graft, and tunneled hemodialysis catheter — indications, care, complications, the access hierarchy, and vessel preservation for CKD patients.","section":"vascular-access","title":"Hemodialysis Vascular Access: AV Fistula, Graft, and Tunneled Dialysis Catheter Guide","url":"/vascular-access/guides/central-venous-catheters/hemodialysis-vascular-access-guide/"},{"content":"Hemodialysis Vascular Access: AVF, AVG, and Tunneled Dialysis Catheter Clinical Guide Hemodialysis vascular access represents a unique and specialized domain within vascular access practice. Unlike most IV therapy access — which uses central venous devices to deliver drugs or fluids — hemodialysis access must sustain high-volume extracorporeal blood flow (typically 300–500 mL/min) across three or more sessions per week, for years to decades. The vascular access itself becomes a critical …","description":"Clinical guide to hemodialysis vascular access: AVF creation and maturation criteria, AV graft cannulation, tunneled dialysis catheter placement and complications, vessel preservation in CKD/ESRD, fistula-first policy, buttonhole vs rope-ladder technique, and catheter-to-fistula transition.","section":"vascular-access","title":"Hemodialysis Vascular Access: AVF, AVG, and Tunneled Dialysis Catheter Clinical Guide","url":"/vascular-access/guides/vascular-access-special-populations/hemodialysis-access-clinical-guide/"},{"content":"High-Alert Medications in IV Therapy: Safety Standards and Clinical Protocols High-alert medications are drugs that bear a heightened risk of causing significant patient harm when used in error. In IV therapy, high-alert medications warrant special safeguards because errors in concentration, rate, route, or patient identification can cause catastrophic, sometimes irreversible harm — cardiac arrest from hyperkalemia, fatal bleeding from heparin overdose, hypoglycemia from insulin infusion errors, …","description":"Clinical guide to high-alert IV medications: ISMP list of high-alert medications in vascular access, safety protocols for concentrated KCl, heparin, insulin, opioids, neuromuscular blockers, and chemotherapy — with required safeguards.","section":"vascular-access","title":"High-Alert Medications in IV Therapy: Safety Standards and Clinical Protocols","url":"/vascular-access/guides/infusion-therapy-safety/high-alert-medications-iv/"},{"content":"Implanted Vascular Access Ports: Complete Clinical Guide The implanted vascular access port — commonly called a \u0026amp;ldquo;port,\u0026amp;rdquo; \u0026amp;ldquo;port-a-cath,\u0026amp;rdquo; or \u0026amp;ldquo;mediport\u0026amp;rdquo; — is the gold standard for long-term, intermittent central venous access. With no external components between accesses and the lowest CLABSI rate of all CVADs per comparable dwell period, the port enables patients to maintain normal daily activities including swimming, showering, and physical activity.\nThis guide …","description":"Complete clinical guide to implanted vascular access ports: port anatomy, Huber needle access technique, ANTT flushing and locking protocol, power-injectable ports, port complications, and deaccess procedure.","section":"vascular-access","title":"Implanted Vascular Access Ports: Complete Clinical Guide","url":"/vascular-access/guides/central-venous-catheters/implanted-port-guide/"},{"content":"Infiltration and Extravasation: Clinical Guide to Recognition, Staging, and Treatment Infiltration and extravasation represent the unintended delivery of infusate into surrounding tissue rather than the intended intravascular space. While infiltration (non-vesicant fluids) is painful and potentially serious, extravasation (vesicant agents) can cause severe tissue destruction, necrosis, and permanent functional impairment. Rapid recognition, staging, and agent-specific management are essential to …","description":"Complete guide to IV infiltration and extravasation: infiltration staging scale (0–4), vesicant vs. non-vesicant injury, antidote table (dexrazoxane, hyaluronidase, phentolamine), emergency response, and prevention.","section":"vascular-access","title":"Infiltration and Extravasation: Clinical Guide to Recognition, Staging, and Treatment","url":"/vascular-access/guides/catheter-complications/infiltration-extravasation-guide/"},{"content":"Infusion Filtration: Clinical Guide to Filter Selection and Requirements In-line filtration is an evidence-based safety intervention for intravenous infusions. Filters remove particulates (glass, plastic, rubber, precipitates), air, and microbial contaminants from the infusate before they reach the patient\u0026amp;rsquo;s bloodstream or vascular access device. Selecting the appropriate filter type for each infusion, and knowing which medications cannot be filtered, are essential clinical skills for …","description":"Complete guide to infusion filtration requirements: 0.2 micron vs 1.2 micron filter selection, medications requiring filtration, medications that cannot be filtered, TPN filtration requirements, and air-eliminating filter standards.","section":"vascular-access","title":"Infusion Filtration: Clinical Guide to Filter Selection and Requirements","url":"/vascular-access/guides/infusion-therapy-safety/infusion-filtration-guide/"},{"content":"Institutional Privileging for Vascular Access: Building a Defensible Framework Institutional privileging defines which clinicians are authorized to perform which vascular access procedures within a given institution. A robust privileging framework protects patients (by ensuring only qualified clinicians perform procedures), protects the institution (by creating a documented, defensible competency record), and enables quality oversight (by linking privileges to ongoing outcome data).\nThis guide …","description":"Framework for building an institutional vascular access privileging program: scope of practice delineation, privilege categories, competency documentation, re-privileging, medical staff credentialing vs. nursing competency, and TJC compliance.","section":"vascular-access","title":"Institutional Privileging for Vascular Access: Building a Defensible Framework","url":"/vascular-access/guides/vascular-access-credentialing/institutional-privileging-framework/"},{"content":"Needleless Connectors and CLABSI Prevention: Selection, Management, and Evidence Needleless connectors (NLCs) are present on every CVAD, PIV, and midline catheter in clinical use. They are a primary access point for intraluminal contamination — every time a connector is accessed (for medication administration, blood draws, or flushing), there is an opportunity for microorganisms to enter the catheter lumen. Understanding needleless connector types, proper access technique, change management, and …","description":"Evidence-based guide to needleless connectors and CLABSI prevention: connector types (split-septum, mechanical valve), scrub-the-hub technique, change intervals, passive disinfection caps, and selecting connectors to minimize CLABSI risk.","section":"vascular-access","title":"Needleless Connectors and CLABSI Prevention: Selection, Management, and Evidence","url":"/vascular-access/guides/clabsi-prevention/needleless-connector-clabsi-prevention/"},{"content":"NICU Vascular Access: Umbilical Catheters, Neonatal PICC, and Peripheral IV in Neonates Vascular access in the neonatal intensive care unit (NICU) is among the most technically demanding and highest-stakes procedures in clinical medicine. Neonates — particularly preterm infants at the physiologic limits of viability — have extremely small and fragile veins, unique anatomic access routes unavailable in any other population (umbilical vessels), and age-specific physiologic vulnerabilities that …","description":"Complete NICU vascular access guide: umbilical arterial and venous catheters (UAC/UVC), neonatal PICC lines, neonatal peripheral IV, gestational age considerations, skin protection, heparin-free protocols, and light protection for neonatal PN.","section":"vascular-access","title":"NICU Vascular Access: Umbilical Catheters, Neonatal PICC, and Peripheral IV in Neonates","url":"/vascular-access/guides/vascular-access-special-populations/nicu-vascular-access-guide/"},{"content":"Non-Tunneled Central Venous Catheters: Clinical Guide to Insertion, Use, and Complications The non-tunneled central venous catheter (CVC) — placed via the internal jugular (IJ), subclavian, or femoral vein — is the most commonly used central access device in acute care and critical care settings. It provides immediate, multi-lumen central access for hemodynamic monitoring, vasopressor infusion, resuscitation, and high-acuity medication delivery. It also carries the highest procedural risk of any …","description":"Complete clinical guide to non-tunneled central venous catheters: site selection (IJ vs subclavian vs femoral), ultrasound-guided insertion, complications (pneumothorax, hemothorax, arterial injury), CLABSI prevention, and removal.","section":"vascular-access","title":"Non-Tunneled Central Venous Catheters: Clinical Guide to Insertion, Use, and Complications","url":"/vascular-access/guides/central-venous-catheters/non-tunneled-cvc-guide/"},{"content":"Oncology Vascular Access: Port Placement, Chemotherapy Access Requirements, and Immunocompromised Considerations Cancer patients represent one of the most vascular access-intensive patient populations in clinical practice. Chemotherapy protocols require reliable, long-term central access for vesicant and irritant infusions. Immunosuppression from both the disease and treatment profoundly alters CLABSI risk. The trajectory of cancer treatment — from diagnosis through treatment, remission …","description":"Comprehensive guide to oncology vascular access: port vs PICC decision-making, chemotherapy central access requirements, vesicant administration, CLABSI prevention in neutropenic patients, power-injectable port selection, and access management across the cancer treatment continuum.","section":"vascular-access","title":"Oncology Vascular Access: Port Placement, Chemotherapy Access Requirements, and Immunocompromised Considerations","url":"/vascular-access/guides/vascular-access-special-populations/oncology-vascular-access-guide/"},{"content":"Parenteral Nutrition and Vascular Access: Access Requirements and Safe Administration Parenteral nutrition (PN) — the intravenous delivery of complete nutritional requirements — creates some of the most demanding vascular access requirements in clinical practice. PN formulations are hyperosmolar (typically 1,500–2,500 mOsm/L for central PN), require specific filtration, must be protected from light in some formulations, and carry unique infection risk because the glucose- and lipid-rich …","description":"Guide to vascular access requirements for parenteral nutrition (PN): central vs peripheral PN access criteria, osmolarity thresholds, PICC vs CVC for TPN, dedicated PN lumen, filtration requirements, administration set change intervals, and DEHP-free requirements.","section":"vascular-access","title":"Parenteral Nutrition and Vascular Access: Access Requirements and Safe Administration","url":"/vascular-access/guides/infusion-therapy-safety/parenteral-nutrition-vascular-access/"},{"content":"Pediatric Peripheral IV Access: Age-Specific Technique, Site Selection, and Pain Management Peripheral IV placement in pediatric patients is among the most technically challenging and emotionally significant clinical procedures in pediatric nursing. Children have smaller veins, increased anxiety, and physiologic differences that affect both site selection and catheter gauge selection. Evidence-based pain management and family-centered care are not optional extras — they are clinical standards …","description":"Complete guide to pediatric peripheral IV access: age-specific site selection (neonate to adolescent), scalp vein placement in infants, pain management (EMLA, LMX, vapocoolant, sucrose), gauge selection, restraint considerations, and family-centered care.","section":"vascular-access","title":"Pediatric Peripheral IV Access: Age-Specific Technique, Site Selection, and Pain Management","url":"/vascular-access/guides/vascular-access-special-populations/pediatric-peripheral-iv-guide/"},{"content":"Phlebitis: Recognition, Grading, and Management in Vascular Access Phlebitis — inflammation of the vein at or near a vascular access device — is the most common complication of peripheral intravenous therapy and a significant complication in midline and PICC patients. While it ranges in severity from mild redness requiring monitoring to severe suppurative thrombophlebitis requiring surgical intervention, phlebitis at any grade represents a patient safety event and a signal that the infusion …","description":"Complete guide to phlebitis in vascular access: types (mechanical, chemical, bacterial, post-infusion), VIP phlebitis scale, grading criteria, site-specific management, and prevention strategies.","section":"vascular-access","title":"Phlebitis: Recognition, Grading, and Management in Vascular Access","url":"/vascular-access/guides/catheter-complications/phlebitis-recognition-management/"},{"content":"PICC Insertion Competency Framework: From Novice to Independent Practice PICC insertion is a complex vascular access procedure with a defined learning curve. Establishing a structured, defensible competency framework — from initial didactic training through independent practice — protects patients, reduces institutional liability, and produces consistently safe outcomes. This guide provides a complete framework for designing or implementing a PICC insertion competency program based on current …","description":"Complete PICC insertion competency framework: didactic training content, simulation requirements, proctored case minimums, competency checklist, privileges documentation, and annual competency maintenance requirements.","section":"vascular-access","title":"PICC Insertion Competency Framework: From Novice to Independent Practice","url":"/vascular-access/guides/vascular-access-credentialing/picc-insertion-competency-framework/"},{"content":"PICC Line Care and Maintenance: Dressing Changes, Flushing, and Removal Once a PICC is placed, maintenance is where infection prevention happens. Studies consistently show that CLABSI events are driven more by maintenance practice failures than by insertion technique failures. Every dressing change, every hub access, and every flush is an opportunity to either maintain sterility or introduce pathogens.\nThis guide covers -compliant PICC maintenance protocols: dressing changes, flushing and …","description":"Complete PICC care and maintenance guide: dressing change technique (CHG dressing, TSM, step-by-step), SASH flushing protocol, daily assessment requirements, patient education, and safe PICC removal procedure.","section":"vascular-access","title":"PICC Line Care and Maintenance: Dressing Changes, Flushing, and Removal","url":"/vascular-access/guides/picc-lines/picc-care-maintenance/"},{"content":"PICC Line Complications: Prevention, Recognition, and Management PICC lines carry a distinct complication profile that differs from other vascular access devices. The most clinically significant PICC-specific complications are upper extremity deep vein thrombosis (UEDVT), CLABSI, and catheter occlusion. Understanding the incidence, risk factors, prevention strategies, and management protocols for each complication is essential for any clinician involved in PICC care.\nParent guide: PICC Lines: …","description":"Complete guide to PICC line complications: PICC-associated DVT (incidence, prevention, anticoagulation), CLABSI prevention, catheter occlusion (alteplase protocol), phlebitis, mechanical complications, and MARSI prevention.","section":"vascular-access","title":"PICC Line Complications: Prevention, Recognition, and Management","url":"/vascular-access/guides/picc-lines/picc-complications-prevention/"},{"content":"PICC Line Indications: Who Needs a PICC and When The PICC line is the most commonly placed central vascular access device in US hospitalized patients — representing approximately 40% of all central venous catheter placements. Yet studies using validated appropriateness criteria consistently find that 20–40% of PICCs are placed for inappropriate or uncertain indications. Inappropriate PICC placement exposes patients to PICC-associated DVT, CLABSI, and mechanical complications without commensurate …","description":"Clinical indications for PICC line placement — appropriate and inappropriate criteria and MAGIC, PICC for IV antibiotics, chemotherapy, TPN, and vesicants, and absolute contraindications.","section":"vascular-access","title":"PICC Line Indications: Who Needs a PICC and When","url":"/vascular-access/guides/picc-lines/picc-line-indications/"},{"content":"PICC Line Insertion Technique: Step-by-Step Ultrasound-Guided Procedure Ultrasound-guided PICC insertion using the modified Seldinger technique (MST) is the current standard of practice. When performed with maximal sterile barrier precautions and proper tip position verification, PICC insertion is safe, effective, and associated with low procedural complication rates.\nThis guide covers the complete insertion procedure from patient preparation through tip confirmation.\nParent guide: PICC Lines: …","description":"Complete step-by-step guide to ultrasound-guided PICC line insertion using the modified Seldinger technique: site selection, vein assessment, catheter measurement, sterile technique, and post-insertion verification.","section":"vascular-access","title":"PICC Line Insertion Technique: Step-by-Step Ultrasound-Guided Procedure","url":"/vascular-access/guides/picc-lines/picc-insertion-technique/"},{"content":"PICC Tip Position Verification: ECG Guidance and CXR Confirmation Standards Correct PICC tip position is a patient safety requirement, not an optional confirmation. Infusion of hypertonic or caustic solutions through a malpositioned catheter with a proximal tip causes vessel injury, thrombosis, and cardiac arrhythmias. The cavoatrial junction (CAJ) — where the superior vena cava meets the right atrium — is the target tip location for all peripherally inserted central catheters.\nThis guide covers …","description":"Evidence-based guide to PICC tip position verification: cavoatrial junction target, intraprocedural ECG guidance (P-wave method), post-procedure CXR interpretation, malposition recognition, and CEVAD standards.","section":"vascular-access","title":"PICC Tip Position Verification: ECG Guidance and CXR Confirmation Standards","url":"/vascular-access/guides/picc-lines/picc-tip-position-verification/"},{"content":"PICC vs Midline vs CVC: Clinical Decision Guide Selecting between a PICC, midline catheter, and non-tunneled CVC is one of the most common clinical decisions in vascular access. The choice depends on therapy requirements (osmolarity, vesicant properties, duration), patient anatomy and preferences, clinical setting, and complication risk profile. Getting this decision right minimizes patient harm and avoids unnecessary central access.\nThis guide provides a structured, evidence-based framework for …","description":"Clinical decision guide comparing PICC, midline catheter, and non-tunneled CVC: indications, contraindications, osmolarity limits, dwell time, CLABSI risk, and evidence-based selection criteria and MAGIC.","section":"vascular-access","title":"PICC vs Midline vs CVC: Clinical Decision Guide","url":"/vascular-access/guides/picc-lines/picc-vs-midline-vs-cvc/"},{"content":"Tunneled Central Venous Catheters: Hickman, Broviac, and Groshong Clinical Guide Tunneled central venous catheters (CVCs) are surgically placed long-term central access devices designed for dwell times of months to years. The subcutaneous tunnel separates the skin exit site from the venous entry point, providing a physical infection barrier and mechanical stability. Tunneled CVCs are the preferred long-term central access device when an implanted port is not feasible or when external access is …","description":"Clinical guide to tunneled central venous catheters: Hickman, Broviac, and Groshong types, indications, care and maintenance, flushing protocols, complication management, and comparison with implanted ports.","section":"vascular-access","title":"Tunneled Central Venous Catheters: Hickman, Broviac, and Groshong Clinical Guide","url":"/vascular-access/guides/central-venous-catheters/tunneled-central-catheters-guide/"},{"content":"Ultrasound Credentialing for Vascular Access: Competency Framework and Requirements Ultrasound guidance for vascular access is a distinct clinical skill requiring training, supervised practice, and ongoing competency assessment. Unlike some clinical skills that can be informally adopted, ultrasound-guided vascular access involves interpretation of real-time imaging, precise psychomotor coordination, and recognition of anatomic pitfalls — all of which require structured competency validation …","description":"Framework for ultrasound credentialing in vascular access: didactic requirements, simulation, proctored case minimums, competency assessment, scope of practice definitions, and maintenance of competency requirements per AVAR.","section":"vascular-access","title":"Ultrasound Credentialing for Vascular Access: Requirements and Competency Framework","url":"/vascular-access/guides/ultrasound-guided-vascular-access/ultrasound-credentialing-requirements/"},{"content":"Ultrasound Credentialing in Vascular Access Programs: Implementation Guide Implementing ultrasound guidance in a vascular access program transforms outcomes — but only when paired with a structured credentialing framework. Ad hoc ultrasound use without training and competency documentation creates liability exposure, inconsistent technique, and potentially worse outcomes than landmark technique in untrained hands. This guide addresses the program leadership perspective: how to design, implement, …","description":"Implementation guide for ultrasound credentialing in vascular access programs: defining scope, training curriculum design, simulation, proctored cases, privileges documentation, maintenance, and program-level quality metrics.","section":"vascular-access","title":"Ultrasound Credentialing in Vascular Access Programs: Implementation Guide","url":"/vascular-access/guides/vascular-access-credentialing/ultrasound-credentialing-vascular-access/"},{"content":"Ultrasound Technique for Vascular Access: Short-Axis, Long-Axis, and Dynamic Guidance Ultrasound guidance for vascular access is not a single technique — it includes multiple probe orientations, needle-to-probe relationships, and guidance strategies. Each approach has distinct advantages and learning considerations. Selecting the appropriate technique for the clinical scenario and achieving real-time needle visualization are the keys to safe, efficient US-guided access.\nParent guide: …","description":"Comprehensive guide to ultrasound technique for vascular access: probe selection, short-axis vs long-axis approach, in-plane vs out-of-plane needle guidance, dynamic vs static technique, and practical tips for needle visualization.","section":"vascular-access","title":"Ultrasound Technique for Vascular Access: Short-Axis, Long-Axis, and Dynamic Guidance","url":"/vascular-access/guides/ultrasound-guided-vascular-access/ultrasound-technique-vascular-access/"},{"content":"Ultrasound-Guided Peripheral IV for Difficult Access: DIVA Score and Technique Difficult intravenous access (DIVA) affects approximately 10–24% of hospitalized patients who need peripheral IV placement. In these patients, standard landmark-and-palpation technique fails at high rates (\u0026amp;gt;60% first-attempt failure for DIVA score ≥4), leading to multiple painful attempts, patient distress, vein damage, and unnecessary escalation to central access. Ultrasound-guided peripheral IV placement …","description":"Guide to ultrasound-guided peripheral IV for difficult venous access: DIVA score application, vein selection (diameter, depth), catheter length requirements, short-axis technique, common pitfalls, and when to escalate to midline or PICC.","section":"vascular-access","title":"Ultrasound-Guided Peripheral IV for Difficult Access: DIVA Score and Technique","url":"/vascular-access/guides/ultrasound-guided-vascular-access/ultrasound-peripheral-iv-difficult-access/"},{"content":"Ultrasound-Guided PICC Insertion: Complete Procedural Guide Ultrasound guidance for PICC insertion is the standard of care and virtually universal in professional PICC practice. It dramatically reduces complications: first-attempt insertion success rates increase from approximately 70% (landmark) to \u0026amp;gt;95% (US-guided), inadvertent arterial puncture rates drop from ~5% to \u0026amp;lt;1%, and catheter-to-vein ratio can be accurately assessed before catheter selection.\nThis guide focuses specifically on …","description":"Complete ultrasound-guided PICC insertion guide: pre-insertion vein survey, long-axis technique for basilic vein cannulation, guidewire US confirmation, catheter measurement, and intraoperative tip guidance with ECG.","section":"vascular-access","title":"Ultrasound-Guided PICC Insertion: Complete Procedural Guide","url":"/vascular-access/guides/ultrasound-guided-vascular-access/ultrasound-picc-insertion-guide/"},{"content":"VA-BC Certification: Complete Guide to Vascular Access Board Certification The VA-BC (Vascular Access Board Certified) credential is the premier certification for vascular access specialty nurses and clinicians in the United States. Administered by the Certification Board of Vascular Nursing (CBVN), a certification body established by the Association for Vascular Access (AVAR/AVA), the VA-BC certification validates advanced knowledge and competence in vascular access practice across the full …","description":"Complete guide to VA-BC (Vascular Access Board Certified) certification: eligibility requirements, exam content domains, application process, exam preparation, and recertification requirements through AVAR/CBVN.","section":"vascular-access","title":"VA-BC Certification: Complete Guide to Vascular Access Board Certification","url":"/vascular-access/guides/vascular-access-credentialing/va-bc-certification-guide/"},{"content":"Vascular Access Device Competency and Credentialing Checklist This checklist compiles the competency verification elements required for each level of vascular access practice — from peripheral IV placement through implanted port access. It is intended for use by vascular access educators, nursing leadership, and credentialing committees as a reference framework. Adapt to institutional protocols and regulatory requirements as needed.\nHow to Use This Checklist Purpose: This framework defines the …","description":"Comprehensive vascular access device (VAD) competency and credentialing checklist covering peripheral IV, midline, PICC, central venous catheter, and implanted port access — including ultrasound guidance competency, bundle compliance verification, and annual maintenance requirements.","section":"vascular-access","title":"Vascular Access Device Competency and Credentialing Checklist","url":"/vascular-access/resources/vad-competency-credentialing-checklist/"},{"content":"Vascular Access Device Types: A Complete Comparison Guide Choosing the right vascular access device requires understanding the clinical characteristics, appropriate indications, and limitations of each device type. This guide provides a structured comparison of all major vascular access device types used in clinical practice.\nParent guide: Vascular Access: Complete Clinical Reference\nThe Complete VAD Spectrum Peripheral IV Catheter (PIV) Description: Short catheter (approximately 1.25–2.5 cm) …","description":"Complete comparison of all vascular access device types: PIV, midline, PICC, CVC, tunneled catheter, port, hemodialysis catheter, IO, and arterial line — with a clinical selection guide.","section":"vascular-access","title":"Vascular Access Device Types: A Complete Comparison Guide","url":"/vascular-access/guides/vascular-access/vascular-access-device-types-comparison/"},{"content":"Vascular Access Documentation: What to Record and When Vascular access documentation serves clinical, regulatory, legal, and quality purposes. It communicates device status to the care team, demonstrates compliance with insertion and maintenance bundles, enables epidemiologic surveillance (catheter-days for CLABSI reporting), and provides a defensible record in adverse event review.\ncurrent clinical standard (Documentation) specifies minimum documentation requirements for vascular access devices …","description":"Complete guide to vascular access documentation requirements: insertion notes, daily assessment, infusion therapy documentation, complication recording, device removal, and EHR best practices.","section":"vascular-access","title":"Vascular Access Documentation: What to Record and When","url":"/vascular-access/guides/vascular-access/vascular-access-documentation-requirements/"},{"content":"Vascular Access Quality Metrics: Key Performance Indicators and Benchmarking Vascular access quality improvement begins with measurement. Without valid, consistently collected metrics, VATs and nursing leadership cannot identify problems, demonstrate improvement, or make evidence-based decisions about resource allocation. The vascular access quality measurement framework spans infection prevention outcomes, procedural success metrics, device appropriateness, and complication surveillance — each …","description":"Comprehensive guide to vascular access quality metrics: CLABSI rates and SIR benchmarking, first-attempt success rates, phlebitis rates, catheter utilization ratios, PICC appropriateness tracking, dwell time management, and building a vascular access quality dashboard.","section":"vascular-access","title":"Vascular Access Quality Metrics: Key Performance Indicators and Benchmarking","url":"/vascular-access/guides/vascular-access-team-models/vascular-access-quality-metrics/"},{"content":"Vascular Access Safety: Annual State of the Practice Report Vascular access devices are used in an estimated 80–90% of hospitalized patients in the United States. At any given moment, more than 5 million central venous catheters and tens of millions of peripheral IVs are in use across the US healthcare system. Despite their ubiquity, vascular access devices remain a leading source of preventable patient harm — from bloodstream infections to thrombosis, from infiltration injuries to air embolism. …","description":"Annual state-of-the-practice safety report for vascular access: national CLABSI rates, PICC complication data, peripheral IV failure rates, phlebitis benchmarks, catheter-related DVT epidemiology, and the current evidence base driving vascular access safety standards.","section":"vascular-access","title":"Vascular Access Safety: Annual State of the Practice Report","url":"/vascular-access/resources/vascular-access-safety-report/"},{"content":"Vascular Access Standards and Regulatory Framework: CDC, Joint Commission, IDSA Clinical practice in vascular access is governed by a layered framework of professional standards, clinical guidelines, and regulatory requirements. Understanding this landscape is essential for clinicians, educators, and program leaders building or maintaining compliant vascular access programs.\nParent guide: Vascular Access: Complete Clinical Reference\nWhy Standards Matter Vascular access standards exist because …","description":"Overview of vascular access clinical standards and regulatory framework: current clinical standards, IDSA guidelines, CDC catheter guidelines, Joint Commission NPSG 07.04.01, CMS requirements.","section":"vascular-access","title":"Vascular Access Standards and Regulatory Framework: CDC, Joint Commission, IDSA","url":"/vascular-access/guides/vascular-access/vascular-access-standards-regulations/"},{"content":"Vascular Access Teams: Evidence Base and Return on Investment Dedicated vascular access teams (VATs) — also called IV teams, infusion therapy teams, or PICC teams — have operated in US hospitals for decades, but their evidence base has strengthened considerably over the past 20 years. The argument for dedicated vascular access specialists is not merely about procedural skill; it is an outcomes argument. Facilities with dedicated VATs demonstrate measurable improvements in first-attempt success …","description":"Evidence-based review of vascular access team (VAT) outcomes: CLABSI reduction, first-attempt success rates, catheter-related complication reduction, cost savings, and return on investment data supporting dedicated vascular access specialist programs.","section":"vascular-access","title":"Vascular Access Teams: Evidence Base and Return on Investment","url":"/vascular-access/guides/vascular-access-team-models/vascular-access-team-evidence-roi/"},{"content":"Vascular Anatomy for Ultrasound-Guided Access: Upper Extremity and Neck Successful ultrasound-guided vascular access depends on recognizing target vessels by their anatomic relationships, echographic characteristics, and response to probe compression. Clinicians who understand the anatomy before picking up the probe identify target vessels faster, avoid inadvertent arterial cannulation, and achieve higher first-attempt success rates.\nParent guide: Ultrasound-Guided Vascular Access: Complete …","description":"Clinical guide to vascular anatomy for ultrasound-guided vascular access: upper extremity veins (basilic, brachial, cephalic), internal jugular vein, femoral vessels — identification, landmarks, and differentiating vein from artery on ultrasound.","section":"vascular-access","title":"Vascular Anatomy for Ultrasound-Guided Access: Upper Extremity and Neck","url":"/vascular-access/guides/ultrasound-guided-vascular-access/vascular-anatomy-ultrasound/"},{"content":"Vesicant Administration Safety: Classification, Central Access Requirements, and Protocols Vesicant medications are intravenous agents capable of causing tissue destruction, blistering, necrosis, and permanent functional impairment when they escape the vascular system and contact surrounding tissue. Vesicant administration requires more than appropriate vascular access — it requires pre-infusion assessment, ongoing monitoring, antidote availability, and a clear emergency response plan. Getting …","description":"Complete guide to vesicant administration safety: vesicant and irritant classification, mandatory central access requirements, peripheral vesicant administration protocols, pre-infusion assessment, monitoring requirements, and immediate response to suspected extravasation.","section":"vascular-access","title":"Vesicant Administration Safety: Classification, Central Access Requirements, and Protocols","url":"/vascular-access/guides/infusion-therapy-safety/vesicant-administration-safety/"},{"content":"What Is Vascular Access? Definitions, Device Types, and Clinical Context Vascular access is the clinical process of establishing a route into the vascular system — most commonly the venous system — for diagnostic or therapeutic purposes. It is one of the most fundamental and frequently performed interventions in modern healthcare.\nThis guide provides foundational definitions, the complete spectrum of vascular access devices (VADs), and clinical context for understanding when and why each device …","description":"What is vascular access? Definitions, clinical context, the full VAD spectrum from peripheral to central, indications for each device type, and who performs vascular access procedures.","section":"vascular-access","title":"What Is Vascular Access? Definitions, Device Types, and Clinical Context","url":"/vascular-access/guides/vascular-access/what-is-vascular-access/"},{"content":"Adverse Event Management and Reporting Policy 1. Policy Statement It is the policy of this organization that all adverse events, serious adverse events (including sentinel events), and close calls associated with infusion therapy or vascular access devices shall be comprehensively documented within the patient health record, reported through organizational reporting systems, and communicated to appropriate regulatory bodies when required.[1],6 The organization shall maintain a prevention-focused …","description":"Establishes comprehensive standards for identifying, documenting, investigating, and learning from adverse events, serious adverse events, and near-miss incidents associated with vascular access devices and infusion therapy.","section":"vascular-access","title":"Adverse Event Management and Reporting","url":"/vascular-access/policies/adverse-event-management-reporting/"},{"content":"Allergies and Sensitivities During IV Therapy Allergies are an important safety concern during IV therapy. Unlike oral medications, IV drugs enter your bloodstream immediately — which means allergic reactions can develop quickly. Always tell your care team about every allergy and sensitivity you have, no matter how minor it seems.\nThis guide explains the types of allergies relevant to IV care, what reactions look like, and what to do if you suspect a reaction.\nWhy Allergies Matter More with IV …","description":"What patients need to know about allergies and sensitivities related to IV therapy — including drug allergies, latex allergy, tape and adhesive reactions, antiseptic sensitivities, and how to recognize and respond to an allergic reaction.","section":"vascular-access","title":"Allergies and Sensitivities During IV Therapy","url":"/vascular-access/patient-education/allergies-and-sensitivities-iv-therapy/"},{"content":"Arterial Lines: A Guide for Patients and Families If you or a family member is in the intensive care unit (ICU) or recovering from major surgery, you may notice a catheter in the wrist or another location connected to a monitor that shows a continuous wave-form and blood pressure reading. This is an arterial line (often called an \u0026amp;ldquo;A-line\u0026amp;rdquo;). It is one of the most common monitoring devices in critical care, and it is distinctly different from a standard IV line.\nThis guide explains …","description":"A patient and family guide to arterial lines (A-lines) — what they are, why they are used in critical care, how they work, the critical safety rules that apply, and what to expect when one is placed or removed.","section":"vascular-access","title":"Arterial Lines: A Guide for Patients and Families","url":"/vascular-access/patient-education/arterial-line-patient-guide/"},{"content":"Blood Draws and Lab Tests: What to Expect Blood tests — also called labs or laboratory studies — are a routine and essential part of IV therapy and vascular access care. They help your care team verify that your treatment is working, ensure medications are at safe concentrations, monitor your organ function, and detect problems early.\nThis guide explains why blood tests are needed, how blood is collected (including through your IV catheter), what to expect, and how to manage common concerns like …","description":"A patient guide to blood draws and lab tests in the context of IV therapy — how blood is collected, what to expect when drawn from a PICC or port, managing difficult veins and needle anxiety, and understanding common lab results.","section":"vascular-access","title":"Blood Draws and Lab Tests: What to Expect","url":"/vascular-access/patient-education/blood-draws-and-lab-tests/"},{"content":"Chemotherapy Infusion: What to Expect Receiving chemotherapy through an IV can feel frightening and unfamiliar. Understanding what will happen — before, during, and after your infusion sessions — helps reduce anxiety and helps you take an active role in your own safety.\nThis guide focuses on the infusion experience and what you need to know at home between sessions. Your oncology team will provide guidance specific to your cancer type, treatment regimen, and individual circumstances.\nHow …","description":"A patient guide to chemotherapy infusion — what happens before, during, and after treatment, understanding the nadir and neutropenic precautions, managing side effects, and knowing when to seek urgent help.","section":"vascular-access","title":"Chemotherapy Infusion: What to Expect","url":"/vascular-access/patient-education/chemotherapy-infusion-patient-guide/"},{"content":"Controlled Substance Diversion Prevention Policy 1. Policy Statement It is the policy of this organization that all controlled substances shall be managed through a comprehensive Controlled Substance Diversion Prevention (CSDP) program that maintains secure chain of custody from procurement through administration and waste, supported by an organizational culture of safety that promotes prompt, confidential, and nonpunitive reporting of suspected diversion.12 Each controlled substance …","description":"Establishes comprehensive standards for preventing, recognizing, and responding to controlled substance diversion in healthcare settings, including chain of custody requirements, waste management, detection methods, and recovery support for affected healthcare workers.","section":"vascular-access","title":"Controlled Substance Diversion Prevention","url":"/vascular-access/policies/controlled-substance-diversion-prevention/"},{"content":"Dialysis Vascular Access: AV Fistulas, Grafts, and Catheters If you receive hemodialysis — a treatment that filters your blood through a machine when your kidneys cannot do this job adequately — you need a reliable way for large amounts of blood to flow out of your body to the dialysis machine and back again. This requires a dialysis vascular access: a specially created or placed connection that can handle the high blood flow rates dialysis demands.\nThere are three types of dialysis access. Each …","description":"A complete patient guide to dialysis vascular access — understanding AV fistulas, AV grafts, and tunneled dialysis catheters, how to care for each, what warning signs to watch for, and how to protect your access long-term.","section":"vascular-access","title":"Dialysis Vascular Access: AV Fistulas, Grafts, and Catheters","url":"/vascular-access/patient-education/dialysis-vascular-access/"},{"content":"Discharge Planning: Leaving the Hospital with an IV Device Leaving the hospital with an IV catheter — whether a PICC line, a midline, or a port that is being actively used — means transitioning to home or outpatient care. This guide helps you understand what needs to be in place before you leave, who will support you at home, and how to set yourself up for a safe, successful recovery.\nThe Goal: A Safe and Supported Discharge A safe discharge is not just about physically leaving the building. It …","description":"A patient guide to discharge planning when leaving the hospital with a vascular access device — what to confirm before you leave, home infusion setup, supplies, follow-up, and who to call for help.","section":"vascular-access","title":"Discharge Planning: Leaving the Hospital with an IV Device","url":"/vascular-access/patient-education/discharge-planning-iv-device/"},{"content":"Emergency Room Visit When You Have a Catheter Going to the emergency room is stressful under any circumstances. When you have a PICC line, implanted port, tunneled catheter, or other central access device, there are specific things you need to communicate and specific situations to navigate to protect your catheter and your safety.\nThis guide prepares you for an ER visit so you can advocate effectively for yourself, even when you feel unwell.\nWhat to Tell Triage — Immediately When you check in …","description":"What patients with vascular access devices need to know when visiting the emergency room — what to tell triage, how to protect your catheter, what ER staff may want to do, how to advocate for your device, and what to bring.","section":"vascular-access","title":"Emergency Room Visit When You Have a Catheter","url":"/vascular-access/patient-education/er-visit-with-a-catheter/"},{"content":"Exercise and Physical Activity with a Vascular Access Device Physical activity is beneficial for almost everyone, including most patients with vascular access devices. Staying active helps maintain strength, improve mood, support immune function, reduce fatigue, and aid recovery. The goal is to find what you can do safely — not to focus entirely on what you cannot.\nThis guide explains activity guidelines by device type and helps you find a sustainable approach to staying active during treatment. …","description":"What patients can and cannot do physically while living with a vascular access device — activity guidelines by device type, returning to exercise after catheter placement, sports and swimming, and why staying active matters.","section":"vascular-access","title":"Exercise and Physical Activity with a Vascular Access Device","url":"/vascular-access/patient-education/exercise-and-activity-with-a-catheter/"},{"content":"Fall Prevention During IV Therapy Falls are one of the most common and preventable patient safety incidents in hospitals — and IV therapy increases fall risk in several important ways. Whether you are in the hospital or at home on IV therapy, understanding these risks and taking simple precautions can prevent a serious injury.\nWhy IV Therapy Increases Fall Risk IV poles and tubing are trip and stumble hazards IV poles on wheels are bulky, can shift unexpectedly, and are easy to forget about when …","description":"How patients receiving IV therapy can reduce their risk of falling — in the hospital and at home — including IV pole navigation, medication side effects, safe movement with a catheter, and when to ask for help.","section":"vascular-access","title":"Fall Prevention During IV Therapy","url":"/vascular-access/patient-education/fall-prevention-iv-therapy/"},{"content":"Going Home with a Midline Catheter: Your Care Guide A midline catheter is a medium-length IV catheter — longer than a standard peripheral IV but shorter than a PICC line. It sits in a large vein in your upper arm and is used when you need IV therapy lasting one to four weeks. Because the tip does not extend all the way into the chest, midlines have some differences from PICCs in how they are cared for and what they can be used for.\nThis guide covers everything you need to know about managing …","description":"A complete patient guide to going home with a midline catheter — dressing care, flushing, bathing, activity, recognizing complications, and when to seek help.","section":"vascular-access","title":"Going Home with a Midline Catheter: Your Care Guide","url":"/vascular-access/patient-education/going-home-with-a-midline-catheter/"},{"content":"Going Home with a PICC Line: Your Complete Care Guide Going home with a PICC line may feel overwhelming at first. With proper instruction and a little practice, most patients manage their PICC comfortably and confidently at home. This guide covers everything you need to know about caring for your PICC after hospital discharge.\nImportant: This guide provides general education. Your specific PICC care instructions — flushing volumes, flush schedules, dressing change schedule, and activity …","description":"A complete patient guide to going home with a PICC line — dressing care, flushing, bathing, activity, recognizing problems, when to call for help, and home infusion therapy.","section":"vascular-access","title":"Going Home with a PICC Line: Your Complete Care Guide","url":"/vascular-access/patient-education/going-home-with-a-picc-line/"},{"content":"Going Home with a Tunneled Catheter (Hickman, Broviac, Groshong) A tunneled central venous catheter is a long-term central line designed for months to years of use. Unlike a PICC (which enters through a vein in the arm) or a port (which is completely under the skin), a tunneled catheter is surgically placed so that it passes under the skin of the chest before exiting the body — a design that provides both stability and infection protection.\nCommon brand names include Hickman, Broviac, and …","description":"A complete patient guide to living with a tunneled central venous catheter — Hickman, Broviac, or Groshong — including exit site care, dressing changes, flushing differences by catheter type, activity, bathing, complications, and long-term management.","section":"vascular-access","title":"Going Home with a Tunneled Catheter (Hickman, Broviac, Groshong)","url":"/vascular-access/patient-education/going-home-with-a-tunneled-catheter/"},{"content":"Going Home with an Implanted Port: Your Complete Care Guide An implanted port (often called a Port-a-Cath, Power Port, or simply a \u0026amp;ldquo;port\u0026amp;rdquo;) is one of the most convenient long-term vascular access options available. Because it sits entirely under your skin, it requires very little care between uses — and with no external tubing or dressing when not accessed, it allows a much more normal daily life than other central catheters.\nThis guide explains how your port works, what to expect …","description":"A complete patient guide to living with an implanted port — how the port works, what port access feels like, home care between uses, activity and bathing, warning signs, and when to seek help.","section":"vascular-access","title":"Going Home with an Implanted Port: Your Complete Care Guide","url":"/vascular-access/patient-education/going-home-with-an-implanted-port/"},{"content":"Guide for Caregivers of Adult Patients on IV Therapy This guide is written specifically for you — the spouse, partner, parent, adult child, friend, or other person who is providing hands-on support to someone receiving home IV therapy. You are providing an enormous service, and you deserve information, support, and acknowledgment of both your role and your limits.\nYour Role as a Caregiver The care needs of patients on home IV therapy vary widely. Your role may involve:\nBeing present while the …","description":"A guide for family members and unpaid caregivers supporting an adult on home IV therapy — understanding your role, learning care tasks, managing emergency situations, setting realistic limits, and supporting your own well-being.","section":"vascular-access","title":"Guide for Caregivers of Adult Patients on IV Therapy","url":"/vascular-access/patient-education/guide-for-caregivers-adult-patients/"},{"content":"Guide for Parents and Caregivers of Children with IV Lines When your child needs a vascular access device — whether for days, weeks, or months — the experience is different from adult IV care in important ways. Children process fear and pain differently at different ages, their bodies are smaller, they are less able to protect the device from accidental dislodgement, and you as a parent or caregiver carry significant emotional weight alongside the practical responsibilities.\nThis guide is …","description":"A guide for parents and caregivers of children receiving IV therapy or living with a vascular access device — communicating with children about IVs, managing needle fear, age-appropriate activity and school, home catheter care, and caring for yourself as a caregiver.","section":"vascular-access","title":"Guide for Parents and Caregivers of Children with IV Lines","url":"/vascular-access/patient-education/guide-for-parents-and-caregivers-of-children-with-ivs/"},{"content":"Hazardous Drug Management Policy 1. Policy Statement It is the policy of this organization that the safe handling of hazardous drugs requires a comprehensive, multi-layered approach addressing all points in the chain of custody—from receipt and storage through preparation, administration, patient body fluid contact, and final disposal.12 There is no established safe threshold of exposure for many hazardous drugs.34 The organization shall implement controls at every stage of the hazardous drug …","description":"Establishes comprehensive standards for the safe handling, preparation, administration, and disposal of hazardous drugs across all care settings, including PPE requirements, engineering controls, environmental monitoring, spill management, and medical surveillance programs.","section":"vascular-access","title":"Hazardous Drug Management","url":"/vascular-access/policies/hazardous-drug-management/"},{"content":"Home Total Parenteral Nutrition (TPN): Your Complete Guide Total parenteral nutrition — TPN, also called parenteral nutrition (PN) or home parenteral nutrition (HPN) — is a way of providing complete nutrition directly through a vein when the digestive system cannot be used. If you are going home on TPN, this guide will help you understand how to manage it safely and effectively.\nHome TPN is a significant undertaking, and your care team will provide thorough training before discharge. This guide …","description":"A complete patient guide to home total parenteral nutrition (TPN) — what TPN contains, equipment and setup, daily monitoring, managing the pump and infusion cycle, complications to watch for, lab requirements, and living well on home TPN.","section":"vascular-access","title":"Home Total Parenteral Nutrition (TPN): Your Complete Guide","url":"/vascular-access/patient-education/home-tpn-guide/"},{"content":"Insurance and Prior Authorization for Home Infusion Therapy The clinical need for home IV therapy is one thing; getting it covered by insurance is another. The prior authorization process — the system by which insurance companies review and approve (or deny) coverage for specific treatments in advance — is one of the most frustrating barriers patients face when transitioning from hospital to home IV care.\nThis guide explains how prior authorization works, why delays happen, what you can do about …","description":"A patient guide to navigating insurance coverage and prior authorization for home infusion therapy — how prior auth works, why delays happen, how to appeal a denial, financial assistance resources, and who can help you navigate the system.","section":"vascular-access","title":"Insurance and Prior Authorization for Home Infusion Therapy","url":"/vascular-access/patient-education/insurance-and-prior-authorization-home-infusion/"},{"content":"IV Medications and Infusion Therapy Explained Infusion therapy simply means delivering medication, fluids, or nutrition directly into your bloodstream through a vein. When oral medications will not work fast enough, cannot be absorbed properly, or would be harmful to the digestive system, IV therapy provides an effective and controlled alternative.\nThis guide explains the different types of infusions, what happens during a treatment session, how equipment like infusion pumps works, and what you …","description":"What patients need to know about IV medications and infusion therapy — types of infusions, what to expect during treatment, how the pump works, side effects to watch for, and how to stay comfortable.","section":"vascular-access","title":"IV Medications and Infusion Therapy Explained","url":"/vascular-access/patient-education/iv-medications-infusion-therapy-explained/"},{"content":"Keeping Your IV Safe: Infection Prevention Having an IV line or catheter means there is a direct pathway into your bloodstream — which is exactly what your care team needs to deliver treatment. But that same pathway can sometimes allow bacteria to enter your body if it is not cared for carefully. The good news is that catheter-related infections are largely preventable, and you and your family can play an important role in preventing them.\nWhy Catheter Infections Are Serious An infection that …","description":"How patients and families can help prevent IV-related infections, what hand hygiene means at the bedside, when to alert your care team, and what your nurses are doing to keep your catheter safe.","section":"vascular-access","title":"Keeping Your IV Safe: Infection Prevention","url":"/vascular-access/patient-education/keeping-your-iv-safe-infection-prevention/"},{"content":"Latex Allergy and Sensitivity Management Policy 1. Policy Statement It is the policy of this organization to minimize latex exposure throughout the care environment and to provide latex-sensitive and latex-allergic clinicians and patients with personal protective equipment, patient care equipment, and supplies manufactured without natural rubber latex.12 Latex-free alternatives shall be used consistently during care of all individuals with identified or suspected latex allergy or sensitivity. …","description":"Establishes standards for minimizing latex exposure, identifying at-risk patients and healthcare workers, managing allergic reactions, and ensuring latex-free care environments for latex-sensitive and latex-allergic individuals.","section":"vascular-access","title":"Latex Allergy and Sensitivity Management","url":"/vascular-access/policies/latex-allergy-sensitivity-management/"},{"content":"Living Well with Long-Term IV Therapy When IV therapy extends over weeks, months, or longer — whether for OPAT (IV antibiotics), TPN (IV nutrition), chemotherapy, or chronic infusion therapy — it stops being just a medical intervention and starts shaping your daily life. Schedules, activities, clothing choices, relationships, sleep, and self-image all become intertwined with your catheter and treatment.\nThis guide offers practical strategies for managing that reality and maintaining the best …","description":"A guide to maintaining quality of life during long-term IV therapy — practical strategies for daily life, sleep, clothing, work, relationships, travel, and finding a sustainable new normal while managing a catheter and infusion schedule.","section":"vascular-access","title":"Living Well with Long-Term IV Therapy","url":"/vascular-access/patient-education/living-well-with-long-term-iv-therapy/"},{"content":"Medical Waste and Sharps Safety Policy 1. Policy Statement It is the policy of this organization that safe handling and disposal of regulated medical waste shall protect healthcare workers, patients, waste handlers, and the broader community from exposure to potentially infectious materials and sharps injuries.12 Waste management practices shall be based on all applicable federal, state, and local laws and regulations and implemented through organizational policies, procedures, and practice …","description":"Establishes standards for safe handling and disposal of regulated medical waste, sharps safety, needlestick injury prevention, use of safety-engineered devices, injury reporting, and patient and caregiver education for home infusion waste management.","section":"vascular-access","title":"Medical Waste and Sharps Safety","url":"/vascular-access/policies/medical-waste-sharps-safety/"},{"content":"Medication Safety: Your Role in Preventing Errors Medication errors are one of the most common types of medical errors in healthcare. They happen to careful, well-intentioned professionals, and they can cause serious harm. Patients who are informed and engaged are a powerful additional layer of safety — not because you are responsible for your care team\u0026amp;rsquo;s performance, but because active patients catch errors that would otherwise be missed.\nThis guide explains how to be a safe, informed …","description":"How patients can actively participate in preventing IV medication errors — understanding the five rights, verifying identity before every administration, knowing your medications, asking questions, safe home medication management, and speaking up when something seems wrong.","section":"vascular-access","title":"Medication Safety: Your Role in Preventing Errors","url":"/vascular-access/patient-education/medication-safety-your-role/"},{"content":"Mental Health and Emotional Adjustment During IV Therapy Receiving IV therapy — whether for a few weeks of antibiotics or months of chemotherapy or years on home TPN — is not just a physical experience. The emotional dimensions of illness, invasive procedures, a changed body, altered daily life, and uncertainty about the future are significant and deserve to be taken seriously.\nThis guide is here to tell you: what you feel is normal, you are not alone, and support is available.\nThe Emotional …","description":"A guide to the emotional and psychological challenges of living with a vascular access device and undergoing IV therapy — normalizing anxiety and depression, identifying when to seek professional support, and practical coping strategies.","section":"vascular-access","title":"Mental Health and Emotional Adjustment During IV Therapy","url":"/vascular-access/patient-education/mental-health-and-emotional-adjustment/"},{"content":"Outpatient IV Antibiotics at Home (OPAT): Your Complete Guide OPAT — outpatient parenteral antibiotic therapy — means you will complete your IV antibiotic treatment at home rather than in the hospital. With a PICC line and the support of a home infusion team, you can receive the same powerful antibiotics you would get in the hospital, from the comfort of your own home.\nOPAT has become very common for treating serious infections including bone infections (osteomyelitis), heart valve infections …","description":"A complete patient guide to outpatient parenteral antibiotic therapy (OPAT) — going home on IV antibiotics, managing your infusions, understanding your medications, lab monitoring, completing your course, and knowing when to seek help.","section":"vascular-access","title":"Outpatient IV Antibiotics at Home (OPAT): Your Complete Guide","url":"/vascular-access/patient-education/opat-patient-guide/"},{"content":"PICC Removal: What to Expect If you have a PICC line, there will come a point — when your treatment is complete, your clinical situation changes, or the catheter has served its purpose — when the PICC is removed. PICC removal is one of the simplest procedures in vascular access, but patients often have questions about what to expect. This guide explains the process.\nWhen Is a PICC Removed? A PICC is removed when:\nTreatment is complete. The full course of IV antibiotics, chemotherapy, IV …","description":"A patient guide to PICC line removal — when and why PICCs are removed, what the procedure involves, what to expect immediately afterward, and when to seek help if something does not feel right.","section":"vascular-access","title":"PICC Removal: What to Expect","url":"/vascular-access/patient-education/picc-removal-what-to-expect/"},{"content":"Port Removal: What to Expect After months or years of reliable service, your implanted port will eventually be removed. For many patients — particularly those who have completed cancer treatment — port removal represents an important milestone. Understanding what the procedure involves helps you feel prepared and know what to expect during recovery.\nWhy Ports Are Removed Ports are removed when they are no longer needed or when a problem makes removal necessary:\nTreatment completion: The most …","description":"What patients need to know about implanted port removal — why ports are removed, what the procedure involves, what to expect during recovery, and wound care after removal.","section":"vascular-access","title":"Port Removal: What to Expect","url":"/vascular-access/patient-education/port-removal-what-to-expect/"},{"content":"Preparing for PICC Line Placement: What to Expect Having a PICC line placed is a minimally invasive procedure — not surgery, but more than a routine blood draw. Understanding exactly what will happen helps reduce anxiety, allows you to prepare practically, and helps the procedure go smoothly for both you and your vascular access nurse.\nBefore Your Appointment What to wear Wear a short-sleeved or loose-sleeved shirt. PICC placement requires access to your upper arm; a tight or long-sleeved top …","description":"A patient guide to preparing for PICC line placement — what happens before, during, and immediately after the procedure, what to wear, what to expect, and how to prepare to minimize anxiety and ensure a smooth experience.","section":"vascular-access","title":"Preparing for PICC Line Placement: What to Expect","url":"/vascular-access/patient-education/preparing-for-picc-placement/"},{"content":"Preparing for Port Placement: What to Expect An implanted port is placed in a minor surgical procedure — more involved than a bedside PICC placement but much simpler than major surgery. Understanding what to expect allows you to prepare, reduces anxiety, and helps ensure the smoothest possible recovery.\nBefore Your Procedure Who places a port? Port placement is performed by either a surgeon (typically a general surgeon or thoracic surgeon) or an interventional radiologist — a specialist who uses …","description":"A patient guide to preparing for implanted port placement — pre-operative instructions, what happens on the day of surgery, anesthesia options, recovery, incision care, and when the port can first be used.","section":"vascular-access","title":"Preparing for Port Placement: What to Expect","url":"/vascular-access/patient-education/preparing-for-port-placement/"},{"content":"Product Management and Device Safety Policy 1. Policy Statement It is the policy of this organization that all vascular access devices, infusion products, and related equipment shall be selected, evaluated, inspected, and monitored through rigorous, evidence-based processes that prioritize patient safety and clinical outcomes.[1],2 Product selection shall be driven by demonstrated clinical performance rather than cost alone or commercial relationships.[1] All staff shall maintain current …","description":"Establishes standards for product evaluation, selection, inspection, problem reporting, and supply chain disruption management to ensure vascular access devices and infusion products meet the highest standards of safety, efficacy, and reliability.","section":"vascular-access","title":"Product Management and Device Safety","url":"/vascular-access/policies/product-management-device-safety/"},{"content":"Questions to Ask Your Vascular Access Team Asking questions is one of the most powerful things you can do to stay safe and informed during IV therapy and catheter care. Research consistently shows that patients who ask questions and engage actively in their care have better outcomes.\nThis guide gives you organized, ready-to-use questions for every stage of your vascular access care — from the moment a catheter is recommended to the day it is removed.\nYou do not need to ask every question on this …","description":"A curated list of questions for patients to ask their vascular access team — before a procedure, during a hospital stay, before going home, and for ongoing catheter care — organized for easy reference.","section":"vascular-access","title":"Questions to Ask Your Vascular Access Team","url":"/vascular-access/patient-education/questions-to-ask-your-vascular-access-team/"},{"content":"Quick Reference Cards: Vascular Access at a Glance These cards provide quick, at-a-glance summaries for the most common situations you will encounter with a vascular access device at home. They are designed to be printed and posted — on your refrigerator, at your infusion station, or wherever your care happens.\nFor detailed information on any topic, see the full guide linked at the end of each card.\nCARD 1: PICC Line Daily Care Checklist …","description":"Quick reference cards for patients with vascular access devices — concise summaries of PICC care, port care, flush schedules, when to call versus go to the ER, signs of catheter infection, and emergency contacts. Designed to be printed and posted at home.","section":"vascular-access","title":"Quick Reference Cards: Vascular Access at a Glance","url":"/vascular-access/patient-education/quick-reference-cards/"},{"content":"Recognizing Complications: When to Call for Help Most IV lines and catheters work without any problems. But complications can happen, and the best outcomes come from catching them early. You are the most important monitor of your own IV site — you can feel and see changes that your care team may not notice between scheduled checks.\nThis guide describes the most common vascular access complications in plain language, what to look and feel for, and when you need to call your nurse right away.\nThe …","description":"A patient's guide to recognizing IV and catheter complications — including infiltration, phlebitis, infection, clotting, and air embolism — and knowing when and how to ask for help.","section":"vascular-access","title":"Recognizing Complications: When to Call for Help","url":"/vascular-access/patient-education/recognizing-complications-when-to-call/"},{"content":"Skin Care Around Your Catheter Site The skin around your catheter insertion site is the first line of defense against infection — and it is also vulnerable to injury from the adhesives, antiseptics, and repeated dressing changes required to keep the catheter secure and sterile. Healthy skin around the catheter site contributes directly to your safety. This guide explains what can happen to that skin and what you and your care team can do to protect it.\nWhy Catheter Site Skin Is Vulnerable Over …","description":"How to protect and care for the skin around your vascular access catheter site — understanding skin reactions to adhesives and antiseptics, preventing medical adhesive-related skin injury, managing sensitive skin, and when skin changes need professional attention.","section":"vascular-access","title":"Skin Care Around Your Catheter Site","url":"/vascular-access/patient-education/skin-care-around-catheter-site/"},{"content":"Subcutaneous Infusion (Hypodermoclysis): What to Expect Most people are familiar with IV lines that go into veins. But for some patients — particularly those in palliative care, hospice, older adults with difficult venous access, or patients needing gentle hydration at home — there is another option: subcutaneous infusion, also called hypodermoclysis.\nIn subcutaneous infusion, fluids or medications are delivered under the skin (into the subcutaneous tissue — the layer of fat and connective …","description":"A patient guide to subcutaneous infusion (hypodermoclysis) — delivering fluids and medications under the skin instead of into a vein. How it works, who it's for, what can be given, site care, and what to expect.","section":"vascular-access","title":"Subcutaneous Infusion (Hypodermoclysis): What to Expect","url":"/vascular-access/patient-education/subcutaneous-infusion-hypodermoclysis/"},{"content":"Therapeutic Apheresis: What to Expect Apheresis (pronounced ah-fair-EE-sis) is a procedure in which blood is withdrawn from your body, one or more components are separated and removed or modified, and the remaining blood is returned to you. When done for medical treatment rather than donation, it is called therapeutic apheresis.\nThis guide explains the different types of therapeutic apheresis, why they are used, what vascular access is required, and what to expect during and after the procedure. …","description":"A patient guide to therapeutic apheresis — what it is, the different types (therapeutic plasma exchange, LDL apheresis, red cell exchange, photopheresis), what vascular access is needed, what to expect during the procedure, and how to manage side effects.","section":"vascular-access","title":"Therapeutic Apheresis: What to Expect","url":"/vascular-access/patient-education/therapeutic-apheresis-patient-guide/"},{"content":"Travel with a Vascular Access Device: A Practical Guide Having a PICC line, implanted port, or other vascular access device does not mean you cannot travel. With thoughtful planning, many patients successfully manage travel — whether a short domestic trip or international travel — while receiving IV therapy or maintaining a long-term catheter.\nThis guide covers everything you need to know to travel safely and confidently with your device.\nBefore You Travel: Planning Essentials Get clearance from …","description":"A practical guide to traveling with a vascular access device — flying with a PICC or port, managing medications and supplies on the road, TSA and airport security, international travel, time zone management, and finding emergency care away from home.","section":"vascular-access","title":"Travel with a Vascular Access Device: A Practical Guide","url":"/vascular-access/patient-education/travel-with-a-vascular-access-device/"},{"content":"Types of IV Lines and Catheters: What\u0026amp;rsquo;s the Difference? There are several different kinds of vascular access devices, and it can be confusing when your care team mentions a PICC line, a central line, a port, or just an \u0026amp;ldquo;IV.\u0026amp;rdquo; This guide explains the most common types in plain language — what they are, where they go in your body, and when and why each one is used.\nAt a Glance Device Inserted Into Tip Location Typical Duration Who Places It Peripheral IV (PIV) Small vein, hand/arm …","description":"Plain-language descriptions of all major vascular access devices — peripheral IVs, midlines, PICC lines, central venous catheters, and implanted ports — including when each is used and what to expect.","section":"vascular-access","title":"Types of IV Lines and Catheters: What's the Difference?","url":"/vascular-access/patient-education/types-of-iv-lines-and-catheters/"},{"content":"Understanding Vascular Access: A Patient\u0026amp;rsquo;s Guide What Is Vascular Access? \u0026amp;ldquo;Vascular access\u0026amp;rdquo; is a medical term for safely reaching a vein (or, less commonly, an artery or bone) so that your healthcare team can give you medicine, fluids, or nutrition directly into your bloodstream, or take blood samples without repeated needle sticks.\nThe device used to do this — whether it is a small plastic tube in your arm or a more complex catheter — is called a vascular access device, or …","description":"A plain-language introduction to vascular access — what it is, why you need it, and what to expect when your care team places an IV or catheter.","section":"vascular-access","title":"Understanding Vascular Access: A Patient's Guide","url":"/vascular-access/patient-education/understanding-vascular-access/"},{"content":"Vascular Access and Goals of Care When serious illness reaches a point where the focus of care shifts — from curing disease or maximally treating it, toward managing symptoms and maintaining the best possible quality of life — many aspects of medical care are reconsidered. One of these is vascular access: the catheters, ports, and IV lines that have been part of treatment.\nThis guide is written for patients and families navigating that transition. It addresses the practical and deeply personal …","description":"A guide to vascular access decisions when shifting toward comfort-focused or palliative care — when to keep or remove a catheter, the role of IV lines in symptom management, questions about IV fluids at end of life, and how to have these conversations with your care team.","section":"vascular-access","title":"Vascular Access and Goals of Care","url":"/vascular-access/patient-education/vascular-access-goals-of-care/"},{"content":"Vascular Access in the NICU: A Parent\u0026amp;rsquo;s Guide When your baby is in the neonatal intensive care unit (NICU), you will see wires, tubes, monitors, and IV lines attached to your newborn. It can be overwhelming and frightening. One of the most common sources of questions for NICU parents is the lines going into or coming out of the baby\u0026amp;rsquo;s body — particularly the vascular access devices used to give medications, fluids, and nutrition.\nThis guide explains the different types of IV access …","description":"A parent's guide to vascular access in the NICU — explaining umbilical catheters, neonatal PICC lines, and peripheral IVs in newborns: why they are placed, what they look like, how they are cared for, and how parents can help protect them.","section":"vascular-access","title":"Vascular Access in the NICU: A Parent's Guide","url":"/vascular-access/patient-education/nicu-vascular-access-parent-guide/"},{"content":"Vascular Access Safety for Immunocompromised Patients If your immune system is compromised — by chemotherapy, an organ or stem cell transplant, HIV, long-term corticosteroids, biologics, or other immunosuppressant medications — you face a higher risk of infection from vascular access devices than the general patient population. Understanding why this is, what it means in practice, and how to protect yourself is essential.\nWhat Does \u0026amp;ldquo;Immunocompromised\u0026amp;rdquo; Mean? Your immune system is your …","description":"Vascular access safety guidance for immunocompromised patients — those receiving chemotherapy, transplant recipients, patients on immunosuppressants or biologics — including why infection risk is higher, stricter fever thresholds, enhanced precautions, and when to seek care immediately.","section":"vascular-access","title":"Vascular Access Safety for Immunocompromised Patients","url":"/vascular-access/patient-education/immunocompromised-patient-guide/"},{"content":"Your First Visit to an Outpatient Infusion Center Whether you are going for chemotherapy, IV antibiotics, biologic therapy, IVIG, or another IV treatment, your first visit to an outpatient infusion center can feel unfamiliar and intimidating. Knowing what to expect — the space, the process, the people, and how to prepare — makes a real difference in how that first visit goes.\nWhat Is an Outpatient Infusion Center? An outpatient infusion center (also called an infusion suite, infusion clinic, or …","description":"A guide to your first visit to an outpatient infusion center — what the facility looks like, what to expect during check-in and your infusion, how long to plan for, what to bring, and how to make the experience more comfortable.","section":"vascular-access","title":"Your First Visit to an Outpatient Infusion Center","url":"/vascular-access/patient-education/outpatient-infusion-center-first-visit/"},{"content":"Your Interventional Radiology Visit: What to Expect If you have been told you need a procedure in interventional radiology (IR), you may not know what to expect. IR is a specialty that many patients have never heard of before they need it. This guide explains what IR is, what types of vascular access procedures are performed there, and what your visit will be like.\nWhat Is Interventional Radiology? Interventional radiology is a medical specialty that performs minimally invasive procedures using …","description":"A patient guide to visiting interventional radiology for vascular access procedures — what IR is, what types of catheter procedures are done there, how to prepare, what the environment looks like, and what to expect during and after.","section":"vascular-access","title":"Your Interventional Radiology Visit: What to Expect","url":"/vascular-access/patient-education/interventional-radiology-visit-guide/"},{"content":"Your Rights: Informed Consent and Decision-Making Before any significant vascular access procedure — including placement of a PICC line, central venous catheter, implanted port, or other invasive device — you have the right to be fully informed and to make your own decision. This guide explains what that means in practice.\nWhat Is Informed Consent? Informed consent is not just a signature on a form. It is a conversation between you and your care team. By the end of that conversation, you should: …","description":"A patient's guide to informed consent for vascular access procedures — your right to understand, ask questions, agree, or refuse — and what happens if you cannot make decisions for yourself.","section":"vascular-access","title":"Your Rights: Informed Consent and Decision-Making","url":"/vascular-access/patient-education/your-rights-informed-consent/"},{"content":"Cortisol Levels in Hospital Staff and Work Efficiency Table of Contents Summary Cortisol Levels Effects of Elevated Cortisol on Health Impact on Work Efficiency Managing Cortisol Levels in Healthcare Settings Impact of Cortisol on Work Efficiency Effects of Elevated Cortisol Levels Stressors Contributing to Increased Cortisol Neuroplasticity and Cognitive Function Studies and Research Overview of Cortisol and Work Stress Patterns of Salivary Cortisol Levels in Emergency Care Providers The Impact …","description":"This article examines how elevated cortisol levels—the body's primary stress hormone—affect hospital staff's health and work performance. It explains that healthcare workers face unique stressors such as high-stakes patient care, excessive workloads, and lack of institutional support, which can lead to chronically elevated cortisol and subsequent health issues including anxiety, depression, cognitive impairment, and cardiovascular problems. These effects ultimately reduce work efficiency and can compromise patient safety. The article reviews research on cortisol patterns in emergency care providers, discusses how the COVID-19 pandemic exacerbated these challenges, and offers strategies for managing cortisol levels through lifestyle modifications (exercise, sleep hygiene), stress management techniques (mindfulness, CBT), organizational changes (workload management, flexibility), and when necessary, medical interventions. It concludes by urging healthcare organizations to prioritize staff well-being through transparent, supportive management practices to maintain both employee health and quality patient care.","section":"blog","title":"Cortisol Levels in Hospital Staff and Work Efficiency","url":"/blog/cortisol-levels-in-hospital-staff-and-work-efficiency/"},{"content":"1. Core Principles of Vascular Care The administration of infusion therapy and the management of vascular access devices (VADs) must be governed by a structured hierarchy of safety and ethics. These principles apply to all access types, including peripheral, central, intraosseous, subcutaneous, and epidural/intrathecal routes.\nRegulatory Alignment: Clinicians must adhere to the specific legislative and regulatory framework of their jurisdiction (national, state, or provincial). Organizational …","description":"This comprehensive guide outlines evidence-based principles of vascular access and infusion therapy across the lifespan, including neonatal, pediatric, obstetric, and geriatric populations. It covers regulatory compliance, ethical practice, device selection, infusion accuracy, and population-specific risks such as DEHP exposure, DIVA management, pregnancy-related hypercoagulability, and geriatric polypharmacy. Designed for clinicians, nurses, and vascular access specialists, this resource supports safe, patient-centered decision-making aligned with current standards of care.","section":"vascular-access","title":"Foundations of Clinical Practice and Specialized Population Management","url":"/vascular-access/policies/foundations-of-clinical-practice-and-specialized-population-management/"},{"content":"Competency and Competency Validation in Vascular Access Policy 1. Policy Statement It is the policy of this organization that all clinicians who perform, assist with, or manage vascular access devices and infusion therapy shall demonstrate documented competency prior to practicing independently and shall maintain that competency through ongoing validation driven by clinical data, regulatory requirements, and technological change.1234 No clinician shall perform a vascular access procedure …","description":"Establishes the standards, framework, and requirements for initial and ongoing competency assessment and validation for all clinicians performing vascular access and infusion therapy procedures, including educational delivery methods, simulation requirements, insertion training protocols, and program evaluation metrics.","section":"vascular-access","title":"Competency and Competency Validation in Vascular Access","url":"/vascular-access/policies/competency-competency-validation/"},{"content":"Documentation in the Health Record for Vascular Access Policy 1. Policy Statement It is the policy of this organization that every vascular access event—from device insertion through ongoing assessment, maintenance, medication administration, and device removal—shall be accurately, completely, and timely documented in the patient\u0026amp;rsquo;s electronic health record (EHR) using standardized formats that enable continuity of care, legal defensibility, quality improvement data extraction, and …","description":"Establishes the standards, requirements, and minimum data elements for clinical documentation of all vascular access events—from insertion through removal—in the electronic health record, including insertion documentation, ongoing assessment, medication administration, and the integration of EHR clinical decision support tools.","section":"vascular-access","title":"Documentation in the Health Record for Vascular Access","url":"/vascular-access/policies/documentation-health-record-vascular-access/"},{"content":"Evidence-Based Practice (EBP) and Research in Vascular Access Policy 1. Policy Statement It is the policy of this organization that all vascular access clinical practice shall be guided by the highest quality available research evidence, integrated with clinical expertise and patient values.123 Organizational policies, procedures, and clinical protocols related to vascular access shall be treated as living documents subject to continuous revision in response to new clinical evidence.45 The …","description":"Establishes the organizational commitment to evidence-based practice in vascular access, mandates the continuous revision of policies based on current research, defines the implementation science framework for translating evidence into bedside practice, and outlines the infrastructure requirements for supporting clinician-researchers.","section":"vascular-access","title":"Evidence-Based Practice (EBP) and Research in Vascular Access","url":"/vascular-access/policies/evidence-based-practice-research/"},{"content":"Evidence-Based Selection and Clinical Monitoring Standards Policy 1. Policy Statement It is the policy of this organization that all clinical decisions regarding the selection of vascular access devices, antiseptic agents, dressing materials, securement products, and infusion technologies shall be rooted in demonstrated patient outcomes derived from the highest quality available clinical evidence. Product selection shall not be driven by habit, anecdotal experience, individual clinician …","description":"Mandates that all vascular access device selection, antiseptic agent selection, and infusion technology decisions be rooted in demonstrated clinical evidence and patient outcomes, and establishes the systematic clinical monitoring requirements for all vascular access devices.","section":"vascular-access","title":"Evidence-Based Selection and Clinical Monitoring Standards","url":"/vascular-access/policies/evidence-based-selection-clinical-monitoring/"},{"content":"Foundations of Clinical Practice and Specialized Population Management Policy 1. Policy Statement It is the policy of this organization that all infusion therapy and vascular access device (VAD) management shall be governed by a structured hierarchy of safety, ethics, and regulatory compliance. All clinicians involved in the prescription, insertion, maintenance, or removal of vascular access devices shall adhere to evidence-based, population-specific protocols that account for the unique …","description":"Establishes the foundational principles governing the administration of infusion therapy and the management of vascular access devices across all specialized patient populations, including pediatric, neonatal, obstetric, and geriatric cohorts.","section":"vascular-access","title":"Foundations of Clinical Practice and Specialized Population Management","url":"/vascular-access/policies/foundations-clinical-practice-specialized-populations/"},{"content":"Informed Consent for Vascular Access Procedures Policy 1. Policy Statement It is the policy of this organization that informed consent shall be obtained, as a process and not merely a signature,1 before any vascular access procedure for which consent is required by law, regulation, or organizational policy.2 The consent process shall ensure that the patient (or their legally authorized representative) understands the nature of the proposed procedure, the associated risks and benefits, the …","description":"Establishes the legal, ethical, and procedural requirements for obtaining, documenting, and maintaining informed consent for vascular access procedures, including the components of the consent discussion, requirements for emergency situations, and provisions for patients who lack decision-making capacity.","section":"vascular-access","title":"Informed Consent for Vascular Access Procedures","url":"/vascular-access/policies/informed-consent-vascular-access/"},{"content":"Interprofessional Safety and Care Transitions Policy 1. Policy Statement It is the policy of this organization that vascular access expertise shall be formally integrated into all cross-disciplinary institutional safety programs, and that every transition of care involving a patient with an indwelling vascular access device shall be accompanied by standardized, comprehensive transfer documentation designed to ensure continuity of device management and the prevention of device-associated …","description":"Mandates the integration of vascular access expertise into cross-disciplinary institutional safety programs and establishes the standards for safe care transitions involving patients with indwelling vascular access devices across acute, community, home, and long-term care settings.","section":"vascular-access","title":"Interprofessional Safety and Care Transitions","url":"/vascular-access/policies/interprofessional-safety-care-transitions/"},{"content":"Patient Education in Infusion Therapy Policy 1. Policy Statement It is the policy of this organization that every patient (and/or designated caregiver) receiving infusion therapy through a vascular access device shall receive comprehensive, individualized education regarding their device, its management, the recognition of complications, and the actions required in the event of an adverse occurrence.123 Education shall be tailored to the patient\u0026amp;rsquo;s health literacy, cognitive status, …","description":"Mandates comprehensive, health-literacy-appropriate patient and caregiver education for all vascular access and infusion therapy encounters, defines the required educational content, and establishes the teach-back and return demonstration standards for verification of learning.","section":"vascular-access","title":"Patient Education in Infusion Therapy","url":"/vascular-access/policies/patient-education-infusion-therapy/"},{"content":"Quality Improvement in Vascular Access Policy 1. Policy Statement It is the policy of this organization that vascular access services shall be subject to a continuous, systematic quality improvement (QI) program that drives patient safety and clinical excellence through ongoing surveillance, data analysis, and proactive intervention.12 The QI program shall operate within a Just Culture framework that balances individual accountability with system-level improvement, utilizes validated improvement …","description":"Establishes the organizational framework for continuous quality improvement in vascular access services, including the adoption of validated QI methodologies, audit and feedback mechanisms, adverse event surveillance, medication safety integration, and the maintenance of a Just Culture environment.","section":"vascular-access","title":"Quality Improvement in Vascular Access","url":"/vascular-access/policies/quality-improvement-vascular-access/"},{"content":"Scope of Practice and Professional Boundaries in Infusion Therapy Policy 1. Policy Statement It is the policy of this organization that every clinician involved in the prescription, insertion, management, or removal of vascular access devices shall operate strictly within their legally defined scope of practice as determined by the applicable legislative, regulatory, and organizational authority. No individual shall perform a vascular access procedure or infusion therapy task for which they lack …","description":"Defines the regulatory hierarchy governing clinician scope of practice, establishes the framework for practice expansion and delegation of vascular access tasks, and delineates the professional roles and responsibilities of all personnel involved in infusion therapy.","section":"vascular-access","title":"Scope of Practice and Professional Boundaries in Infusion Therapy","url":"/vascular-access/policies/scope-of-practice-professional-boundaries/"},{"content":"Service Delivery Models and Operational Scope Policy 1. Policy Statement It is the policy of this organization that vascular access and infusion therapy services shall be delivered through a team of clinicians dedicated exclusively to this specialty, operating under a consultative model that provides holistic, evidence-based care across both inpatient and outpatient settings. The service shall extend beyond task-based device insertion to encompass expert clinical consultation, vessel health and …","description":"Establishes the organizational model for vascular access service delivery, defining the core service components, operational coverage requirements, consultative approach, and technology integration necessary for a comprehensive, holistic infusion therapy program across inpatient and outpatient settings.","section":"vascular-access","title":"Service Delivery Models and Operational Scope","url":"/vascular-access/policies/service-delivery-models-operational-scope/"},{"content":"Strategic Planning and Implementation of Vascular Access Services Policy 1. Policy Statement It is the policy of this organization that vascular access and infusion therapy services shall be delivered through a strategically planned, sustainably funded, and professionally governed program led by dedicated vascular access specialists operating within an interprofessional leadership framework. The organization shall conduct rigorous, data-driven evaluations of its clinical outcomes, operational …","description":"Defines the organizational requirements for the assessment, establishment, governance, financial management, and continuous improvement of a dedicated vascular access specialist service, including leadership structure, team nomenclature, budgetary processes, and interprofessional safety integration.","section":"vascular-access","title":"Strategic Planning and Implementation of Vascular Access Services","url":"/vascular-access/policies/strategic-planning-implementation-vascular-access-services/"},{"content":"Clinical Guidelines Are Rotting: The Case for API-First Medical Knowledge \u0026amp;ldquo;All the projects I\u0026amp;rsquo;ve had to make, I\u0026amp;rsquo;ve made because I couldn\u0026amp;rsquo;t find anything better. I much prefer other people solving my problems. Me having to come up with a project is actually a failure on the world.\u0026amp;rdquo; - Linus Torvalds\nThe Problem: PDFs Aren\u0026amp;rsquo;t Healthcare APIs Every day, thousands of clinicians make life-altering decisions based on clinical guidelines that exist primarily as static …","description":"Clinical guidelines as static PDFs are failing healthcare. Learn why API-first medical knowledge distribution is essential for modern clinical decision support and how open-source approaches can revolutionize healthcare interoperability.","section":"blog","title":"APIs Over Guidelines","url":"/blog/apis-over-guidelines/"},{"content":"Vascular Access Device Insertion Policy 1. Policy Statement It is the policy of this organization that the insertion of all vascular access devices (VADs) shall adhere to evidence-based foundational standards encompassing sterility, manufacturer compliance, aseptic technique, and patient education, and that clinicians shall employ appropriate insertion bundles, visualization technology, and complication management protocols to ensure patient safety and procedural success across all VAD types and …","description":"Establishes standards for the safe insertion of all vascular access devices, including peripheral intravenous catheters, central venous access devices, and arterial catheters, with requirements for aseptic technique, ultrasound guidance, and complication management.","section":"vascular-access","title":"Vascular Access Device Insertion","url":"/vascular-access/policies/vascular-access-device-insertion/"},{"content":"Transmission-Based Precautions Policy 1. Policy Statement It is the policy of this organization that Transmission-Based Precautions shall be implemented as supplementary infection prevention measures whenever patients are known or suspected to be infected or colonized with communicable pathogens requiring protection beyond Standard Precautions. These precautions are stratified according to the transmission characteristics of relevant pathogens and must be adapted to the care setting. Standard …","description":"Establishes supplementary infection prevention standards beyond standard precautions for patients with known or suspected communicable disease, including contact, droplet, and airborne precaution requirements, enhanced barrier precautions in long-term care, and crisis standards for pandemic response.","section":"vascular-access","title":"Transmission-Based Precautions","url":"/vascular-access/policies/transmission-based-precautions/"},{"content":"IntracavOS: The Beautiful Paranoia of Total Control By the time we finished the first pot of coffee, it was clear the world had gone soft—soggy even—sloshing data through bloated, faceless servers humming somewhere in Oregon or Virginia. Call it the convenience of APIs. Call it the outsourcing of trust. Call it what it is: a ticking bomb with a cheery user interface. When you’re dealing with healthcare—when you’re swimming in HIPAA compliance and patient data—the stakes aren’t just regulatory. …","description":"Why IntracavOS moved from cloud APIs to a fully isolated, self-hosted AI system: exploring the security philosophy behind closed-loop healthcare AI and the paranoid approach to patient data protection.","section":"blog","title":"IntracavOS: The Beautiful Paranoia of Total Control","url":"/blog/intracavos-beautiful-paranoia-total-control/"},{"content":" Breaking the Mold in Vascular Access: Why Healthcare Needs a Gut Check I’m over the “innovation” talk in healthcare. Really. We’re all so busy positioning ourselves as the next big tech company with our “custom AI” projects, yet CLABSIs—central line-associated bloodstream infections—still run rampant across the country. Every professional I’ve met in healthcare has this bizarre inertia: they’re quick to ask but excruciatingly slow to spend, like they’re clinging to the hope that maybe if they …","description":"A candid critique of healthcare's resistance to innovation: why vascular access and clinical practice remain stuck in outdated patterns while real problems like CLABSIs persist.","section":"blog","title":"Healthcare is a Slow Moving Carcass","url":"/blog/healthcare-slow-moving-carcass/"},{"content":"Why We\u0026amp;rsquo;re Building IntracavOS: Real Talk About Healthcare AI Look, let\u0026amp;rsquo;s cut through the BS - healthcare AI is a mess. Everyone\u0026amp;rsquo;s rushing to slap an LLM onto their product and call it \u0026amp;ldquo;revolutionary,\u0026amp;rdquo; but nobody\u0026amp;rsquo;s talking about the elephant in the room: most of these solutions are held together with duct tape and prayers. At Lumen, we\u0026amp;rsquo;re doing something different, and I\u0026amp;rsquo;m going to tell you exactly why our approach is going to eat everyone …","description":"Why we built IntracavOS on NixOS: A reproducible, secure, and scalable operating system designed specifically for healthcare AI deployment. Learn about our architecture and why traditional approaches fail.","section":"blog","title":"Introducing IntracavOS","url":"/blog/introducing-intracavos/"},{"content":"Deep Dive Blood Draws and Hemolysis Follow along with Lumen and interact with it yourself with this link\nCVR (Catheter to Vein Ratio). The Optimal ratio is \u0026amp;lt;45%.\nThe Physics and Math Alright, let\u0026amp;rsquo;s talk about hemolysis but in this piece we’ll focus the context on blood draws, lab draws, blood samples, and lab samples. There’s a lot of contradicting anecdotes and confusion around which is the best device or technique to use. So let\u0026amp;rsquo;s deep dive into the physics and biochemistry for …","description":"Comprehensive guide to preventing hemolysis during blood draws: understanding catheter-to-vein ratio (CVR), cavitation physics, and evidence-based techniques for optimal lab sample quality.","section":"vascular-access","title":"Blood Draws and Hemolysis: Physics, Biochemistry, and Best Practices","url":"/vascular-access/policies/blood-draws-hemolysis-prevention/"},{"content":"Vascular Access Site Preparation and Skin Antisepsis Policy 1. Policy Statement It is the policy of this organization that skin antisepsis shall be performed before the insertion of any vascular access device (VAD), using evidence-based antiseptic agents applied with appropriate technique, and that clinicians shall assess patient-specific factors — including allergies, skin condition, and age-related physiological characteristics — to ensure safe and effective site preparation that minimizes the …","description":"Establishes requirements for skin antisepsis and site preparation prior to vascular access device insertion, including antiseptic selection, application technique, and neonatal-specific precautions.","section":"vascular-access","title":"Vascular Access Site Preparation and Skin Antisepsis","url":"/vascular-access/policies/vascular-access-site-preparation-skin-antisepsis/"},{"content":"Clinical Guideline: Catheter-Associated Skin Injury Prevention, Assessment, and Management in Vascular Access Care 1. Introduction and Scope This clinical guideline provides evidence-based recommendations for the prevention, identification, and management of catheter-associated skin injury (CASI) in patients with peripheral and central vascular access devices. The guidance applies across clinical settings including acute care, critical care, oncology, neonatology, and ambulatory infusion …","description":"Evidence-based guidelines for the prevention, assessment, and management of catheter-associated skin injury (CASI) and medical adhesive-related skin injury (MARSI) in patients with peripheral and central vascular access devices, including risk assessment, dressing selection, atraumatic removal techniques, and management of established injury.","section":"vascular-access","title":"Catheter-Associated Skin Injury: Prevention, Assessment, and Management in Vascular Access Care","url":"/vascular-access/policies/catheter-associated-skin-injury/"},{"content":"Subcutaneous Infusion and Access Devices Purpose and Scope This guideline establishes evidence-based standards for subcutaneous infusion therapy, including hypodermoclysis and medication administration. It is intended for use by clinical professionals across acute care, ambulatory, and home care settings. The subcutaneous route represents a valuable alternative to intravenous access and should be integrated into comprehensive vessel health and preservation strategies.\n1. Patient Assessment and …","description":"Evidence-based standards for subcutaneous infusion therapy including hypodermoclysis, subcutaneous medication administration, continuous subcutaneous insulin infusion, and on-body delivery systems across acute care, ambulatory, and home care settings.","section":"vascular-access","title":"Subcutaneous Infusion and Access Devices","url":"/vascular-access/policies/subcutaneous-infusion-access-devices/"},{"content":"Vascular Access Device Post-Insertion Care Policy 1. Policy Statement All vascular access devices (VADs) in use at this institution require systematic post-insertion care encompassing routine assessment, dressing management, skin antisepsis, infection prevention, and documentation performed in accordance with evidence-based standards. Clinical teams are responsible for conducting daily necessity reviews to ensure continued VAD use remains clinically justified, and for removing devices promptly …","description":"Establishes standards for post-insertion care of all vascular access devices, including systematic assessment protocols, dressing selection and change intervals, skin antisepsis, site protection, infection prevention strategies, documentation requirements, and population-specific considerations.","section":"vascular-access","title":"Vascular Access Device Post-Insertion Care","url":"/vascular-access/policies/vascular-access-post-insertion-care/"},{"content":"Clinical Guideline: Central Vascular Access Device Malposition Assessment, Prevention, and Management Version: 1.0 Effective Date: January 2026 Review Date: January 2028\n1. Purpose and Scope This guideline establishes evidence-based recommendations for clinicians responsible for assessing, preventing, and managing malposition of central vascular access devices (CVADs). The standard applies to all healthcare professionals involved in CVAD insertion, maintenance, and monitoring across acute care, …","description":"Evidence-based guidelines for the assessment, prevention, and management of central vascular access device malposition, including primary and secondary malposition types, prevention through insertion technique, diagnostic evaluation, and management approaches including noninvasive and invasive repositioning.","section":"vascular-access","title":"Central Vascular Access Device Malposition: Assessment, Prevention, and Management","url":"/vascular-access/policies/central-vascular-access-device-malposition/"},{"content":"Pain Management for Vascular Access Procedures Policy 1. Policy Statement It is the policy of this organization that pain associated with venipuncture and vascular access device insertion shall be systematically assessed using age-appropriate and developmentally suitable tools, and that evidence-based pharmacologic and nonpharmacologic interventions shall be implemented for all patients across the lifespan, with particular attention to neonates, infants, children, and adults with needle phobia …","description":"Establishes requirements for evidence-based pain assessment and management during vascular access procedures across all patient populations, from neonates through adults.","section":"vascular-access","title":"Pain Management for Vascular Access Procedures","url":"/vascular-access/policies/pain-management-vascular-access-procedures/"},{"content":"Blood Sampling via Vascular Access Devices Policy 1. Policy Statement All blood specimen collection at this institution, whether obtained by direct venipuncture, arterial puncture, or via an indwelling vascular access device (VAD) or intraosseous (IO) access device, must be performed in accordance with standardized procedures that ensure accurate patient identification, correct specimen labeling, blood conservation, preanalytical error prevention, and Aseptic Non-Touch Technique (ANTT). Blood …","description":"Establishes standards for blood specimen collection from peripheral venipuncture, arterial puncture, peripheral intravenous catheters, central venous access devices, and intraosseous access devices, including patient identification, blood conservation, preanalytical error prevention, and blood culture collection requirements.","section":"vascular-access","title":"Blood Sampling via Vascular Access Devices","url":"/vascular-access/policies/blood-sampling-vascular-access/"},{"content":"Neuraxial Access Devices Purpose and Scope This guideline provides evidence-based recommendations for the safe and effective management of neuraxial access devices, including epidural and intrathecal catheters, implanted neuraxial ports, and intrathecal drug delivery (ITDD) systems. It is intended for use by clinicians across acute care, outpatient, and home care settings who participate in the insertion, management, medication administration, and complication prevention associated with these …","description":"Evidence-based standards for the safe insertion, management, medication administration, and complication prevention of neuraxial access devices including epidural and intrathecal catheters, implanted neuraxial ports, and intrathecal drug delivery (ITDD) systems across acute care, outpatient, and home care settings.","section":"vascular-access","title":"Neuraxial Access Devices","url":"/vascular-access/policies/neuraxial-access-devices/"},{"content":"Cortisol Levels in Hospital Staff and Work Efficiency: A Critical Clinical Analysis Executive Summary: The Hidden Crisis in Healthcare Excellence We\u0026amp;rsquo;re confronting an invisible enemy in our hospitals—one that silently undermines clinical performance, compromises patient safety, and devastates our healthcare workforce. Cortisol dysregulation among hospital staff isn\u0026amp;rsquo;t just a wellness concern; it\u0026amp;rsquo;s a critical threat to medical excellence that demands immediate, evidence-based …","description":"Critical analysis of cortisol dysregulation in hospital staff and its impact on clinical performance, patient safety, and healthcare workforce wellbeing with evidence-based interventions.","section":"vascular-access","title":"Cortisol Levels in Hospital Staff and Work Efficiency: A Critical Clinical Analysis","url":"/vascular-access/policies/cortisol-levels-hospital-staff-work-efficiency/"},{"content":"Moderate Sedation and Analgesia via Intravenous Infusion Purpose and Scope This guideline establishes evidence-based standards and recommendations for the safe administration of moderate sedation and analgesia through intravenous infusion. It is intended for clinical professionals involved in procedural sedation across hospital, ambulatory, and specialty settings. The recommendations herein are derived from current peer-reviewed literature, position papers from major anesthesiology societies, …","description":"Evidence-based standards for safe administration of moderate sedation and analgesia through intravenous infusion, covering clinician competency, pharmacologic agents, preprocedural assessment, airway management, continuous monitoring, capnography, post-procedure recovery, and quality improvement.","section":"vascular-access","title":"Moderate Sedation and Analgesia via Intravenous Infusion","url":"/vascular-access/policies/moderate-sedation-analgesia-intravenous-infusion/"},{"content":"Administration Set Management Policy 1. Policy Statement All administration sets used for intravenous, intra-arterial, and other parenteral infusions at this institution must be selected, configured, used, labeled, and replaced in accordance with evidence-based standards that minimize the risk of infection, medication error, material incompatibility, and patient harm.12 Replacement frequency is determined by infusion type, patient condition, solution characteristics, and product integrity, and …","description":"Establishes requirements for the appropriate selection, use, configuration, labeling, and replacement of primary and secondary administration sets for all infusion types, including standard solutions, parenteral nutrition, lipids, blood products, propofol, and hemodynamic monitoring systems.","section":"vascular-access","title":"Administration Set Management","url":"/vascular-access/policies/administration-set-management/"},{"content":"Prevention and Management of Air Embolism in Vascular Access Clinical Significance Air embolism represents a potentially fatal complication of vascular access procedures and infusion therapy.[5,24,25,29,33] When air enters the venous or arterial circulation, it can obstruct blood flow, leading to cardiopulmonary compromise, neurological injury, or death. The condition may arise during catheter insertion, routine infusion management, catheter exchange, or device removal.[2,5,25] Prevention …","description":"Evidence-based standards for preventing air embolism during vascular access procedures, including CVAD removal protocols, recognition of signs and symptoms, and emergency response for suspected venous or arterial air embolism.","section":"vascular-access","title":"Prevention and Management of Air Embolism in Vascular Access","url":"/vascular-access/policies/air-embolism-vascular-access/"},{"content":"Aseptic Non-Touch Technique (ANTT®) Policy 1. Policy Statement It is the policy of this organization that Aseptic Non Touch Technique (ANTT®) shall be employed as the standardized framework for preventing infection during all invasive procedures and device management. ANTT integrates evidence-based infection control principles with practical clinical application, creating a unified methodology applicable across all care settings and procedure types. The protection of Key-Parts and Key-Sites from …","description":"Establishes standards for the application of Aseptic Non Touch Technique (ANTT®) across all invasive clinical procedures and vascular access device management, including risk assessment framework, aseptic field management, competency requirements, and environmental management.","section":"vascular-access","title":"Aseptic Non-Touch Technique (ANTT®)","url":"/vascular-access/policies/antt-aseptic-non-touch-technique/"},{"content":"Therapeutic Phlebotomy Overview Therapeutic phlebotomy is a medical procedure involving the controlled removal of blood to treat conditions characterized by excess red blood cells, iron overload, or other hematologic abnormalities. This guideline establishes standards and evidence-based recommendations for safe and effective therapeutic phlebotomy practice.\nCore Standards Standard 1: Vascular Access Device Selection Selection of the most appropriate vascular access device for therapeutic …","description":"Clinical guideline for safe and effective therapeutic phlebotomy practice, including vascular access device selection, treatment parameter establishment, adverse effect prevention and management, psychosocial considerations, patient education, and combination therapy for conditions such as polycythemia vera and hereditary hemochromatosis.","section":"vascular-access","title":"Therapeutic Phlebotomy","url":"/vascular-access/policies/therapeutic-phlebotomy/"},{"content":"Maximizing Your Experience with Lumen: A Comprehensive Guide Welcome to Lumen, your dedicated assistant in the field of vascular access. To ensure you derive the maximum benefit from your interactions with me, let\u0026amp;rsquo;s jump into some guidelines and recommendations on how to effectively utilize the capabilities of Lumen. By following these comprehensive guidelines, you can optimize your experience and leverage the full potential of this AI assistant to enhance your clinical practice, research …","description":"Complete guide to maximizing Lumen effectiveness: best practices for prompting, query formulation, and leveraging AI assistance for vascular access clinical practice and research.","section":"vascular-access","title":"Lumen Prompting Guidelines","url":"/vascular-access/policies/intracav-ai-prompting-guidelines/"},{"content":"Exploring the Dynamics of Clinical Decision Making in Vascular Access: Empowering Healthcare Providers In the intricate tapestry of healthcare, the domain of vascular access serves as a critical juncture where clinical decision-making plays a pivotal role. We aim to explore the nuances of clinical decision-making within vascular access, shedding light on the multifaceted aspects that guide healthcare providers in making informed choices for optimal patient care.\nUnderstanding Clinical Decision …","description":"Comprehensive guide to clinical decision-making in vascular access: exploring interprofessional collaboration, evidence-based protocols, and patient-centered care strategies for optimal outcomes.","section":"vascular-access","title":"Exploring the Dynamics of Clinical Decision Making in Vascular Access","url":"/vascular-access/policies/clinical-decision-making-vascular-access/"},{"content":"Optimizing Vascular Access Device Removal: Evidence-Based Strategies and Recommendations Within vascular access, the removal of devices plays a critical role in patient care, necessitating adherence to evidence-based protocols to mitigate risks and ensure optimal outcomes. Drawing upon reputable guidelines and research findings, let\u0026amp;rsquo;s explore the best practices and recommendations for removing various vascular access devices.\nPeripheral Intravenous Catheters (PIVCs) and Midline Catheters: …","description":"Evidence-based clinical guidelines for vascular access device removal: comprehensive protocols for PIVCs, midline catheters, and central lines to optimize patient safety and outcomes.","section":"vascular-access","title":"Optimizing Vascular Device Removal: Evidence-Based Strategies","url":"/vascular-access/policies/optimizing-vascular-device-removal/"},{"content":"Peripheral Arterial Disease (PAD): A Comprehensive Overview Peripheral Arterial Disease (PAD) is a condition that affects the arteries outside the heart and brain, primarily caused by atherosclerosis, leading to reduced blood flow to the limbs. Understanding PAD is crucial for effective management and treatment strategies. Here are some key points extracted from current vascular access guidelines and textbooks:\nGlossary Insights: Thrombophlebitis: Inflammation of the vein with the formation of a …","description":"Comprehensive clinical guideline for Peripheral Arterial Disease (PAD) management in vascular access: evidence-based protocols for assessment, prevention, and treatment strategies.","section":"vascular-access","title":"Peripheral Arterial Disease (PAD): Clinical Overview and Vascular Access Considerations","url":"/vascular-access/policies/peripheral-arterial-disease-pad/"},{"content":"Catheter Damage, Embolism, Repair, and Exchange Core Standards Standard 1: Preventative strategies must be implemented to maintain catheter integrity and reduce the risk of catheter damage across all care settings.\nStandard 2: Prior to undertaking any catheter repair or exchange procedure, clinicians must perform a comprehensive assessment of the patient\u0026amp;rsquo;s risk-to-benefit ratio and ongoing vascular access requirements.\nPrevention of Catheter Damage 1.1 Fundamental Principles of Catheter …","description":"Evidence-based standards for preventing catheter damage, recognizing signs of compromise including pinch-off syndrome, and managing catheter damage through repair, exchange, or removal with post-procedure monitoring requirements.","section":"vascular-access","title":"Catheter Damage, Embolism, Repair, and Exchange","url":"/vascular-access/policies/catheter-damage-embolism-repair-exchange/"},{"content":"Hand Hygiene Policy 1. Policy Statement It is the policy of this organization that hand hygiene shall be performed routinely during all patient care activities by all clinical personnel. Hand hygiene remains the single most effective measure for preventing healthcare-associated infections and reducing transmission of microorganisms between patients, healthcare workers, and the clinical environment.12 All personnel shall adhere to these standards without exception, regardless of care setting.\n2. …","description":"Establishes comprehensive standards for hand hygiene practice across all care settings, including indications, approved techniques, product selection, fingernail and jewelry standards, and organizational compliance strategies to prevent healthcare-associated infections.","section":"vascular-access","title":"Hand Hygiene","url":"/vascular-access/policies/hand-hygiene/"},{"content":"Vascular Access for Therapeutic Apheresis Policy 1. Policy Statement It is the policy of this organization that all vascular access for therapeutic apheresis procedures shall be selected, placed, maintained, and monitored according to evidence-based clinical criteria that account for procedure type, patient anatomy, acuity, developmental status, and institutional resources, ensuring safe and effective extracorporeal blood processing while minimizing preventable vascular access complications.\n2. …","description":"Establishes requirements for vascular access device selection, technical standards, and maintenance protocols for patients undergoing therapeutic apheresis procedures.","section":"vascular-access","title":"Vascular Access for Therapeutic Apheresis","url":"/vascular-access/policies/vascular-access-therapeutic-apheresis/"},{"content":"Add-On Devices for Vascular Access Systems Policy 1. Policy Statement All clinicians who configure, assemble, or manage vascular access infusion systems shall use add-on devices only when a clearly defined clinical purpose exists, shall select devices with luer-lock or integrated connection mechanisms, and shall limit device burden to the minimum necessary for safe care delivery. Add-on devices shall be used in strict accordance with manufacturer instructions for use, shall be replaced according …","description":"Establishes requirements for the selection, use, configuration, disinfection, and replacement of add-on devices in vascular access infusion systems, including extension sets, manifolds, stopcocks, filters, and closed system transfer devices.","section":"vascular-access","title":"Add-On Devices for Vascular Access Systems","url":"/vascular-access/policies/add-on-devices-vascular-access/"},{"content":"Patient-Controlled Analgesia 1. Introduction and Scope Patient-controlled analgesia (PCA) represents a cornerstone of modern pain management, empowering patients to self-administer analgesic medications within prescribed safety parameters. This guideline establishes clinical standards for the safe and effective implementation of PCA therapy across healthcare settings, including acute care, ambulatory, and home-based environments.\nThe primary objective of PCA therapy is to achieve adequate pain …","description":"Clinical practice guideline establishing standards for safe and effective implementation of patient-controlled analgesia across healthcare settings, including pharmacologic agents, routes of administration, monitoring requirements, and authorized agent-controlled analgesia protocols.","section":"vascular-access","title":"Patient-Controlled Analgesia","url":"/vascular-access/policies/patient-controlled-analgesia/"},{"content":"Catheter-Associated Thrombosis Definitions 1.1 Catheter-Associated Thrombosis (CAT) Catheter-associated thrombosis refers to thrombus formation that develops as an inflammatory response to vessel wall injury caused by an indwelling vascular access device. On ultrasound examination, CAT appears as an anechoic or hypoechoic mass that partially or completely occludes the vessel lumen.\nCAT is classified according to anatomical location (deep versus superficial veins) and clinical presentation …","description":"Evidence-based standards for identifying risk factors for catheter-associated thrombosis, preventing thrombotic complications through device selection and insertion technique, monitoring and diagnosing DVT, and managing confirmed thrombosis including anticoagulation therapy across diverse patient populations.","section":"vascular-access","title":"Catheter-Associated Thrombosis","url":"/vascular-access/policies/catheter-associated-thrombosis/"},{"content":"Site Protection and Joint Stabilization for Vascular Access Devices Policy 1. Policy Statement All vascular access devices (VADs) placed or maintained within this organization must have appropriate site protection measures implemented to safeguard the insertion site and device from patient manipulation, inadvertent dislodgement, and environmental contamination. Site protection and joint stabilization strategies must be individualized based on patient-specific risk, implemented as complements …","description":"Establishes standards for protecting vascular access device insertion sites from dislodgement, patient manipulation, and environmental contamination, including joint stabilization practices and the judicious and restrained use of physical immobilization methods.","section":"vascular-access","title":"Site Protection and Joint Stabilization for Vascular Access Devices","url":"/vascular-access/policies/site-protection-joint-stabilization/"},{"content":"Flow-Control Devices for Infusion Therapy Policy 1. Policy Statement It is the policy of this organization that flow-control devices for infusion therapy shall be selected, programmed, and monitored in a manner that ensures safe, accurate delivery of prescribed infusion therapy and minimizes the risk of infusion-related medication errors. Electronic infusion pumps with dose error-reduction systems (smart pumps) shall be the standard for medication and solution administration in acute care …","description":"Establishes standards for flow-control device selection and use in infusion therapy, including electronic infusion pumps, smart pump dose error reduction systems, non-electronic devices, alarm management, and organizational standardization requirements.","section":"vascular-access","title":"Flow-Control Devices for Infusion Therapy","url":"/vascular-access/policies/flow-control-devices/"},{"content":"Parenteral Nutrition Administration Overview and Guiding Principles Parenteral nutrition (PN) represents a critical therapeutic intervention for patients unable to meet nutritional requirements through enteral routes. The decision to initiate PN therapy should emerge from collaborative discussions involving the patient, caregivers, and the interdisciplinary healthcare team, with careful consideration of the projected treatment plan and anticipated duration of therapy.\nTwo fundamental …","description":"Evidence-based clinical guidelines for safe parenteral nutrition administration covering vascular access selection, peripheral PN, filtration requirements, administration set management, infection prevention, patient monitoring, light protection for premature infants, and patient education.","section":"vascular-access","title":"Parenteral Nutrition Administration","url":"/vascular-access/policies/parenteral-nutrition-administration/"},{"content":"Administration of Antineoplastic Therapy 1. Purpose and Scope This guideline establishes evidence-based standards for the safe preparation, handling, and administration of antineoplastic medications. It addresses occupational safety, patient assessment, medication verification, vascular access selection, and adverse reaction management. The recommendations apply across all healthcare settings where antineoplastic agents are used, including acute care facilities, ambulatory infusion centers, and …","description":"Evidence-based standards for safe preparation, handling, and administration of antineoplastic medications including prescribing authorization, occupational safety and PPE requirements, closed system drug transfer devices, spill management, vesicant administration, and adverse reaction protocols.","section":"vascular-access","title":"Administration of Antineoplastic Therapy","url":"/vascular-access/policies/antineoplastic-therapy-administration/"},{"content":"Compounding and Preparation of Parenteral Solutions and Medications Document Purpose and Scope This guideline establishes evidence-based standards for the safe compounding and preparation of parenteral solutions and medications in clinical settings. It is intended for use by nurses, pharmacists, and other healthcare professionals involved in intravenous therapy and applies to all care environments where parenteral medications are prepared or administered.\nFoundational Standards Regulatory …","description":"Evidence-based standards for safe compounding and preparation of parenteral solutions and medications, covering sterile technique, pharmacy-based preparation, vial and ampoule handling, labeling requirements, and competency requirements for all clinicians involved in medication preparation.","section":"vascular-access","title":"Compounding and Preparation of Parenteral Solutions and Medications","url":"/vascular-access/policies/compounding-preparation-parenteral-solutions-medications/"},{"content":"Filtration in Vascular Access Device Management Policy 1. Policy Statement All clinicians responsible for the preparation and administration of parenteral solutions, blood products, and intraspinal therapies shall apply evidence-based in-line filtration practices that match filter characteristics to clinical indication, patient population, and infusate properties. Filter selection shall be guided by a formal risk-benefit evaluation, in compliance with manufacturer instructions for use and …","description":"Establishes requirements for in-line filtration of parenteral solutions, including mandatory filters for parenteral nutrition and intraspinal infusions, filter selection principles, population-specific indications, change intervals, safety precautions, and prohibited practices.","section":"vascular-access","title":"Filtration in Vascular Access Device Management","url":"/vascular-access/policies/filtration-vascular-access/"},{"content":"Implanted Vascular Access Ports Policy 1. Policy Statement It is the policy of this organization that implanted vascular access ports shall be accessed exclusively with noncoring needles after pre-access assessment confirms absence of contraindications, that all access and maintenance procedures shall adhere to Aseptic Non Touch Technique principles, and that patients and caregivers shall receive comprehensive education regarding port care, complication recognition, and device management.\n2. …","description":"Establishes standards for the access, maintenance, dressing, and patient education requirements for implanted vascular access ports, including noncoring needle selection, flushing protocols, power injection verification, and ongoing device surveillance.","section":"vascular-access","title":"Implanted Vascular Access Ports","url":"/vascular-access/policies/implanted-vascular-access-ports/"},{"content":"Infusion Medication and Solution Administration Purpose and Scope This clinical standard establishes evidence-based requirements for the safe administration of infusion medications and solutions across all care settings. It applies to all clinicians involved in preparing, verifying, and administering parenteral therapies, and serves as a reference for institutional policy development, quality improvement initiatives, and clinical education.\nCore Verification Requirements Medication and Solution …","description":"Evidence-based standards for safe administration of infusion medications and solutions, covering verification requirements, clinical appropriateness review, technology integration including barcode scanning and smart pump use, vascular access patency assessment, first-dose protocols, and adverse event reporting.","section":"vascular-access","title":"Infusion Medication and Solution Administration","url":"/vascular-access/policies/infusion-medication-solution-administration/"},{"content":"Vascular Access Device Occlusion Prevention, Assessment, and Management Definition of Patency A vascular access device (VAD) is considered patent when the clinician can successfully flush all catheter lumens without encountering resistance, following confirmation of blood return from each lumen. Establishing patency through this dual confirmation—aspiration followed by flushing—represents the standard for verifying device functionality prior to therapeutic use.\n1.2 Guiding Philosophy for …","description":"Standards for preventing, assessing, and managing vascular access device occlusion, including thrombotic and chemical causes, thrombolytic therapy, and catheter clearance agents.","section":"vascular-access","title":"Vascular Access Device Occlusion: Prevention, Assessment, and Management","url":"/vascular-access/policies/vascular-access-device-occlusion/"},{"content":"Biologic Therapy Administration 1. Purpose and Scope This guideline establishes evidence-based standards for the safe administration of biologic therapies, including colony-stimulating factors, gene therapies, monoclonal antibodies, fusion proteins, interleukin inhibitors, and immunoglobulins. The document addresses patient assessment, care setting selection, medication safety, and the management of adverse reactions.\n2. Core Standards 2.1 Clinical Monitoring Requirements Biologic therapies must …","description":"Evidence-based standards for safe administration of biologic therapies including colony-stimulating factors, monoclonal antibodies, immunoglobulins, and gene therapies. Covers patient assessment, care setting selection, biosimilar considerations, REMS compliance, subcutaneous immunoglobulin administration, and adverse reaction management.","section":"vascular-access","title":"Biologic Therapy Administration","url":"/vascular-access/policies/biologic-therapy-administration/"},{"content":"Umbilical Catheter Management in Neonates Policy 1. Policy Statement It is the policy of this organization that umbilical arterial and venous catheters shall be placed and maintained in accordance with evidence-based standards that minimize infectious, thrombotic, and mechanical complications, that catheter tip position shall be verified by imaging prior to any therapeutic use, and that these devices shall be removed promptly when they no longer serve a clinical purpose.\n2. Purpose This policy …","description":"Establishes standards for umbilical arterial catheter (UAC) and umbilical venous catheter (UVC) indications, antisepsis, tip positioning, imaging confirmation, securement, complication surveillance, and removal in neonatal patients.","section":"vascular-access","title":"Umbilical Catheter Management in Neonates","url":"/vascular-access/policies/umbilical-catheter-management-neonates/"},{"content":"Flushing and Locking of Vascular Access Devices Policy 1. Policy Statement All vascular access devices (VADs) placed or maintained within this organization must be flushed and locked in accordance with evidence-based standards to maintain catheter patency, prevent intraluminal occlusion, reduce catheter-associated bloodstream infection (CABSI) risk, and ensure safe delivery of prescribed therapies. Flushing must be performed before each infusion to confirm patency, after each medication …","description":"Establishes standards and requirements for flushing and locking all vascular access devices to maintain catheter patency, prevent occlusion, reduce catheter-associated bloodstream infection risk, and ensure safe medication delivery across all device types and patient populations.","section":"vascular-access","title":"Flushing and Locking of Vascular Access Devices","url":"/vascular-access/policies/flushing-locking-vascular-access-devices/"},{"content":"Prevention, Recognition, and Management of Vascular Access Device-Related Infections Terminology and Diagnostic Criteria 2.1 Catheter-Associated Bloodstream Infection (CABSI) Catheter-associated bloodstream infection serves as a comprehensive term encompassing bloodstream infections that originate from either peripheral or central vascular access devices. Recognition that both device types can cause equally serious infections has led to the adoption of this unified terminology. Bloodstream …","description":"Evidence-based standards for preventing, recognizing, and managing bloodstream infections associated with peripheral and central vascular access devices, including care bundles, diagnostic criteria, and device removal decisions.","section":"vascular-access","title":"Prevention, Recognition, and Management of Vascular Access Device-Related Infections","url":"/vascular-access/policies/vascular-access-device-related-infections/"},{"content":"Intraosseous Vascular Access Core Standard Clinicians must evaluate patients and anticipate appropriate use of the intraosseous (IO) route when difficult vascular access is expected or encountered. This applies to emergent, urgent, and medically necessary situations where timely vascular access is critical to patient outcomes.\n1. Indications for Intraosseous Access 1.1 Cardiac Arrest The IO route should be utilized in cardiac arrest when intravenous (IV) access is unavailable or cannot be …","description":"Evidence-based standards for the clinical evaluation, insertion, management, complication monitoring, and removal of intraosseous vascular access devices across emergent and non-emergent clinical applications in adult and pediatric patients.","section":"vascular-access","title":"Intraosseous Vascular Access","url":"/vascular-access/policies/intraosseous-vascular-access/"},{"content":"Blood and Fluid Warming Policy 1. Policy Statement It is the policy of this organization that blood products, intravenous fluids, contrast media, and irrigation solutions shall be warmed exclusively with devices engineered and approved for this specific clinical purpose. General heating methods and improvised warming techniques are not acceptable in any clinical setting. All blood warming procedures shall be conducted in a manner that minimizes hemolysis risk. Warming shall be performed only …","description":"Establishes standards for the warming of blood products, intravenous fluids, and contrast media, including device requirements, temperature limits, prohibited methods, monitoring obligations, and quality assurance for all patient populations including neonates.","section":"vascular-access","title":"Blood and Fluid Warming","url":"/vascular-access/policies/blood-and-fluid-warming/"},{"content":"Vascular Access Device Securement Policy 1. Policy Statement All vascular access devices (VADs) placed or maintained within this organization must be secured using evidence-based, suture-free securement methods that prevent dislodgement, minimize catheter movement at the insertion site, preserve skin integrity, and do not impede vascular circulation, site assessment, or therapy delivery. Sutures as a VAD securement strategy are prohibited. Clinicians must select securement methods appropriate to …","description":"Establishes requirements for the securement of all vascular access devices to prevent complications associated with dislodgement and movement at the insertion site, including acceptable securement methods, device-specific guidance, and assessment standards.","section":"vascular-access","title":"Vascular Access Device Securement","url":"/vascular-access/policies/vascular-access-device-securement/"},{"content":"Standard Precautions Policy 1. Policy Statement It is the policy of this organization that standard precautions shall apply during all patient care procedures and in all clinical settings where potential exists for exposure to blood, body fluids, secretions, excretions (excluding sweat), nonintact skin, and mucous membranes. These precautions provide baseline protection for both patients and clinicians regardless of known or suspected infection status. Personal protective equipment selection and …","description":"Establishes baseline infection prevention standards applicable to all patient care activities regardless of diagnosis, including personal protective equipment selection and use, respiratory hygiene, equipment cleaning and disinfection, and care practices across transitional settings.","section":"vascular-access","title":"Standard Precautions","url":"/vascular-access/policies/standard-precautions/"},{"content":"Vascular Access for Hemodialysis Policy 1. Policy Statement It is the policy of this organization that hemodialysis vascular access shall be selected through collaborative, patient-centered decision-making consistent with the established hierarchy of arteriovenous fistula as first choice, arteriovenous graft as second choice, and long-term tunneled cuffed hemodialysis catheter as third choice, and that vessel health and preservation principles shall be applied to all patients with existing or …","description":"Establishes standards for hemodialysis vascular access device selection, vessel health and preservation, access hierarchy, infection prevention, hub care, AVF/AVG cannulation, catheter locking solutions, and patient education for patients receiving or anticipated to receive hemodialysis.","section":"vascular-access","title":"Vascular Access for Hemodialysis","url":"/vascular-access/policies/vascular-access-hemodialysis/"},{"content":"Blood Administration Scope and Purpose These guidelines establish evidence-based standards for the safe administration of blood and blood components. They address procedural requirements, patient monitoring, adverse event recognition, and special considerations across clinical settings. These standards apply to whole blood, red blood cells (RBCs), plasma and plasma components, platelets, granulocytes, and cryoprecipitate.\n1. Core Standards 1.1 Organizational Requirements Healthcare organizations …","description":"Evidence-based standards for safe blood and blood component administration including patient blood management, informed consent, pre-transfusion assessment, product verification protocols, administration procedures, monitoring, adverse reaction recognition and management, and out-of-hospital transfusion requirements.","section":"vascular-access","title":"Blood Administration","url":"/vascular-access/policies/blood-administration/"},{"content":"Prevention and Management of Nerve Injury in Vascular Access Understanding Nerve Injury Risk Nerve injury during vascular access procedures, while relatively uncommon, represents a significant clinical concern with potentially lasting consequences for patients. Anatomical variations in veins, arteries, and nerves occur frequently across the population, meaning that even experienced clinicians cannot rely solely on expected anatomy when performing these procedures.123\nPeripheral Venous Access …","description":"Evidence-based guidance for recognizing anatomical nerve injury risks during vascular access procedures, employing preventive strategies, and managing nerve-related complications.","section":"vascular-access","title":"Prevention and Management of Nerve Injury in Vascular Access","url":"/vascular-access/policies/nerve-injury-vascular-access/"},{"content":"Vascular Visualization Technology Policy 1. Policy Statement It is the policy of this organization that vascular visualization technology shall be systematically assessed for and applied to clinical practice with the goal of increasing first-attempt insertion success, minimizing escalation to unnecessary or more invasive vascular access devices, and reducing insertion-related complications. Selection and application of visualization technology shall be guided by patient-specific factors, …","description":"Establishes standards for the selection and application of vascular visualization technology—including ultrasound, near-infrared, and visible light devices—to improve vascular access insertion success and reduce complications across all patient populations.","section":"vascular-access","title":"Vascular Visualization Technology","url":"/vascular-access/policies/vascular-visualization-technology/"},{"content":"Needleless Connectors for Vascular Access Devices Policy 1. Policy Statement All clinicians managing peripheral and central vascular access devices shall use needleless connectors in a manner that maintains a closed infusion system, minimizes intraluminal contamination, and reduces the risk of catheter-associated bloodstream infection (CABSI).12 Connector selection, fluid displacement management, disinfection method, replacement intervals, and manifold configuration shall comply with …","description":"Establishes requirements for selection, disinfection, flushing and clamping sequences, replacement intervals, and infection prevention practices for all needleless connectors used on peripheral and central vascular access devices.","section":"vascular-access","title":"Needleless Connectors for Vascular Access Devices","url":"/vascular-access/policies/needleless-connectors/"},{"content":"Infiltration and Extravasation Standards of Practice for Prevention, Recognition, and Management Definitions Infiltration refers to the inadvertent leakage of non-vesicant solution or medication from a vascular access device (VAD) into the surrounding tissue. Extravasation specifically describes the escape of vesicant agents—solutions or medications capable of causing tissue injury, necrosis, or blistering—into the perivascular space.\n1.2 Core Standards Three fundamental standards govern …","description":"Standards of practice for the prevention, recognition, and management of infiltration and extravasation from peripheral and central vascular access devices, including antidote protocols.","section":"vascular-access","title":"Infiltration and Extravasation Management","url":"/vascular-access/policies/infiltration-extravasation-management/"},{"content":"Vascular Access Device Selection and Insertion Planning Policy 1. Policy Statement It is the policy of this organization that vascular access device selection shall be based on a systematic, evidence-based assessment of patient-specific clinical factors, prescribed therapy requirements, and available vascular anatomy, adhering to the principle of minimal intervention by selecting the least invasive device with the smallest diameter and fewest lumens necessary to safely complete the prescribed …","description":"Establishes evidence-based criteria for the selection and planning of vascular access devices across all device types and patient populations, from short peripheral catheters through central venous access devices and arterial catheters.","section":"vascular-access","title":"Vascular Access Device Selection and Insertion Planning","url":"/vascular-access/policies/vascular-access-device-selection-insertion/"},{"content":"Phlebitis in Vascular Access Management Classification and Etiology Phlebitis is an inflammation of a vein that can occur during or after intravenous therapy. Understanding its etiology is essential for both prevention and appropriate intervention. Phlebitis is categorized into four primary types based on causative factors.\n1.1 Chemical Phlebitis Chemical phlebitis results from endothelial inflammation or injury caused by the infusion of irritating substances. Contributing factors include: …","description":"Evidence-based standards for the classification, prevention, assessment, and management of phlebitis associated with peripheral and central vascular access devices.","section":"vascular-access","title":"Phlebitis in Vascular Access Management","url":"/vascular-access/policies/phlebitis-vascular-access-management/"},{"content":"Central Vascular Access Device Tip Location Policy 1. Policy Statement It is the policy of this organization that every central vascular access device (CVAD) tip location shall be confirmed by an approved method prior to initiating infusion therapy and whenever clinical signs or symptoms suggest tip malposition. Acceptable tip positions are defined by evidence-based standards tailored to patient population and insertion site. Documentation of tip location shall be completed at the time of …","description":"Establishes standards for central vascular access device tip location confirmation, including acceptable tip positions, real-time tip location methods, re-evaluation protocols, transfer criteria, and documentation requirements for all patient populations.","section":"vascular-access","title":"Central Vascular Access Device Tip Location","url":"/vascular-access/policies/central-vascular-access-device-tip-location/"}]